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Therapeutic efficacies of IgG monoclonal antibodies (mAbs) depend on their physicochemical 
structural integrity, stability, flexibility and biological functionality. IgG-Fc glycosylation at 
Asn-297 is important for the structural integrity and effector function activities of IgG mAb 
therapeutics and is a key contributor of their heterogeneity. Molecular heterogeneities (like 
glycosylation) must be closely monitored and assessed during development of mAbs from drug 
candidate to marketed product and during biosimilar development. A variety of techniques are 
being developed to monitor chemical structure and glycosylation profiles of mAbs, however, 
novel analytical techniques are needed to better understand the effects of glycosylation on their 
complex higher order structures and dynamics for their effective development. In comparability 
and biosimilarity exercises, analytical characterization tools serve as the foundation for 
establishing similarity between pre change versus post change products and biosimilar versus 
innovator product. Hence, better tools are needed for drawing comparisons between the results. 
In this study, four highly purified, well-defined recombinant IgG1-Fc glycoform variants (High-
mannose-Fc (HM-Fc), Man5-Fc (truncated glycoform), GlcNAc-Fc (truncated glycoform), and 
non-glycosylated-Fc (N297Q-Fc) were produced which served as model glycoproteins to study 
the effect of IgG1-Fc N-linked glycosylation on various pharmaceutical properties. This work 
explores the utility of yeast expression along with in vitro enzymatic digestion for obtaining 
homogenous glycoform profiles of IgG Fc glycans; which is extremely challenging to achieve 
considering the observed inherent glycan heterogeneity in expression hosts. We developed and 
utilized various orthogonal analytical techniques to explore the relationship between 
glycosylation and physical stability of these IgG1-Fc glycoforms and compared their physical 




be formulated differently. Hence, this study contributed towards the ongoing development of 
data visualization and mathematical modeling tools for comparability and biosimilarity 
assessments. To simulate a more practical biosimilar comparability scenario, various mixtures of 
the four glycoforms were made to mimic heterogeneity found in biosimilars. The physical 
stability of these mixtures was evaluated by combination of high-throughput biophysical 
techniques. The ability of various biophysical techniques to demonstrate the estimated 
differences between the physical stability of the mixtures was examined. Even though the 
biophysical techniques utilized in this study are the most commonly used tools in the industry, 
these are low in resolution and only show the average conformational outcome. Hence, to obtain 
high-resolution peptide-level information on changes in local dynamics because of changes in 
IgG1-Fc glycans, hydrogen exchange (HX-MS) in combination with pepsin proteolytic digestion 
and liquid chromatography-mass spectrometry (LC-MS) was utilized. Previous HX-MS studies 
on IgG mAbs in our laboratory showed an increased flexibility of a particular peptide segment in 
the Fc region in the presence of excipients and salts. This result was attributed to the disruption 
in packing of the heterogeneous glycan structures with the Fc region. Another goal of this 
dissertation was to explore the mechanisms of interactions between glycans and IgG1-Fc. The 
correlations between glycosylation and physicochemical structure, stability and flexibility of 
well-defined IgG1-Fc glycoforms in this dissertation, will serve as important tools to enable 
rational design and optimization of stable IgG formulation conditions to avoid conformational 
destabilization and aggregation issues during their manufacture, long-term storage and 
administration. The extensive analytical characterization approach utilized in this dissertation 
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1.1 Role of Sugars in Nature 
Monosaccharide sugar molecules (or more generally as carbohydrates), when linked 
together via glycosidic bonds to form multimers referred to as glycans or oligosaccharides (2-20 
monosaccharides) or polysaccharides (or more generally as carbohydrate)1, are one of the major 
macromolecular building blocks of life along with nucleic acids, proteins and lipids. The 
biological roles of glycans are vast and complex and could be broadly classified into three 
categories, first being structural and modulatory roles, second being extrinsic/intrinsic 
interspecies recognition and third being molecular mimicry of host glycans by 
microorganisms.2,3 The roles of glycans specifically in modulating functions of proteins to which 
they are attached are very important topics biologically, as well as for pharmaceutical 
development of glycoproteins as therapeutic drugs or vaccine antigens. Structural and regulatory 
roles of glycans with respect to glycoproteins include contribution to aqueous solubility, 
glycoprotein folding, protection against proteases, and modulation of membrane receptor binding 
and signaling along with tuning a wide range of biological functions of proteins. Extrinsic and 
intrinsic recognition roles of glycans include binding of proteins like viral agglutins (e.g., 
influenza virus), bacterial and plant toxins to enter cells and evade immune responses, mediating 
recognition, uptake and processing of antigenic proteins containing terminal mannose (Man) or 
N-acetyl glucosamine (GlcNAc) glycans through C-type lectin interactions and acting as 
antigenic epitopes to trigger immune reactions. Lastly, molecular mimicry functions include 
evolution of glycan patterns of microorganisms to mimic glycans that are present in the host 
system.2,4  
Majority of protein molecules in clinical development as therapeutic drug candidates are 





better understand the underlying mechanisms that affect these functions by developing 
systematic approaches and techniques to analyze them.2 In recent years, there has been a huge 
increase in development and regulatory approvals of monoclonal antibody (mAb) therapeutics 
firstly, due to their specific action and secondly their use as vehicles for targeted delivery of 
other therapeutic entities (e.g., small molecules in case of antibody drug conjugates (ADCs) and 
proteins in case of Fc-fusion therapeutics) that lead to fewer side effects.5 Biologically, five 
classes/isotypes of antibodies (which are IgG, IgM, IgA, IgD and IgE) mediate the adaptive 
immune response in humans for long-term protection against potential environmental pathogens. 
The combined effects of all the antibody isotypes result in removal and destruction of pathogens 
during an attack towards the immune system. However, the IgG class of antibodies is the popular 
choice for antibody molecules for therapeutic development due to their high abundance (~75%) 
in human serum as compared to the other types. Hence, the primary focus of our work will be on 
the IgG type of antibodies, especially the fragment crystallizable (Fc) which is glycosylated. 
1.2 Structure and Function of IgG1 Antibodies 
IgG1, IgG2, IgG3 and IgG4 are four subclasses of IgG antibodies having unique profiles of 
biological activities.6 The IgG1 subclass is not only the abundant subclass present in the human 
serum, but also is the most well studied and the most popular choice for development as 
therapeutic antibody drug candidates.  In addition, when developing a recombinant monoclonal 
antibody (rmAb) therapy, the selection of IgG subclass depends on the required biological effect 
these proteins can produce. The IgG1 glycoprotein (similar to other IgG subclasses) is a 
homodimer containing two heavy chains and two light chains connected by intra and 
intermolecular disulfide linkages which are folded to form two fragment antigen-binding (Fab) 





chain linked to the heavy chain by a disulfide bond while the Fc domain is made of two heavy 
chains that exist as a dimer held together by two disulfide bonds in a hinge region as seen in 
Figure 1.1. Each Fab domain consists of two variable domains and two constant CH1 domains, 
while the Fc has each of two constant CH3 and CH2 domains. The CH2 domains have two N-
linked-glycans attached to Asn-297 residue at each side and are packed together with N-glycans 
that fill the horseshoe shaped pocket between two CH2 domains. The two CH3 domains form 
multiple noncovalent interactions with one another.7 The Fab domains of IgG1 antibodies 
neutralize antigens by specific binding and the glycosylated Fc domain is responsible for 
removal and destruction of antigens by governing biological functions like antibody-dependent 
cellular cytotoxicity (ADCC), complement dependent cytotoxicity (CDC), and clearance.8 The 
N-glycans modulate binding of the Fc to different Fc ɣ receptors (FcɣR/FcR) to govern ADCC 
and CDC activities. It was commonly believed that FcRn binding is unaffected by glycosylation, 
however, in a recent study it was shown that glycans might affect FcRn binding which could 
ultimately affect antibody clearance.9  
1.3  Glycosylation in IgG1 Antibodies 
Protein glycosylation is the ubiquitous post-translational modification (PTM) and governs 
an immense array of biological functions due to their remarkable complexity and diversity 
between various organisms.2-4,10-12 Almost 50 % of human genes encode a conserved site for 
glycan attachment comprising of an amino acid sequence –N-X-S/T- (X can be any AA other 
than proline) which is called an N-liked glycosylation site. This attachment takes place as co 
and/or post-translational events in the endoplasmic reticulum (ER) and the Golgi apparatus. 
Another site of glycan attachment lies in the oxygen of hydroxyl groups of side chains of amino 





attachment takes place in the Golgi.13 Antibodies are glycoproteins and contain predominantly 
N-linked glycans at different Asn residues in the conserved sequence of both Fab and Fc 
domains.6 Further, in IgG1 class of antibodies, the conserved N-liked glycosylation site lies on 
the Asn-297 residue in the Fc domain and is extremely crucial for the non-antigen binding 
biological functions of antibodies via the Fc. However, N-glycosylation in the Fab domains is 
variable (∼15–25%),14 and may or may not be present, depending on the presence of the 
conserved glycosylation AA sequence.  
1.4 Structure and Type of N-linked Glycans in Human Serum IgG1 
There are three broad classes of N-linked oligosaccharides associated with antibodies, 
which are the complex, the high-mannose and the hybrid type (as seen in Figure 1.1). Neither the 
high-mannose type nor the hybrid type glycans occur naturally on human IgG1 antibodies. The 
high-mannose type has been detected in antibodies expressed in yeast cell lines along with some 
minor amounts produced in rodent mammalian cell lines such as Chinese hamster ovary (CHO) 
and mouse myeloma (NS0).15 As seen in Figure 1.1, glycans present on the human serum IgG1 
Fc of polyclonal IgG, attached at Asn297, consists of complex biantennary types that have a core 
heptasaccharide that is conserved throughout all the glycoforms. Macro-heterogeneity exists due 
to the site of glycan attachment and can be symmetric or asymmetric depending on whether same 
or different glycans are attached to both the glycosylation sites on each of the Fc CH2 domains. 
Micro-heterogeneity exists due to the type of glycan attachments to the core. For example, the 
attachment of glycans like fucose (Fuc), galactose (Gal), bisecting N-acetylglucosamine 
(GlcNAc) and N-acetylneuraminic acid (NANA or sialic acid) to the heptasaccharide core can 
cause heterogeneity. All the different combinations of these glycans attached to the core produce 





glycosylation, the Fab glycans (if present) consists of high amounts of bisecting GlcNAc, 
galactose, and sialic acid and low core fucose. In human serum, around 4% of the polyclonal IgG 
Fabs have high-mannose glycans, however, they are rarely present in the Fc regions.14 
1.5 Altered glycosylation in disease states 
In humans, protein glycosylation plays an important role in growth and development and it 
has been observed that the glycoform profile of IgG varies with age, gender, over the term of 
pregnancy and disease conditions.17 Changed glycosylation pattern is especially observed in 
many chronic and inflammatory autoimmune diseases18 like rheumatoid arthritis, Crohn’s 
disease and vasculitis, different types of cancers and hypercholesterolemia.16,19,20 Previous 
studies have shown that decreased galactosylation of total serum IgG was observed in 
rheumatoid arthritis, Crohn’s disease and cancer as compared with healthy individual.16,20 The 
amounts and types of Fab glycans too can vary during certain physiological and pathological 
conditions, suggesting that N-glycosylation on polyclonal IgG might contribute to immune 
suppression or pathophysiology and potentially serve as biomarkers.14 
1.6 Structure and Type of N-linked Glycans in Recombinantly Produced IgG 
Therapeutics 
For mAb therapeutics to be fully biologically active, it is essential that they have fully 
occupied N-glycosylation sites in the CH2 domain of the Fc (aglycosylated mAbs can still bind 
antigen and in some cases are very active since Fc effector function not required).16,21,22 Figure 
1.2 shows the common types of N-glycans found in therapeutic mAbs. Mammalian cells (CHO) 
and murine cells (NS0 or SP2/0) are the most commonly used expression hosts for production of 





human serum IgGs, except for the bisecting GlcNAc and terminal sialic acid (NANA) which are 
present in relatively low amounts in human serum IgGs.23 NS0 or SP2/0 cells produce rmAbs 
with have low levels of galactose-α1, 3-galactose and N-glycolylneuraminic acid (NGNA) 
instead of NANA which could be immunogenic in humans. All the production vessels above 
may add a α2, 3-linked N-glycylneuraminic acid which is not present in humans (α2, 6-linked N-
glycylneuraminic acid in humans).16 E. coli is also used for production of non-glycosylated 
mAbs or Fab fragments in the cases where Fc effector functions are not needed. 
1.7 Influence of Glycosylation on Physicochemical Properties and Stability of IgG 
Therapeutic antibodies are proteins, which are structurally complex high molecular weight 
molecules that are sensitive to their environment. Certain change during their production, 
purification, manufacturing, storage and delivery might lead to changes to their primary structure 
(also post-translational modification) or higher order structure (HOS). Primary structural changes 
occur to amino acid residues which are known as chemical instabilities in mAbs are deamidation 
(Asn to Asp, Gln to Glu), oxidation (Cys, His, Met, Tyr, Trp), isomerization (Asp to isoAsp), 
racemization (L and D), formation of acidic species (e.g. glycation with reducing sugars, 
deamidation by aspartic acid formation, addition of sialic acid glycans), formation of basic 
species (e.g., pyroGlu formation and succinimide formation during deamidation), proteolytic 
degradation, C-terminal clipping, fragmentation and disulfide bond heterogeneity (shuffling, 
thioether and trisulfide formation). Another aspect of primary structure changes are changes in 
glycosylation profiles which can occur during the production and commercial manufacturing of 
mAbs. Glycosylation is highly dependent upon the type of expression host, cell culture 
conditions and parameters, which could change during process development, large-scale 





Changes in higher order structures of proteins (secondary, tertiary and quaternary 
structures) known as physical instabilities are aggregation, denaturation, precipitation and 
surface adsorption. All these structural instabilities pose the biggest challenges for mAb 
pharmaceutical development and can negatively influence their therapeutic efficacies by 
decreasing dose, causing immunogenicity and lowering target binding.5,24 In case of traditional 
small molecule drugs, the physicochemical instabilities are easier to predict and control due their 
much simpler structures than proteins. Even though protein drugs show well-defined chemical 
instabilities, the additional layers of their secondary, tertiary and quaternary structures lead to 
complicated higher order structures. Thus, overall, the rate and extent of chemical and physical 
degradations of proteins become interdependent. Additionally, glycosylation is a natural 
chemical modification to the Asn297 residue in both the CH2 domains of the IgG antibodies, and 
is known to affect the chemical and physical structure of antibodies as discussed below. 
1.7.1 Oxidation 
His, Met, Cys, Trp, and Tyr amino acids are prone to oxidation. Many studies have 
identified oxidation prone residues in antibodies and their effect on thermal stability, aggregation 
and antigen and/or receptor binding capacities. For example, Trp-277 was identified as an 
oxidation site during acid-induced unfolding and aggregation of IgG1 and IgG2 containing G2F 
complex glycoform.25 Another study showed that the oxidation of Met-252 and Met-428 affected 
the thermal stability of the CH2 domain and FcRn binding of an IgG1.26 Additionally, oxidation 
of residues within the complementarity-determining regions (CDRs) affected the antigen binding 
properties of antibodies.27,28 In another study, the impact of Met oxidation was highly dependent 
on its location and the type of glycosylation state of the protein, where Met oxidation in the 





of Met-252 and Met-428 in the CH2 domain caused a large decrease in thermal stability and an 
increase in aggregation rate that was more prominent in aglycosylated mAb than the complex 
glycoform.29 However, correlation with decrease or increase in size of N-linked glycans on 
oxidation of antibodies is yet to be made and it is not known which Met site in the CH2 domain is 
affected predominantly by glycosylation. Also, whether the stabilizing effect of glycans towards 
oxidation is due to their attachment to the protein or due to their radical scavenging capabilities 
is not yet addressed.24 
1.7.2 Deamidation and Isomerization  
Asn deamidation is an important chemical destabilization pathway of proteins that could 
affect their overall stability and therapeutic efficacy during development and storage. There are 
deamidation prone NG motifs at Asn-315 and Asn-384 and DG motifs at Asp-280 and Asp-401 
located in the Fc constant region and in the CDR regions of antibodies.30 Isomerization in the 
CDRs of a mAbs impaired the binding affinity of an antibody for its target antigen resulting in 
reduced drug potency.28 However, the ability of N-linked glycosylation to affect these 
deamidation prone sites along with other chemical instabilities of IgG antibodies remains to be 
tested. 
1.7.3 Proteolytic Degradation 
Glycosylation is known to affect the proteolytic degradation of antibodies. It was found 
that high-mannose, hybrid and sialyl glycoforms of IgG1 and IgG2 antibodies were more 
susceptible to enzymatic degradation by trypsin as compared to complex glycoforms (G0F) of 
IgG1 and IgG2 antibodies.31,32 Not only the type of glycan (hybrid, high-mannose, complex, 
sialyl), but also isoforms of hybrid and sialyl glycoforms showed different susceptibility to 





increased susceptibility towards papain.33 Another study showed that terminal mannose provided 
stability against papain due to local stearic exclusion effects in high mannose glycoform of IgG1. 
Pepsin digestion showed afucosylated form to be more stable than high mannose and 
deglycosylated IgG1 glycoforms while HNE digestion showed no differences in digestion rates 
of these glycoforms, except the deglycosylated form.34 Mechanistically, it was proposed that 
proteolytic stability of glycoproteins arises due to the fact that the glycan’s presence provides a 
steric hindrance around the peptide backbone of the amino acids adjacent to the glycosylation 
site by preventing contact between the glycoprotein’s surfaces.24 However, different higher order 
structures and localized conformational changes in the CH2 domains of IgG antibodies, 
depending on their type and size of glycoform was shown to be the cause of different 
susceptibilities of these antibodies towards enzymatic degradation.31-33   
1.7.4 Secondary, Tertiary and Quaternary Structure 
To investigate influence of N-glycans on IgG-Fc, crystal structures of four truncated 
glycoforms were generated and the results showed sequential collapse of CH2 domains as the 
glycan size was decreased.7 Secondary and tertiary structural changes were not observed upon 
deglycosylation of IgG1 antibodies, however, increased hydrodynamic radius and increased 
Sypro Orange binding (due to increased hydrophobic exposure) upon deglycosylation was 
observed by size exclusion chromatography (SEC) and extrinsic Sypro Orange fluorescence 
respectively.33 At neutral pH and physiological salt concentration, E. coli derived Fc 
(aglycosylated) showed smaller hydrodynamic radius as measured by dynamic light scattering 
(DLS)35 than a CHO-derived Fc(glycosylated) in spite of having two glycans, indicating of a 
more compact structure of the glycosylated Fc. Another study on G0F, afucosylated (G0), high 





changes after in vivo or in vitro glycan modification as observed by various spectroscopic 
techniques.34 These studies also indicated that spectroscopic techniques might not be sensitive 
enough to detect structural changes upon glycan variation. 
1.7.5 Solubility/Precipitation 
Adequate protein solubility is an important property not only for chemistry, 
manufacturing and control (CMC) activities during process and formulation development of a 
mAb therapeutic drug candidate, but also for patient administration of protein based drugs. 
Antibody therapeutics requires high solubility that is generally greater than 100 mg/ml which 
allows for their reduced dosing intervals and self-administration. Further, subcutaneous delivery 
requires mAbs to be formulated at small volume (<1.5 mL) with high concentration (> 10 mg/ kg 
dose).36 It is generally observed that glycosylation increases the solubility of proteins, by 
possibly increasing interactions between the glycoprotein surface and the surrounding solvent24, 
but exceptions to this general observation have been reported. Solubility studies on hybridoma 
antibodies showed that neither the N-glycosylation at Fab nor extreme isoelectric points 
contributed to the high solubility of these proteins.36 It was observed that introducing an N-
linked glycan within a complementarity determining region (CDR) in Fab led to improved 
solubility of an anti-IL-13 monoclonal antibody CNTO607 by shielding an aggregation hotspot 
on the surface of the antibody by the glycans.37 However, another study on an IgG monoclonal 
cryoimmunoglobulin showed dramatic decrease in solubility due to glycosylation in the variable 
region.38 As there were previous attempts to understand the impact of Fab glycosylation on 
solubility of antibodies, there is need for a detailed study to know the contribution of Fc N-
glycosylation on their solubility.  





1.7.6.1 Thermal induced structural alterations 
 Protein higher order structures are sensitive to environmental temperature fluctuations, 
which might cause challenges during development and their storage. Initial studies conducted by 
differential scanning calorimetry to assess the thermal stability of IgG-Fc proteins revealed 
decreased thermal stability of the CH2 domain on deglycosylation suggesting contribution of 
glycosylation for stabilization of secondary and tertiary structures of the CH2 domain.39 Another 
study on serially truncated native (G2F), G0F, truncated (Man3GlcNAc2, ManGlcNAc2) and 
deglycosylated glycoforms of IgG1 showed the highest thermal stability by native and 
degalctosylated with no difference between them, M3N2 and MN2 showed similar and 
decreased stabilities while the deglycosylated was the least thermally stable by DSC.40 Thermal 
stability of the CH2 domain by DSC and intrinsic fluorescence was the highest and similar for G0 
and G0F glycoforms (complex), slightly lower for high mannose forms and the least for non-
glycosylated.34The stabilities of the CH3 domains and Fab regions of IgG1 were not affected as 
dramatically as CH2 domains.33,34,39,40 Along with destabilization at higher temperatures, protein 
higher order structure is sensitive to cold temperatures and may undergo denaturation at ambient 
pressures which could create challenges during production and development involving repeated 
freeze-thaw cycles.24 Effect of glycosylation on cold denaturation of IgG antibodies has not been 
studied in detail. Various studies showing effect of glycosylation on thermal stability of proteins 
showed no correlation with the type of linkage (N or O link) but with the glycan content.  
1.7.6.2 pH induced structural alterations 
 Exposure to various pH conditions during production, purification, storage and 
administration can result in protein destabilization by disruption of various intramolecular and 





general trend of increased stability against pH changes as a consequence of glycosylation, 
probably due to increased internal electrostatic interactions of the proteins, as well as decreased 
intermolecular and solvent interactions. Similarly, stabilities of native (G2F), high mannose and 
non-glycosylated IgG antibodies over a wide pH rage of 4.0-7.5 were tested by DSC and showed 
that the domain stability was related to the solution pH. High mannose and non-glycosylated 
forms had lower stability of the CH2 domain over all the pH conditions studied (more prominent 
at low pH conditions), while the CH3 and Fab regions did not show substantial changes.34 
1.7.6.3 Chemical induced structural alterations 
In addition to electrostatic forces, various noncovalent interactions like hydrophobic 
interaction and hydrogen bonding are responsible for the stabilization of native higher order 
structure of proteins. Glycosylation was observed to increase the stability of various proteins 
towards chemical unfolding by guanidine hydrochloride (GdnHCl), urea or sodium dodecyl 
sulfate (SDS).24 Similarly, IgG antibody unfolding induced by GdnHCl studied by second 
derivative ultraviolet (UV) spectroscopy showed less resistance of deglycosylated mAbs towards 
unfolding which were consistent with the DSC thermal stability results.33 
1.7.7 Aggregation 
Proteins molecules can agglomerate irreversibly as a consequence of covalent and non-
covalent interactions that are triggered by pH, temperature excursions, high concentration, 
excipients, mechanical forces and interaction with surfaces during their production, purification, 
manufacturing, storage, transport and administration. Proteins can aggregate due to their intrinsic 
colloidal properties in an environment or presence of certain sticky/hydrophobic patches, which 
usually lie buried in the protein, might be exposed during these stresses and become available to 





regions also called motifs or hot spot regions can be predicted with some success43 and other 
studies have showed compelling evidence of the involvement of CH2 domain and CDRs in Fab 
domains (especially in residues Phe, Tyr or Trp44) in determining  the aggregation rate and extent 
in IgG antibodies.25,41 It is believed that glycans can cause an increase in steric repulsions 
between aggregation prone regions and reduce or prevent aggregation between proteins.24 In IgG 
antibodies, aggregation in glycosylated and de-glycosylated antibodies was studied and it was 
shown that aglycosylated antibodies were more prone to aggregation especially at lower pH 
conditions and higher temperatures.33,35,42,45,46 It was shown than several aggregation prone 
regions near the glycosylation site (Val-282, Pro-291, Tyr-296, Val-308, Leu-309)33,43 underwent 
localized changes in conformation and/or a hydrophobic segment 249-259 became more solvent 
accessible upon deglycosylation which might be due to decreased protein-glycan 
interactions.42,44,47,48 One study showed that IgG Fc aggregation strongly correlated with degree 
of CH2 domain glycosylation which increased with decrease in size of glycan in the following 
order glycosylated< partially glycosylated < non-glycosylated, however, the effect of various 
sizes and types of N-liked glycans on protein aggregation was not probed in detail in this work.25 
1.7.8  Long term storage stability 
Understanding the forced or accelerated physicochemical stability results in the light of 
long-term storage stability of antibodies is a critical aspect during their therapeutic formulation 
development. N-glycosylation affects the chemical, physical and dynamic properties of 
antibodies and particularly deglycosylation leads to dramatic decreases in stability of these 
molecules. No substantial monomer loss was observed in complex (G2F, G0F), high mannose 
and deglycosylated glycoforms of IgG1 mAbs at 5°C (storage temperature), 30°C and 40°C 





substantial effect on storage stability of IgG1 mAbs.34Another study showed similar results in 
which no substantial difference in aggregates were observed between antibody products 
containing low and high high-mannose glycans over accelerated and real time stability 
conditions.49 This indicated that decreased stability of non-glycosylated IgGs observed during 
forced degradation stability might not reflect their true long-term stability. 
1.7.9 Influence of Glycosylation on Flexibility of IgG 
In order to better understand the structure-function relationship of antibodies, it is 
essential to consider an additional aspect of protein structure that is dynamics and flexibility.50 It 
is seen that an IgG antibody shows intrinsic molecular motions and can exist in multiple 
conformations, which are essential for its function, for example, allowing antibodies to span a 
wider range to search for antigens and to be able to bind various FcɣRs during binding events.50-
52 In addition, understanding the effect of glycosylation on flexibility of antibody is not very well 
understood with respect to physicochemical stability and biological functions. Various methods, 
both experimental and simulations, are required to understand the range of motions shown by 
antibodies.50 X-ray crystallography is one of the most sensitive techniques to study antibody 
structure and flexibility at atomic resolution53 however, it gives snapshot of a particular 
conformation present during the crystallization which also could get distorted by crystal packing 
forces and may not be a true representation of the solution state of the protein. In addition, only a 
limited number of crystal structures of different glycoforms of antibody are available which 
might not represent all the conformations sampled by the IgG in solution. As glycosylation is 
heterogeneous, it is challenging to get good resolution of a particular glycan in an X-ray crystal 
structure making it important to have a homogenous glycan distribution, which might be 





used to probe dynamics of various proteins has been challenging for studying large proteins like 
antibodies, but has shown great success in studying antibody fragments.  Solution NMR allows 
studying the flexibility of both the oligosaccharide chain and the protein chain around the glycan 
site. NMR analysis of G2F glycosylated mAbs revealed that the terminal glycans of both  α1,3 
and α1,6 arms are exposed and highly dynamic along with the additional tumbling motion of the 
Fc molecule.54 Studies on multiple IgG and Fc fragments showed that the overall trend of 
increase in their thermal stability upon glycosylation was attributed to decrease in overall 
dynamics of the structure studied by hydrogen deuterium exchange mass spectrometry (HX-MS) 
and NMR.7,24,55-59 It was also observed that reduction in structural mobility due to glycosylation 
occurred in regions that were far from the glycosylation site suggesting transfer of these local 
effects throughout the entire protein.24  
Previous studies in our laboratory examined the effect of different additives on an IgG1 
mAb backbone flexibility using HX-MS. The results showed increased local flexibility of a 
certain hydrophobic segment in the CH2 domain of the mAb was seen in presence of Hofmeister 
salts such as thiocyanate (as anion) and pharmaceutical excipients such as arginine (as an amino 
acid excipient) that was correlated with decreased thermal stability of the CH2 domain and 
increase in aggregation propensity.47,60 This was attributed to disruption in packing of the 
heterogeneous glycan structures within this hot spot region and the glycans.47 As a continuation 
of this research, the nature of interactions between glycan chains and regions of the CH2 domain 
should be explored to gain more mechanistic insights into changes in physical stability of mAbs. 
As flexibility is an important aspect of the protein structure, the impact of IgG glycosylation on 





not be addressed in detail and is often limited by the complexity and heterogeneous distribution 
of glycoforms of antibody. 
1.8 Influence of Glycosylation on Pharmacodynamics (PD) and Pharmacokinetics (PK)  
Evidence of glycosylation is essential for Fc effector function biological activities like 
ADCC and CDC was observed when deglycosylation of various antibodies led to loss of binding 
to Fc ɣ receptors and failed to activate complement (C1q).61 This result suggested the importance 
of N-glycans for governing the biological activities related to Fc receptors and the complement. 
The type (fucose, galactose, sialic acid, bisecting GlcNAc) and branching (complex verses high 
mannose) of N-glycosylation is shown to affect the Fc effector functions and is extensively 
studied. Presence of core fucosylation showed ~ 50-fold increase in FcɣRIIIa receptor binding of 
IgG mAbs, which enhanced their ADCC both in vitro and in vivo, however binding to FcɣRI, 
C1q and FcRn, were unaffected.62-65 Bisecting GlcNAc was shown to enhance the binding 
affinity to FcɣRIIIa resulting in higher ADCC activities; however, core fucose was shown to be 
more critical for ADCC activity of mAbs.66 Terminal Gal (G2) increased the affinity to C1q two 
fold and increased the CDC activity of IgG mAbs,67,68 however terminal galactosylation did not 
affect ADCC activity.67-69 High mannose glycans (Man5/8/9) on IgG mAbs showed higher 
binding affinity to FcɣRIIIa and hence higher ADCC than non-fucosylated forms probably due 
to lack of fucose.15,70-72 However, high-mannose glycans on IgG mAb also reduced their binding 
to C1q, leading to lower CDC activities.70-72 Terminal sialylation of IgG interfered the binding of 
mAbs to FcɣRIIIa, which lead to decreased ADCC.73 It has also been shown that antibody 
glycosylation in the variable region of Fabs can affect the neutralizing function of mAbs. 
Significant reduction or enhancement of antigen-binding activities of antibodies was observed 





The PK properties of IgG mAbs are primarily governed by binding to neonatal Fc receptor 
(FcRn) which recycles the mAbs intracellularly and thus avoids destruction in the lysozymes; 
this process gives the antibody its long serum half-life.61,74 Different composition, branching or 
removal of glycans does not cause a meaningful impact on the PK properties of IgG in vivo, 
suggesting that glycosylation is not required for IgG antibody’s long half-life.75 An 
aglycosylated IgG1 antibody (mAb ALD518) demonstrated normal human serum half-life of 
around 20-32 days in Phase I clinical trial.76 However, a recent HX-MS study revealed that 
deglycosylation increased the flexibility of the FcɣR binding site of an antibody.9 IgG mAbs 
having high mannose glycans (M5-M9) showed faster clearance than mAbs with complex 
glycans (G0F, G1F and G2F).77,78 However, it was seen that binding affinity towards human 
FcRn of high mannose IgGs was similar to complex and hybrid IgGs.15,74 Another study showed 
that Man5 and Man8/9 IgG glycoforms had similar clearance.79 Thus, high mannose glycoforms 
can have the ability to affect clearance, which makes them critical quality attributes that need to 
be monitored during production of mAbs. The increased ADCC activities of IgG having HM N-
glycans (Man5, Man8 and Man9), their substantial influence on clinical efficacy and 
pharmacokinetics, methods for their modulation and understanding underlying mechanisms are 
important for their future development.80 Additionally, Fab domains can also impact the 
clearance of IgG mAbs depending upon their location of glycosylation.61 The above findings 
demonstrate the ability of glycosylation to affect the PK/PD that could ultimately affect the 
biological outcome of mAb therapeutics. Hence, during novel bio-therapeutic or biosimilar 
development, challenges are associated with PK and PD evaluations, which could affect the 
clinical efficacy or clinical similarity, respectively. 





Different mAb production vehicles show different glycosylation in terms of branching and 
types of glycans. Any production cell line that attaches glycans to mAbs, which are not native to 
those, found in human glycoforms of antibodies, might lead to immunogenicity when these 
mAbs are administered to humans. The most recognized immunogenic glycan linkages and 
glycans are galactose-α1, 3-galactose (α-Gal epitope), N-glycolylneuraminic acid (Neu5Gc 
epitope), β1, 2-xylose (core-xylose epitope), and α1, 3-fucose (core-α1, 3-fucose epitope).81,82 
Cetuximab showed that presence of α-Gal and/or Neu5Gc in Fabs developed severe 
hypersensitivity reactions in patients within minutes after first exposure due to development of 
IgE anti-α-Gal antibodies.81-84 However, α-Gal epitopes in the Fc linked glycans of Infliximab 
were not recognized by IgE anti-α-Gal antibodies, possibly due to the relative low abundance 
of α-Gal epitopes.81,82,84 Additionally, mannose and N-acetyglucosamine glycan can be attached 
to mannose receptor on macrophages, dendritic cells and endothelial cells while fully 
galactosylated IgG glycoforms can undergo uptake by dendritic cells which might have the 
potential to be immunogenic.16  
Humanization of therapeutic antibodies has reduced their risk for eliciting an anti-drug 
immune response compared to chimeric antibodies, but this effect is not absent entirely even in 
fully human mAbs (100% human sequences).84 The potential of protein aggregates of humanized 
(95% human with 5% mouse in the CDRs) and fully human mAbs to cause immunogenicity is 
recognized even though the underlying mechanisms for their correlation are complex and not 
well understood.85 It is an active area of research for mAbs to understand the impact of 
aggregation and immunogenicity. However, deglycosylation increased the propensity of mAbs 
for aggregation,46 and this eventually might increase their propensity for immunogenicity 





1.10 Glycoengineering of N-glycosylation of Therapeutic mAbs 
Efficacy and stability of mAbs has been improved by various antibody engineering 
strategies.86 As discussed above, since N-glycosylation significantly influences the PK, PD, 
antigen binding (Fab glycosylation), tissue targeting and stability of mAb therapeutics, 
glycoengineering  can show promising improvement in their efficacy.87 The main goal of 
glycoengineering is to control the heterogeneity of mAb glycosylation and obtain a glycoform 
distribution as homogenous as possible which will have enhanced  biological activities.88 
Achieving the above goal is challenging, and can be done by the following ways: 1) genetic 
manipulation of expression host glycosylation pathway 2) addition of chemical inhibitors 3) 
optimizing cell culture conditions 4) in vitro glycan synthesis and remodeling, and 5) Expression 
of aglycosylated mAbs. CHO cells have been genetically engineered in a variety of ways and are 
widely used as production host for producing therapeutic antibodies that have no core fucose.89 
Although, CHO cells naturally produce non-fucosylated antibodies, their distribution is 
heterogeneous. Various preclinical and clinical studies showed that controlling glycosylation 
improved the efficacy of various mAbs like mogamulizumab (defucosylation), obinutuzumab 
(defucosylation with bisecting N-acetyglucosamine) and benralizumab.90 Apart from glycan 
engineering, various attempts to increase therapeutic efficacy have been made by protein 
engineering of mAbs.91 
1.10.1 Glycoengineering with Yeast Expressed mAbs 
 Yeast offers several advantages for production of recombinant mAbs such as ease of 
production, ease of genetic manipulation, stable expression, rapid cell growth, high protein yield, 
scalable fermentation processes, low-cost and no risk of human pathogenic virus 





for therapeutic applications due to fungal type high-mannose glycans, which can result in 
immunogenicity and poor PK in vivo.89 Glycoengineered P. pastoris platform can yield 
recombinant antibodies with human N-glycosylation that demonstrated increased FcγRIIIa 
binding and ADCC activities along with similar pharmacokinetic profiles in both mice and 
cynomolgus monkeys as compared to CHO expressed trastuzumab.89 This was attributed to the 
loss of fucose in expression from this glycoengineered yeast strain.89 Additionally, expression of 
mAbs in glycosylation deficient yeast along with in vitro enzymatic synthesis of N-glycans 
allows production of homogenous charge variants of IgG1-Fc as observed from a previous study 
in our labs.92 This approach can be further utilized to obtain IgG mAbs with sequentially 
truncated well-defined homogenous glycans for studying their effect on different properties of 
IgG. Expression of aglycosylated mAbs have been carried out by site directed mutagenesis to get 
rid of the Asn-297 residue, expression in E.coli and treatment of fully glycosylated mAbs with 
PNGase-F (Peptide:N-Glycosidase F) enzyme. Engineered aglycosylated mAbs are beneficial 
when effector functions are unnecessary (e.g. in case of neutralizing antibodies and antibodies 
used to treat inflammatory diseases). Aglycosylated antibodies offer an advantage in 
circumventing the need for N-glycan control along with expression in bacteria of full-length 
mAbs is possible which could have higher yields and will be cost effective.21,22,93 
1.11 Biologic (mAb) Drug Product Development, Comparability and Biosimilarity 
Assessments 
Development of recombinant biological products (like mAbs) and their biosimilar 
counterparts to treat various diseases has many hurdles due to their inherent sensitive and 
complex structure especially, in their characterization, manufacturing, stabilization, formulation 





their pharmaceutical development. To meet the high demand of biologics, it is necessary to scale 
up their manufacturing or transfer their processes to another manufacturing site as summarized in 
Figure 1.3. The scale up and technology transfer might induce changes to the delicate structure 
of proteins along with changes in post-translational modifications like glycosylation, making it 
essential to analyze the pre- and post-manufacturing product for any differences in quality.94,95 
To ensure that changes do not affect the quality, it is the responsibility of the biologic’s 
manufacturer to conduct extensive characterization of the pre and post changed products to 
convince regulatory agencies of the validity of their chosen approach.95,96 As seen in Figure 1.3, 
depending on the level of risk of the change, comparability exercises need to be carried out that 
involves different steps. Extensive physicochemical characterization of the product structure is 
the foundation of comparability exercises and rarely includes the expensive clinical trials unless 
the change poses a high level of risk.94,97-100  
The pharmaceutical market comprises of almost 30% biologics out of which mAbs are 
the fastest and largest growing segment.101,102 Patents on the highest selling mAb therapeutics are 
expiring soon hence, currently; there are many biosimilars in development.96,101,103,104 
Biosimilars are copies of biotherapeutics just like generic version of small molecules drugs, 
which offer a comparatively affordable alternative therapy for patients. Manufacturing of protein 
therapeutics is challenging due to their inherently complex structure and production in living 
cells, which could affect the product quality, one of them being post-translational modifications 
like glycosylation as compared to simpler, robust structure and a well-designed manufacturing 
recipe of small molecule drugs.  However, for biosimilar developers, where the manufacturing 
recipe for an innovator drug is unknown; the biosimilar developer has to figure out their own 





in physicochemical structure, activity, safety and efficacy. Again, it is the responsibility of the 
biosimilar manufacturer to conduct comparative studies with the originator biologic and gather 
all the required data to prove biosimilarity.96 Similarity is established at three levels as seen in 
Figure 1.4, where extensive analytical characterization and biological activity testing are the 
foundation of biosimilar development. If similarity is shown with high confidence at the first 
level then extent of clinical studies needed might be reduced which will ultimately lead to lower 
drug costs. Ongoing research areas in biologic development, comparability and biosimilarity 
include: 1) Structural integrity analysis 2) Assessment of physicochemical degradation pathways 
and their effect on biological activity and potency 3) Optimization of drug stability and delivery 
by formulation development 4) Analytical method development and novel analytical approach 
design, and 5) PK/PD and immunogenicity analysis.95,105,106 Each of the above areas offer 
systematic development of mAb therapeutics during comparability and biosimilarity assessments 
however, there are challenges involved in every steps, which are further complicated by the 
inherent glycan heterogeneity of mAbs.  
1.11.1 Analysis of N-glycosylation in mAbs: Glycan Profiling (Primary Structure) and 
Conformation for Comparability and Biosimilarity Assessments 
It is difficult to predict and control mAb glycosylation patterns as they are highly 
dependent on process manufacturing variables.107 As N-glycosylation of mAbs affects their 
stability, biological activity and efficacy, it is necessary to monitor glycosylation and 
characterize glycan structures in detail throughout the product lifecycle, and know which glycans 
might cause adverse events in humans.108 Various orthogonal analytical tools are used for 
characterization of mAb glycosylation, which are high-performance liquid chromatography 





lectin-based microarray (chromatography and mass spectrometry (MS) being the most 
popular).109,110 It is also important that analytical characterization tools are able to characterize 
glycans for providing critical quality attributes.108 Together, these analytical tools should provide 
a complete glycan fingerprint and identify possible glycosylation sites (macro-heterogeneity, 
ICH guidance Q6B), glycan content (micro-heterogeneity) and glycan structure that involve 
information regarding linkages between the constituting monosaccharides of glycans.110 Another 
aspect of glycan analysis involves rapid glycan comparisons between batches is glycan profiling.  
In addition to primary structure analysis of glycosylation, the effect of the glycan on 
conformation of the protein should also be tested especially during biosimilar comparisons.111. 
Higher order structure is essential for the binding of mAbs to its antigen as well as different Fc 
receptors for their biological activity. It has been recently shown that N-glycans on the CH2 
domain of mAbs are flexible, and show different motions depending on their size and 
structure.54,112 NMR is a popular tool for structural characterization to study motions of different 
N-glycans of IgG Fc as well as the flexibility of the protein.54,59,112-116 However, requirement of 
large amount of protein, slow data processing times and protein size limit have not made its use 
popular for comparability analysis.117 HX-MS can provide useful information on the subtle 
higher-order changes with different glycosylation of IgG and has started being popular for 
comparability and biosimilar comparability analyses as a result of improved automation, faster 
data analysis, less interference from excipients, and requirement of small amounts of 
material.31,47,48,56,57,111,118 The analysis of conformational effects is further complicated by the 
heterogeneous distribution of glycans.119,120 It is difficult to attribute the conformational changes 





glycoforms need sensitive analytical techniques that are able to detect them and hence, no unique 
method is available for characterization.117,121,122 
1.11.2 Assessment of Physicochemical Degradation Pathways of mAbs and their Effect on 
Biological Activity for Comparability and Biosimilarity Assessments 
The main goal of forced degradation studies is to elucidate the physicochemical 
degradation pathway(s) of protein drug substances and products, by subjecting them to stresses 
that might be experienced by them during their production, purification, manufacturing, storage, 
transit and administration.95 Any small amount of impurity or instability (specially the PTMs) 
could potentially lead to serious consequences on the overall stability and efficacy. In case of 
glycoforms, which affect the stability and efficacy of mAbs and are inherently heterogeneous, 
identifying a particular glycoform causing degradation will be extremely challenging. Long term 
and accelerated stability studies measure the rate of given degradation process over time while 
forced degradation studies generate degradants in a much shorter time so that degradants can be 
identified earlier and quicker.123 However, it has been observed that even though accelerated and 
forced degradation studies of different IgG glycoforms showed differences with their N-
glycosylation, the type of glycosylation did not affect their long-term stabilities.34,49 Another 
advantage offered by forced degradation studies is to allow the development of stability 
indicating methods which can be used in later stages for the analysis of accelerated and long term 
stability studies.123 This might be essential to develop analytical tools to detect subtle changes 
that occur due to N-glycosylation of mAbs.  As seen in Figures 1.3 and 1.4, stress study also can 
provide timely recommendations for making improvements in the manufacturing process and 
might be useful to control the glycosylation of mAbs.123 Comparing degradation profiles in 





1.11.3 Formulation and Stability of mAbs for Comparability and Biosimilarity 
Assessments 
A major objective of formulating antibodies as therapeutic agents is to control the rate of 
their degradation during their storage and shipping which will ensure their stability over their 
shelf life. Additionally, a robust formulation is required to support preclinical and clinical studies 
that need demonstration of safety, manufacturability and drug stability. Choice of proper 
formulation excipients and other conditions specific for a particular mAb will help achieve the 
above goals. As mAbs are growing in demand and many candidates are in discovery, it becomes 
critical to accelerate process and formulation development and move them rapidly into clinical 
manufacturing. Evaluating the effect of storage period, excipients and environmental stress on 
the accelerated (and long term) stability of protein drug products is an essential part of 
formulation development and comparability evaluations upon formulation change.95,123 The 
dosage form could be changed from liquid to lyophilized or the drug delivery could be changed 
from IV to pre-filled syringes which again might require changes in formulation and extensive 
comparisons of stability of proteins.95 In biosimilar development, the biosimilar developers have 
to implement a formulation, which might or might not be identical to the originator formulation, 
but does not show different degradation products as compared to the originator. Comparing 
stability profiles of proteins in their actual final dosage form formulations is a critical aspect of 
comparability and biosimilar development.  
1.11.4 Development of Novel Data Visualization Tools for Comparability and Biosimilarity 
Assessments 
In both comparability and biosimilarity exercises, changes occur to manufacturing 





must be characterized to demonstrate their similarity in terms of physicochemical structure, 
biological function, impurity profiles, safety and efficacy. As discussed above, mAbs are 
glycoproteins that show heterogeneous glycosylation, which is extremely sensitive to 
manufacturing conditions making it a critical quality attribute. Not only is glycosylation 
heterogeneous in nature, but also affect various pharmaceutical properties as we saw before, 
which could result in affecting the efficacy and safety of the products in comparability and 
biosimilarity scenarios. Ideally, having identical or homogenous glycosylation profile is desired 
but it is not practically possible as every batch of production might be different and difficult to 
control. Although significant advances have been made for glycosylation comparability analysis 
by various glyco-analysis techniques, the need for more sensitive approaches for the evaluation 
of higher order structures (HOS) of proteins remains an important challenge. Especially, for a 
biosimilar comparability exercise, where the foundation lies in extensive comparative 
physicochemical and biological characterization of the biosimilar and the originator, there is 
need for developing novel analytical approaches for comparability. Effect of N-linked 
glycosylation site occupancy and different charge states in various non-glycosylated forms 
within the CH2 domain was examined which provided a sensitive analysis of subtle differences in 
the higher order structure (HOS) of these glycoproteins.92,124 Various attempts have been made 
previously to develop novel data visualization approaches for accessing HOS of glycoproteins 
including mAbs and charge variants of IgG1-Fcs in the context of comparability.92,95,124,125 These 
approaches include the utilization of empirical phase diagrams (EPD) and radar charts, which 
gives the information on the overall higher order structural stability profile of a protein in a 
holistic manner. This approach can be further investigated to study the effect of N-linked well-





In this work, we have utilized a set of well-defined IgG1 Fc glycoforms as a model for 
biosimilar comparability analysis by performing a series of comparative physical evaluations. 
These well-defined glycoforms differed only in glycosylation state or a single conservative 
amino acid mutation and they will be expected to exhibit a wide range of biophysical properties 
due to the effect of N-glycosylation on IgG1-Fc. Four IgG1-Fc glycoforms were produced using 
a combination of expression in genetically modified yeast and in vitro enzymatic truncation. 
They were extensively characterized for their purity, N-glycosylation structure, high molecular 
weight species and charge variants to ensure that these glycoforms differed only in glycosylation 
state or a single amino acid mutation. Subsequently, these different IgG1-Fc glycoforms were 
extensively characterized for solubility and physical stability properties using multiple low-
resolution biophysical techniques to monitor different aspects of their higher-order structure 
across a wide range of pH and temperature conditions.  
Another goal was to develop stability indicating assays that were sensitive to observe 
subtle differences between the HOS and physical stability of these glycoforms. To develop tools 
for comparability, these glycoforms were formulated in two different formulations (NaCl vs 
sucrose) to mimic mAb biosimilars that might be formulated in two different formulations. 
Further, large biophysical data sets obtained above were then used to construct data visualization 
tools based on EPDs and radar charts for structural comparison between different glycosylation 
states. Using this approach, differences in structural integrity and conformational stability were 
detected at stress conditions that could not be detected by using the same techniques under 
ambient conditions (i.e., no stress). Thus, an evaluation of conformational stability differences 
may serve as an effective surrogate to monitor differences in higher-order structure between 





glycoforms were prepared by combining them in defined ratios to produce well-defined batches 
of IgG1-Fc glycoforms with different physicochemical and biological attributes. Stability 
indicating assays developed before to characterize the solubility and physical stability of the four 
glycoforms were utilized to characterize the mixtures.  
As a final aspect to this work, to gain a better mechanistic understanding of the physical 
stability changes as a function of N-glycosylation and to correlate these results with local 
flexibility, HX-MS was utilized. HX-MS offers higher resolution as compared to biophysical 
techniques for HOS characterization and monitoring flexibility of the IgG1-Fc glycoforms. This 
study contributes towards utilization of these homogenous glycoforms as a model for 
understanding impact of glycosylation on physical stability and flexibility, and their application 
in developing analytical tools for comparability and biosimilarity assessments. 
1.12 Chapter Reviews 
1.12.1 Correlating the Impact of Well-Defined Oligosaccharide Structures on Physical 
Stability Profiles of IgG1-Fc Glycoforms. (Chapter 2) 
The focus of this work was to describe four well-defined IgG1-Fc glycoforms as a model 
system for biosimilarity analysis (High mannose-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc 
aglycosylated) and to draw comparisons of their physical properties. A trend of decreasing 
apparent solubility (thermodynamic activity) by PEG precipitation (pH 4.5, 6.0) and lower 
conformational stability by differential scanning calorimetry (DSC) (pH 4.5) was observed with 
reducing size of the N297-linked oligosaccharide structures.  Using multiple high-throughput 
biophysical techniques, the physical stability of the Fc glycoproteins was then measured in two 
formulations (NaCl and sucrose) across a wide range of temperatures (10-90˚C) and pH (4.0-7.5) 





charts to visualize the regions of protein structural stability.  Each glycoform showed improved 
stability in the sucrose (vs. salt) formulation.  The HM-Fc and Man5-Fc displayed the highest 
relative stability, followed by GlcNAc-Fc, with N297Q-Fc being the least stable.  Thus, the 
overall physical stability profiles of the four IgG1-Fc glycoforms also show a correlation with 
oligosaccharide structure.  These datasets are used to develop a mathematical model for 
biosimilarity analysis. 
1.12.2 Comparative Evaluation of Solubility and Physical Stability Profiles of Well-
Defined Mixtures of IgG1-Fc Glycoforms as a Model for Biosimilar Comparability 
Analysis. (Chapter 3) 
Four well-defined IgG1 Fc glycoforms (HM-Fc, Man5-Fc, GlcNAc-Fc, and N297Q-Fc) 
prepared previously were blended in specific ratios to produce well-defined mixtures to mimic 
biosimilar products. These mixtures had evident and subtle differences in physical and functional 
properties as expected from first studying homogenous glycoforms of IgG1-Fc. The mixtures 
were prepared by mixing HM-Fc with the three glycoforms in pre-defined proportion to make 
two sets of mixtures which were: 90%HM:10%X(subtle differences) and 
50%HM:50%X(evident differences), in which X was N297Q-Fc, Man5-Fc, and GlcNAc-Fc. In 
addition, a more complex system was prepared by blending the four glycoforms (25 % each) to 
model heterogeneous systems typically encountered in monoclonal antibodies. Seven mixtures of 
IgG1-Fc glycoforms were prepared and utilized a model system for biosimilar comparability 
assesment. In addition, the four well-defined glycoforms were used as controls in each 
characterization techniques. The focus of this study was to evaluate the physical characteristics 
of these mixtures as a model system for biosimilar comparability analysis. Solubility and 





and biophysical techniques, including differential scanning calorimetry (DSC), intrinsic 
fluorescence, differential scanning fluorimetry (DSF), light scattering and turbidity, which were 
developed in the previous study. A trend in solubility and stability was observed, which 
depended on the type and composition of the mixtures. Mixtures containing Man5-Fc and HM-
Fc showed higher stability, followed by mixtures of GlcNAc-Fc and HM-Fc and combinations of 
N297Q-Fc and HM-Fc showed the least stability. These datasets are being used to develop a 
mathematical model for biosimilarity analysis. 
1.12.3 Correlating the Impact of Glycosylation on the Backbone Flexibility of Well-Defined 
IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry (HX-MS). 
(Chapter 4) 
We have utilized hydrogen/deuterium exchange mass spectrometry (HX-MS) for 
characterization of localized backbone flexibility of four well-defined homogenous N-linked 
Asn-297 glycoforms of an IgG1-Fc expressed and purified from Pichia pastoris cells, two of 
which were prepared using subsequent in vitro enzymatic treatments. A correlation was 
demonstrated between increased flexibility, especially of specific regions within CH2 domains of 
the Fc and decreased N-linked oligosaccharide size from high mannose (Man8-Man12), Man5, 
GlcNAc and then non-glycosylated N297Q. These results were compared with previously 
published physicochemical stability, aggregation propensity, and Fcɣ receptor binding data with 
the same molecules allowing for more insightful correlations between N-glycosylation status and 
pharmaceutical properties of the IgG1-Fc glycoforms. We identified two potential aggregation 
hot spots where flexibility significantly increased upon glycan truncation. We also observed a 
correlation between increased backbone flexibility for Asn-315 containing peptides, increased 





noted for oxidation of Trp-277 residue. Finally, a trend of increasing C’E glycopeptide loop 
flexibility with decreasing glycan size was observed that correlated with FcɣRIIIa binding data. 
These well-defined IgG1-Fc glycoforms serve as a model system not only to enable rational 
design and optimization of stable IgG formulation conditions, but also to identify 
physicochemical data sets potentially discriminating between various glycoforms for future 
biosimilarity assessments.   
1.12.4 Conclusions and Future Work. (Chapter 5) 
This final chapter summarizes what we learned about the structural integrity, 
conformational stability and flexibility of the various N-linked glycoforms of IgG1-Fc as a 
model system for comparability and biosimilarity assessments. The work from chapters 2-4 
(assay development and characterization of physical properties and stability, characterization of 
mixtures, and correlating effect of glycosylation on physical stability and local flexibility) and 
potential utility of using HX-MS and the new data visualization methods for displaying HOS 
stability data (as discussed in the previous chapters) for comparability and biosimilarity are 







Figure 1.1: Structure of IgG1 antibody, Types of N-glycan and Binding Partners  
Structure of IgG1 antibody and different regions involved with binding to different partners are 
shown. The types of N-glycan structures are shown at the bottom and are reproduced from the 








Figure 1.2: Types of N-glycans found in monoclonal antibody therapeutics. The figure is 











Figure 1.3: Analytical evaluations are the foundation of a comparability exercise in any nature 
of process change. Clinical comparability is performed only when uncertainty exists in 













Figure 1.4: Amount of data required in biosimilar development versus new biologic 
development is shown. Three levels of data are required to demonstrate biosimilarity in which 
physicochemical analytical evaluations are the foundation of a biosimilarity exercise and clinical 
















1. Bertozzi CR RD. 2009. Structural Basis of Glycan Diversity. In Varki A CR, Esko JD, et 
al., editor Essentials of Glycobiology, 2nd edition ed., Cold Spring Harbor (NY): Cold Spring 
Harbor Laboratory Press. 
2. Varki A 2017. Biological roles of glycans. Glycobiology  27(1):3-49. 
3. Moremen KW, Tiemeyer M, Nairn AV 2012. Vertebrate protein glycosylation: diversity, 
synthesis and function. Nature reviews Molecular cell biology  13(7):448-462. 
4. Varki A 2011. Evolutionary forces shaping the Golgi glycosylation machinery: why cell 
surface glycans are universal to living cells. Cold Spring Harbor perspectives in biology  3(6). 
5. Wang W, Singh S, Zeng DL, King K, Nema S 2007. Antibody structure, instability, and 
formulation. Journal of pharmaceutical sciences  96(1):1-26. 
6. Vidarsson G, Dekkers G, Rispens T 2014. IgG subclasses and allotypes: from structure to 
effector functions. Frontiers in immunology  5:520. 
7. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P 2003. Structural Analysis of 
Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural 
Integrity. Journal of Molecular Biology  325(5):979-989. 
8. Schroeder HW, Jr., Cavacini L 2010. Structure and function of immunoglobulins. The 
Journal of allergy and clinical immunology  125(2 Suppl 2):S41-52. 
9. Jensen PF, Larraillet V, Schlothauer T, Kettenberger H, Hilger M, Rand KD 2015. 
Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants 
by hydrogen/deuterium exchange mass spectrometry. Molecular & cellular proteomics : MCP  
14(1):148-161. 
10. Khoury GA, Baliban RC, Floudas CA 2011. Proteome-wide post-translational 
modification statistics: frequency analysis and curation of the swiss-prot database. Scientific 
reports  1:90. 
11. Duan G, Walther D 2015. The Roles of Post-translational Modifications in the Context of 





12. Audagnotto M, Dal Peraro M 2017. Protein post-translational modifications: In silico 
prediction tools and molecular modeling. Computational and Structural Biotechnology Journal  
15:307-319. 
13. Jefferis R 2016. Glyco-engineering of human IgG-Fc to modulate biologic activities. 
Current pharmaceutical biotechnology. 
14. Van de Bovenkamp FS, Hafkenscheid L, Rispens T, Rombouts Y 2016. The Emerging 
Importance of IgG Fab Glycosylation in Immunity. The Journal of Immunology  196(4):1435-
1441. 
15. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi 
R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M 2007. Comparison of biological activity 
among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc 
oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology  17(1):104-118. 
16. Jefferis R 2009. Glycosylation as a strategy to improve antibody-based therapeutics. 
Nature reviews Drug discovery  8(3):226-234. 
17. Jefferis R 2009. Glycosylation of antibody therapeutics: optimisation for purpose. 
Methods in molecular biology  483:223-238. 
18. Kailemia MJ, Park D, Lebrilla CB 2017. Glycans and glycoproteins as specific 
biomarkers for cancer. Analytical and bioanalytical chemistry  409(2):395-410. 
19. Bai L, Li Q, Li L, Lin Y, Zhao S, Wang W, Wang R, Li Y, Yuan J, Wang C, Wang Z, 
Fan J, Liu E 2016. Plasma High-Mannose and Complex/Hybrid N-Glycans Are Associated with 
Hypercholesterolemia in Humans and Rabbits. PloS one  11(3):e0146982. 
20. Zhang D, Chen B, Wang Y, Xia P, He C, Liu Y, Zhang R, Zhang M, Li Z 2016. Disease-
specific IgG Fc N-glycosylation as personalized biomarkers to differentiate gastric cancer from 
benign gastric diseases. Scientific reports  6:25957. 
21. Jung ST, Kang TH, Kelton W, Georgiou G 2011. Bypassing glycosylation: engineering 
aglycosylated full-length IgG antibodies for human therapy. Current opinion in biotechnology  
22(6):858-867. 
22. Hristodorov D, Fischer R, Linden L 2013. With or without sugar? (A)glycosylation of 
therapeutic antibodies. Molecular biotechnology  54(3):1056-1068. 
23. Beck A, Reichert JM 2012. Marketing approval of mogamulizumab: a triumph for glyco-





24. Sola RJ, Griebenow K 2009. Effects of glycosylation on the stability of protein 
pharmaceuticals. Journal of pharmaceutical sciences  98(4):1223-1245. 
25. Latypov RF, Hogan S, Lau H, Gadgil H, Liu D 2012. Elucidation of acid-induced 
unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. The Journal of 
biological chemistry  287(2):1381-1396. 
26. Gao X, Ji JA, Veeravalli K, Wang YJ, Zhang T, McGreevy W, Zheng K, Kelley RF, 
Laird MW, Liu J, Cromwell M 2015. Effect of individual Fc methionine oxidation on FcRn 
binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. 
Journal of pharmaceutical sciences  104(2):368-377. 
27. Qi P, Volkin DB, Zhao H, Nedved ML, Hughes R, Bass R, Yi SC, Panek ME, Wang D, 
Dalmonte P, Bond MD 2009. Characterization of the photodegradation of a human IgG1 
monoclonal antibody formulated as a high-concentration liquid dosage form. Journal of 
pharmaceutical sciences  98(9):3117-3130. 
28. Yan Y, Wei H, Fu Y, Jusuf S, Zeng M, Ludwig R, Krystek SR, Jr., Chen G, Tao L, Das 
TK 2016. Isomerization and Oxidation in the Complementarity-Determining Regions of a 
Monoclonal Antibody: A Study of the Modification-Structure-Function Correlations by 
Hydrogen-Deuterium Exchange Mass Spectrometry. Analytical chemistry  88(4):2041-2050. 
29. Zhang A, Hu P, MacGregor P, Xue Y, Fan H, Suchecki P, Olszewski L, Liu A 2014. 
Understanding the conformational impact of chemical modifications on monoclonal antibodies 
with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and 
structural modeling. Analytical chemistry  86(7):3468-3475. 
30. Sinha S, Zhang L, Duan S, Williams TD, Vlasak J, Ionescu R, Topp EM 2009. Effect of 
protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody. 
Protein science : a publication of the Protein Society  18(8):1573-1584. 
31. Fang J, Richardson J, Du Z, Zhang Z 2016. Effect of Fc-Glycan Structure on the 
Conformational Stability of IgG Revealed by Hydrogen/Deuterium Exchange and Limited 
Proteolysis. Biochemistry  55(6):860-868. 
32. Falck D, Jansen BC, Plomp R, Reusch D, Haberger M, Wuhrer M 2015. Glycoforms of 
Immunoglobulin G Based Biopharmaceuticals Are Differentially Cleaved by Trypsin Due to the 
Glycoform Influence on Higher-Order Structure. Journal of proteome research  14(9):4019-4028. 
33. Zheng K, Bantog C, Bayer R 2011. The impact of glycosylation on monoclonal antibody 





34. Zheng K, Yarmarkovich M, Bantog C, Bayer R, Patapoff TW 2014. Influence of 
glycosylation pattern on the molecular properties of monoclonal antibodies. mAbs  6(3):649-658. 
35. Li CH, Narhi LO, Wen J, Dimitrova M, Wen ZQ, Li J, Pollastrini J, Nguyen X, Tsuruda 
T, Jiang Y 2012. Effect of pH, temperature, and salt on the stability of Escherichia coli- and 
Chinese hamster ovary cell-derived IgG1 Fc. Biochemistry  51(50):10056-10065. 
36. Spencer S, Bethea D, Raju TS, Giles-Komar J, Feng Y 2012. Solubility evaluation of 
murine hybridoma antibodies. mAbs  4(3):319-325. 
37. Wu S-J, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, 
Raju TS, Jacobs SA, Teplyakov A, Gilliland GL, Feng Y 2010. Structure-based engineering of a 
monoclonal antibody for improved solubility. Protein Engineering, Design and Selection  
23(8):643-651. 
38. Middaugh C, Litman G 1987. Atypical glycosylation of an IgG monoclonal 
cryoimmunoglobulin. Journal of Biological Chemistry  262(8):3671-3673. 
39. Ghirlando R, Lund J, Goodall M, Jefferis R 1999. Glycosylation of human IgG-Fc: 
influences on structure revealed by differential scanning micro-calorimetry. Immunology Letters  
68(1):47-52. 
40. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R 
2000. The influence of glycosylation on the thermal stability and effector function expression of 
human IgG1-Fc: properties of a series of truncated glycoforms. Molecular Immunology  37:697-
706. 
41. Wu H, Kroe-Barrett R, Singh S, Robinson AS, Roberts CJ 2014. Competing aggregation 
pathways for monoclonal antibodies. FEBS letters  588(6):936-941. 
42. Iacob RE, Bou-Assaf GM, Makowski L, Engen JR, Berkowitz SA, Houde D 2013. 
Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other 
biophysical measurements. Journal of pharmaceutical sciences  102(12):4315-4329. 
43. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL 2009. Aggregation-prone 
motifs in human immunoglobulin G. J Mol Biol  391(2):404-413. 
44. Voynov V, Chennamsetty N, Kayser V, Helk B, Forrer K, Zhang H, Fritsch C, Heine H, 
Trout BL 2009. Dynamic fluctuations of protein-carbohydrate interactions promote protein 
aggregation. PloS one  4(12):e8425. 
45. Yageta S, Shibuya R, Imamura H, Honda S 2017. Conformational and Colloidal 





Compensatory Participation of Domains in Aggregation of Multidomain Proteins. Molecular 
pharmaceutics  14(3):699-711. 
46. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL 2011. Glycosylation 
influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnology 
Journal  6(1):38-44. 
47. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, Middaugh 
CR, Volkin DB, Weis DD 2013. Effects of salts from the Hofmeister series on the 
conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal 
antibody. Biochemistry  52(19):3376-3389. 
48. Majumdar R, Middaugh CR, Weis DD, Volkin DB 2015. Hydrogen-deuterium exchange 
mass spectrometry as an emerging analytical tool for stabilization and formulation development 
of therapeutic monoclonal antibodies. Journal of pharmaceutical sciences  104(2):327-345. 
49. Lu Y, Westland K, Ma YH, Gadgil H 2012. Evaluation of effects of Fc domain high-
mannose glycan on antibody stability. Journal of pharmaceutical sciences  101(11):4107-4117. 
50. Teilum K, Olsen JG, Kragelund BB 2009. Functional aspects of protein flexibility. 
Cellular and molecular life sciences : CMLS  66(14):2231-2247. 
51. Sandin S, Ofverstedt LG, Wikstrom AC, Wrange O, Skoglund U 2004. Structure and 
flexibility of individual immunoglobulin G molecules in solution. Structure  12(3):409-415. 
52. Zhang X, Zhang L, Tong H, Peng B, Rames MJ, Zhang S, Ren G 2015. 3D structural 
fluctuation of IgG1 antibody revealed by individual particle electron tomography. Scientific 
reports  5:9803. 
53. Saphire EO, Stanfield RL, Max Crispin MD, Parren PWHI, Rudd PM, Dwek RA, Burton 
DR, Wilson IA 2002. Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility. 
Journal of Molecular Biology  319(1):9-18. 
54. Barb AW, Prestegard JH 2011. NMR analysis demonstrates immunoglobulin G N-
glycans are accessible and dynamic. Nature chemical biology  7(3):147-153. 
55. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R 
2000. The influence of glycosylation on the thermal stability and effector function expression of 






56. Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR 2009. Characterization of IgG1 
Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass 
Spectrometry. Analytical chemistry  81(7):2644-2651. 
57. Houde D, Peng Y, Berkowitz S, Engen J 2010. Post-translational Modifications 
Differentially Affect IgG1 Conformation and Receptor Binding. Molecular and Cellular 
Proteomics. 
58. Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, Shitara K, 
Kato K 2006. Glycoform-dependent conformational alteration of the Fc region of human 
immunoglobulin G1 as revealed by NMR spectroscopy. Biochimica et biophysica acta  
1760(4):693-700. 
59. Subedi GP, Hanson QM, Barb AW 2014. Restricted motion of the conserved 
immunoglobulin G1 N-glycan is essential for efficient FcgammaRIIIa binding. Structure  
22(10):1478-1488. 
60. Manikwar P, Majumdar R, Hickey JM, Thakkar SV, Samra HS, Sathish HA, Bishop SM, 
Middaugh CR, Weis DD, Volkin DB 2013. Correlating excipient effects on conformational and 
storage stability of an IgG1 monoclonal antibody with local dynamics as measured by 
hydrogen/deuterium-exchange mass spectrometry. Journal of pharmaceutical sciences  
102(7):2136-2151. 
61. Liu L 2015. Antibody Glycosylation and Its Impact on the Pharmacokinetics and 
Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins. Journal of 
pharmaceutical sciences  104(6):1866-1884. 
62. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, 
Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M 2004. Establishment of FUT8 
knockout Chinese hamster ovary cells: an ideal host cell line for producing completely 
defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnology 
and bioengineering  87(5):614-622. 
63. Satoh M, Iida S, Shitara K 2006. Non-fucosylated therapeutic antibodies as next-
generation therapeutic antibodies. Expert opinion on biological therapy  6(11):1161-1173. 
64. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano 
K, Shitara K, Satoh M 2006. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory 
effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high 
binding to FcγRIIIa. Clinical Cancer Research  12(9):2879-2887. 
65. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG 





Fcgamma RIII and antibody-dependent cellular toxicity. The Journal of biological chemistry  
277(30):26733-26740. 
66. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida 
K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K 2003. The absence of fucose but not 
the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type 
oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. 
The Journal of biological chemistry  278(5):3466-3473. 
67. Raju TS 2008. Terminal sugars of Fc glycans influence antibody effector functions of 
IgGs. Current opinion in immunology  20(4):471-478. 
68. Boyd PN, Lines AC, Patel AK 1995. The effect of the removal of sialic acid, galactose 
and total carbohydrate on the functional activity of Campath-1H. Mol Immunol  32(17-18):1311-
1318. 
69. Hodoniczky J, Zheng YZ, James DC 2005. Control of Recombinant Monoclonal 
Antibody Effector Functions by Fc N-Glycan Remodeling in Vitro. Biotechnology progress  
21(6):1644-1652. 
70. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, 
Pan C, Edmunds T 2008. Development of a simple and rapid method for producing non-
fucosylated oligomannose containing antibodies with increased effector function. Biotechnology 
and bioengineering  99(3):652-665. 
71. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer 
R 2012. Production, characterization, and pharmacokinetic properties of antibodies with N-
linked mannose-5 glycans. mAbs  4(4):475-487. 
72. Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Misaka H, Iida 
S, Wakitani M, Konno Y, Yano K, Shitara K, Hosoi S, Satoh M 2006. Comparison of cell lines 
for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnology and 
bioengineering  94(4):680-688. 
73. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS 2007. Higher levels of sialylated 
Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol  
44(7):1524-1534. 
74. Liu L, Stadheim A, Hamuro L, Pittman T, Wang W, Zha D, Hochman J, Prueksaritanont 
T 2011. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris 
with specific glycoforms: a comparative study with CHO produced materials. Biologicals : 





75. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci 
DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA 2014. Phase I dose-escalation study 
of onartuzumab as a single agent and in combination with bevacizumab in patients with 
advanced solid malignancies. Clinical cancer research : an official journal of the American 
Association for Cancer Research  20(6):1666-1675. 
76. Clarke SJ, Smith JT, Gebbie C, Sweeney C, Olszewski N 2009. A phase I, 
pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 
antibody, in patients with advanced cancer. Journal of Clinical Oncology  27(15S):3025-3025. 
77. Wright A, Morrison SL 1994. Effect of altered CH2-associated carbohydrate structure on 
the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. The 
Journal of experimental medicine  180(3):1087-1096. 
78. Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S 2000. In vivo trafficking and 
catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. 
Glycobiology  10(12):1347-1355. 
79. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan J-P, Bayer 
R 2012. Production, characterization and pharmacokinetic properties of antibodies with N-linked 
Mannose-5 glycans. mAbs  4(4):475-487. 
80. Shi HH, Goudar CT 2014. Recent advances in the understanding of biological 
implications and modulation methodologies of monoclonal antibody N-linked high mannose 
glycans. Biotechnology and bioengineering  111(10):1907-1919. 
81. Kuriakose A, Chirmule N, Nair P 2016. Immunogenicity of Biotherapeutics: Causes and 
Association with Posttranslational Modifications. Journal of immunology research  
2016:1298473. 
82. van Beers MM, Bardor M 2012. Minimizing immunogenicity of biopharmaceuticals by 
controlling critical quality attributes of proteins. Biotechnol J  7(12):1473-1484. 
83. Padler-Karavani V, Varki A 2011. Potential impact of the non-human sialic acid N-
glycolylneuraminic acid on transplant rejection risk. Xenotransplantation  18(1):1-5. 
84. van Schie KA, Wolbink GJ, Rispens T 2015. Cross-reactive and pre-existing antibodies 
to therapeutic antibodies--Effects on treatment and immunogenicity. mAbs  7(4):662-671. 
85. Ratanji KD, Derrick JP, Dearman RJ, Kimber I 2014. Immunogenicity of therapeutic 





86. Chen W, Kong L, Connelly S, Dendle JM, Liu Y, Wilson IA, Powers ET, Kelly JW 
2016. Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic 
Sequon. ACS chemical biology  11(7):1852-1861. 
87. Krasnova L, Wong CH 2016. Exploring human glycosylation for better therapies. 
Molecular aspects of medicine  51:125-143. 
88. Giddens JP, Wang LX 2015. Chemoenzymatic Glyco-engineering of Monoclonal 
Antibodies. Methods in molecular biology  1321:375-387. 
89. Zhang N, Liu L, Dumitru CD, Cummings NR, Cukan M, Jiang Y, Li Y, Li F, Mitchell T, 
Mallem MR, Ou Y, Patel RN, Vo K, Wang H, Burnina I, Choi BK, Huber HE, Stadheim TA, 
Zha D 2011. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in 
preclinical study. mAbs  3(3):289-298. 
90. Niwa R, Satoh M 2015. The current status and prospects of antibody engineering for 
therapeutic use: focus on glycoengineering technology. Journal of pharmaceutical sciences  
104(3):930-941. 
91. Chan AC, Carter PJ 2010. Therapeutic antibodies for autoimmunity and inflammation. 
Nature reviews Immunology  10(5):301-316. 
92. Alsenaidy MA, Okbazghi SZ, Kim JH, Joshi SB, Middaugh CR, Tolbert TJ, Volkin DB 
2014. Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site 
occupancy and Asp/Gln residues at site Asn 297. Journal of pharmaceutical sciences  
103(6):1613-1627. 
93. Crispin M 2013. Therapeutic potential of deglycosylated antibodies. Proceedings of the 
National Academy of Sciences of the United States of America  110(25):10059-10060. 
94. Lubiniecki A, Volkin DB, Federici M, Bond MD, Nedved ML, Hendricks L, Mehndiratta 
P, Bruner M, Burman S, Dalmonte P, Kline J, Ni A, Panek ME, Pikounis B, Powers G, Vafa O, 
Siegel R 2011. Comparability assessments of process and product changes made during 
development of two different monoclonal antibodies. Biologicals : journal of the International 
Association of Biological Standardization  39(1):9-22. 
95. Alsenaidy MA, Jain NK, Kim JH, Middaugh CR, Volkin DB 2014. Protein comparability 
assessments and potential applicability of high throughput biophysical methods and data 
visualization tools to compare physical stability profiles. Frontiers in Pharmacology  5:39. 
96. McCamish M, Woollett G 2011. Worldwide experience with biosimilar development. 





97. Federici M, Lubiniecki A, Manikwar P, Volkin DB 2013. Analytical lessons learned from 
selected therapeutic protein drug comparability studies. Biologicals : journal of the International 
Association of Biological Standardization  41(3):131-147. 
98. 2016. U.S. Food and Drug Administration. Guidance for Industry- Clinical Pharmacology 
Data to Support a Demonstration of Biosimilarity to a Reference Product. 
99. 2015. U.S. Food and Drug Administration. Guidance for Industry-Quality Considerations 
in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. 
100. 2015. U.S. Food and Drug Administration. Guidance for Industry- Scientific 
Considerations in Demonstrating Biosimilarity to a Reference Product. 
101. Blackstone EA, Joseph PF 2013. The Economics of Biosimilars. American Health & 
Drug Benefits  6(8):469-478. 
102. Geng X, Kong X, Hu H, Chen J, Yang F, Liang H, Chen X, Hu Y 2015. Research and 
development of therapeutic mAbs: An analysis based on pipeline projects. Human Vaccines & 
Immunotherapeutics  11(12):2769-2776. 
103. Udpa N, Million RP 2016. Monoclonal antibody biosimilars. Nature reviews Drug 
discovery  15(1):13-14. 
104. Kumar R, Singh J 2014. Biosimilar drugs: Current status. International Journal of 
Applied and Basic Medical Research  4(2):63-66. 
105. Volkin DB, Hershenson S, Ho RJY, Uchiyama S, Winter G, Carpenter JF 2015. Two 
Decades of Publishing Excellence in Pharmaceutical Biotechnology. Journal of pharmaceutical 
sciences  104(2):290-300. 
106. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB 2012. Analytical tools for characterizing 
biopharmaceuticals and the implications for biosimilars. Nature reviews Drug discovery  
11(7):527-540. 
107. Reusch D, Haberger M, Kailich T, Heidenreich AK, Kampe M, Bulau P, Wuhrer M 
2014. High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel 
electrophoresis using a DNA analyzer. mAbs  6(1):185-196. 
108. Prien JM, Stöckmann H, Albrecht S, Martin SM, Varatta M, Furtado M, Hosselet S, 
Wang M, Formolo T, Rudd PM. 2015. Orthogonal Technologies for NISTmAb N-Glycan 
Structure Elucidation and Quantitation.  State-of-the-Art and Emerging Technologies for 
Therapeutic Monoclonal Antibody Characterization Volume 2 Biopharmaceutical 





109. Huhn C, Selman MH, Ruhaak LR, Deelder AM, Wuhrer M 2009. IgG glycosylation 
analysis. Proteomics  9(4):882-913. 
110. Zhang L, Luo S, Zhang B 2016. Glycan analysis of therapeutic glycoproteins. mAbs  
8(2):205-215. 
111. Fang J, Doneanu C, Alley WR, Jr., Yu YQ, Beck A, Chen W 2016. Advanced assessment 
of the physicochemical characteristics of Remicade(R) and Inflectra(R) by sensitive LC/MS 
techniques. mAbs  8(6):1021-1034. 
112. Barb AW, Meng L, Gao Z, Johnson RW, Moremen KW, Prestegard JH 2012. NMR 
characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry  
51(22):4618-4626. 
113. Subedi GP, Barb AW 2016. The immunoglobulin G1 N-glycan composition affects 
binding to each low affinity Fc gamma receptor. mAbs  8(8):1512-1524. 
114. Subedi GP, Barb AW 2015. The Structural Role of Antibody N-Glycosylation in 
Receptor Interactions. Structure  23(9):1573-1583. 
115. Barb AW 2015. Intramolecular N-glycan/polypeptide interactions observed at multiple 
N-glycan remodeling steps through [(13)C,(15)N]-N-acetylglucosamine labeling of 
immunoglobulin G1. Biochemistry  54(2):313-322. 
116. Marchetti R, Perez S, Arda A, Imberty A, Jimenez-Barbero J, Silipo A, Molinaro A 2016. 
"Rules of Engagement" of Protein-Glycoconjugate Interactions: A Molecular View Achievable 
by using NMR Spectroscopy and Molecular Modeling. ChemistryOpen  5(4):274-296. 
117. Marino K, Bones J, Kattla JJ, Rudd PM 2010. A systematic approach to protein 
glycosylation analysis: a path through the maze. Nature chemical biology  6(10):713-723. 
118. Pan J, Zhang S, Chou A, Borchers CH 2016. Higher-order structural interrogation of 
antibodies using middle-down hydrogen/deuterium exchange mass spectrometry. Chem Sci  
7(2):1480-1486. 
119. An Y, Zhang Y, Mueller H-M, Shameem M, Chen X 2014. A new tool for monoclonal 
antibody analysis: Application of IdeS proteolysis in IgG domain-specific characterization. 
mAbs  6(4):879-893. 
120. Chen CL, Hsu JC, Lin CW, Wang CH, Tsai MH, Wu CY, Wong CH, Ma C 2017. Crystal 
Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the 





121. Patwa T, Li C, Simeone DM, Lubman DM 2010. Glycoprotein Analysis Using Protein 
Microarrays and Mass Spectrometry. Mass spectrometry reviews  29(5):830-844. 
122. Reusch D, Haberger M, Maier B, Maier M, Kloseck R, Zimmermann B, Hook M, Szabo 
Z, Tep S, Wegstein J, Alt N, Bulau P, Wuhrer M 2015. Comparison of methods for the analysis 
of therapeutic immunoglobulin G Fc-glycosylation profiles—Part 1: Separation-based methods. 
mAbs  7(1):167-179. 
123. Blessy M, Patel RD, Prajapati PN, Agrawal YK 2014. Development of forced 
degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical 
Analysis  4(3):159-165. 
124. Alsenaidy MA, Kim JH, Majumdar R, Weis DD, Joshi SB, Tolbert TJ, Middaugh CR, 
Volkin DB 2013. High-throughput biophysical analysis and data visualization of conformational 
stability of an IgG1 monoclonal antibody after deglycosylation. Journal of pharmaceutical 
sciences  102(11):3942-3956. 
125. Alsenaidy MA, Wang T, Kim JH, Joshi SB, Lee J, Blaber M, Volkin DB, Middaugh CR 
2012. An empirical phase diagram approach to investigate conformational stability of “second-
generation” functional mutants of acidic fibroblast growth factor-1. Protein science : a 
publication of the Protein Society  21(3):418-432. 
126. Stanley P SH, Taniguchi N. 2009. N-Glycans. In Varki A CR, Esko JD, et al., editor 
Essentials of Glycobiology, 2nd edition ed., Cold Spring Harbor (NY): Cold Spring Harbor 
Laboratory Press. 
127. Bui LA, Hurst S, Finch GL, Ingram B, Jacobs IA, Kirchhoff CF, Ng CK, Ryan AM 2015. 







Chapter 2 Correlating the Impact of Well-Defined Oligosaccharide 



















(More AS, Toprani VM, Okbazghi SZ, Kim JH, Joshi SB, Middaugh CR, Tolbert TJ, Volkin DB 
2016. Correlating the Impact of Well-Defined Oligosaccharide Structures on Physical Stability 







Post-translational modifications such as glycosylation and their effect on the structure, 
function and pharmaceutical properties of antibody molecules have been a topic of interest for 
many years.1,2 With the popularity of monoclonal antibody (mAb) therapeutics (primarily IgG), 
and the development of more affordable biosimilars, the interest in evaluating antibody 
glycosylation has greatly increased.3,4,5,6 Glycosylation of IgGs plays an important biological role 
in maintaining pharmacokinetic attributes (circulation half lives in blood, clearance and 
bioavailability) and controlling biological activity (by affecting the IgG affinity to bind various 
Fc receptors in vivo).7,8,9,10,11,12,13,14,15 For example, mAbs with high mannose N-linked glycans 
show increased clearance (decreased serum half-life) leading to reduced exposure and lower 
efficacy,16 while IgGs containing bisecting GlcNAc glycans show enhanced antibody dependent 
cell mediated cytotoxicity (ADCC) and stronger binding to FcγRIIIa  receptors. 13,16,17,18,19,20  
The IgG1 glycoprotein is a homodimer containing two antigen binding Fab regions 
connected to a Fc region by flexible linkers.21 The IgG1-Fc is a disulfide-bonded homodimer that 
comprises of two non-covalently paired CH2-CH3 domains.22 The N-linked glycosylation site lies 
at the asparagine 297 (Asn297) residue of the consensus sequence Asn-X-Ser/Thr of the CH2 
domain.  The two CH2 domains do not pair directly but are bridged together by the complex di-
antennary glycans, which occupy the inside of a horseshoe-shaped pocket between these 
domains.23 The glycans form various non-covalent interactions with the Fc domains contributing 
to the formation of a stable conformation.7 Structural analysis by X-ray crystallography in 
combination with molecular dynamic simulations have shown that full or partial removal of the 
glycan residues cause conformational changes in the CH2 domain resulting in loss of both 





displays a larger radius of gyration (Rg) than glycosylated Fc in solution suggesting a more open 
conformation (as measured by small-angle X-ray scattering).23 Numerous studies on natural, 
truncated and aglycosylated glycoforms of mAbs have shown that changes in glycosylation 
affect protease susceptibility, flexibility, physicochemical stability and aggregation, often in a 
complex manner.10,17,25-34 
Protein glycosylation is a heterogeneous post-translational modification which includes 
glycosylation site occupancy variation (macro-heterogeneity) and variations in type, length, and 
branching of glycans (micro-heterogeneity).35 During recombinant expression of mAb 
therapeutics, variation in glycosylation occurs as the result of the type of expression hosts, scales 
of manufacturing, and culture conditions.7,13,36-37 Because of these effects, ensuring tight limits of 
glycan heterogeneity during manufacturing is a challenge, and is a critical aspect of mAb 
development, both for innovator and biosimilar protein-drugs.38 Although glycosylation 
engineering holds tremendous potential in improving the efficacy of antibody therapeutics,39,40,35 
more systematic studies are needed to better understand their effects on pharmaceutical 
properties to develop a stable and efficacious glycoprotein formulation. 
Developing new analytical approaches and techniques to better determine and compare 
the complexity of post-translational modifications (such as glycosylation) of protein drugs, and 
to elucidate their higher-order structural integrity, is currently an urgent need for both 
comparability41,42 and biosimilarity assessments.43,44 Extensive analytical characterization can 
serve as a key tool to minimize the extent to which expensive, time consuming clinical trials are 
required to ensure that the safety and efficacy of protein drugs is maintained after process 
changes (comparability) or when made by different manufacturers (biosimilarity).41-44  Previous 





visualization tools such as empirical phase diagrams and radar charts to show that enzymatic 
removal of glycans from the Fc region of an IgG1 mAb decreased physical stability.45  In 
addition, site occupancy and amino acid changes at the Asn297 site within IgG1-Fc molecules 
was shown to affect their physical stability profile by the same experimental approach.45-46 
Similarly, Yageta et al47 has recently used empirical phase diagrams to compare the 
conformational and colloidal stability of isolated constant domains of human IgGs (including 
aglycosylated CH2 domains) under acidic conditions.  One key goal of these types of studies is to 
assess the utility of physical stability profiles in protein comparability assessments.41 
In this work, we report the use of four well-defined IgG1-Fc glycoforms (HM-Fc, Man5-
Fc, GlcNAc-Fc and N297Q-Fc) as a comparative model system for developing a mathematical 
approach for biosimilarity analysis.  The purpose of this study is to compare the apparent 
solubility (thermodynamic activity) and physical stability profiles of these model Fc glycoforms 
under a variety of solution conditions. This was a collaborative project which involved other 
laboratories at KU which carried out (1) thorough biological characterization of these IgG1-Fc 
glycoforms,48 (2) chemical stability evaluations of the four IgG1-Fc glycoforms,49 and (3) 
mathematical modeling of physical stability data presented in this work for the purpose of 
biosimilarity assessments.50 
We have determined the effect of oligosaccharide structure on the relative apparent 
solubility (thermodynamic activity) of the Fc glycoforms using a PEG precipitation assay.  We 
then evaluated the structural integrity and conformational stability using a variety of biophysical 
techniques including intrinsic and extrinsic fluorescence spectroscopy, turbidity measurements 
and differential scanning calorimetry across a variety of pH, temperature and formulation 





regard to differences in glycosylation is generated by the use of data visualization tools including 
three-index empirical phase diagrams and radar charts. These results are not only useful as part 
of preformulation characterization studies during formulation development (as described in this 
chapter), but also provide large datasets for mathematical modeling for biosimilarity assessments 
using data mining and machine learning tools.50 
2.2 Materials and Methods 
2.2.1 Materials 
IgG1-Fc glycoforms (HM-Fc, Man5-Fc, GlcNAc-Fc) were produced using a combination 
of expression in a glycosylation deficient strain of Pichia pastoris (yeast), protein purification 
and in-vitro enzymatic synthesis as described elsewhere (see Okbazghi et al, 2016 and Alsenaidy 
et al, 2014).48,51 The non-glycosylated variant of the IgG1-Fc (N297Q-Fc) was made by mutating 
the N-linked glycosylation site at Asn-297 (EU numbering) to Gln 297 and was produced as 
described elsewhere (see Okbazghi et al, 2016 and Alsenaidy et al, 2014).48,51 After expression 
and purification, the four well-defined IgG1-Fc glycoproteins were concentrated and dialyzed 
into a storage buffer (10% sucrose, 20 mM histidine, pH 6.0) and frozen at −80°C at a 
concentration of 0.2 mg/mL.51 A pictorial summary of the four well-defined IgG1-Fc glycoforms 
used in this work is provided in Figure 2.1. 
For PEG precipitation studies and differential scanning calorimetry (DSC), the four 
IgG1-Fc glycoforms were concentrated to 3 mg/mL using a Millipore Amicon Ultra (EMD 
Millipore, Billerica, MA) with 0.5 mL centrifugal filter device and a 10 kDa MW cut off. All the 
glycoforms were then dialyzed at 4°C overnight in a 20 mM citrate phosphate buffer with ionic 
strength adjusted to 0.15 by NaCl at pH 4.5 and 6.0 to obtain final protein stock solutions of 1 





of two different formulations: (1) 20 mM citrate phosphate buffer adjusted to an ionic strength of 
0.15 with NaCl (pH 4.0-7.5, at 0.5 pH unit increments), and (2) 20 mM citrate phosphate buffer 
containing 10% sucrose (w/v) (pH 4.0-7.5, 0.5 pH unit increments). Dialysis was performed at 
4°C using Slide-A-Lyzer dialysis cassettes (Life technologies, Grand Island, NY) with a 10 kDa 
molecular weight cut off, with three buffer exchanges; two exchanges at 4h intervals and one 
overnight. Components of all buffers including L-Histidine, sodium phosphate and sodium 
chloride as well as PEG-10,000 were purchased from Sigma-Aldrich (St Louis, MO) while 
citric acid anhydrous and citric acid monohydrate were purchased from Fisher Scientific at 
the highest purity grade. Sucrose was obtained from Pfansteihl, Inc. (Waukegan, IL). 
2.2.2 Methods 
2.2.2.1 PEG Precipitation Assay 
The experimental protocol was adapted from Gibson et al52 and Toprani et al.53 Stock 
solutions of PEG-10,000 ranging from 0 to 40% w/v PEG were prepared in 20 mM citrate 
phosphate buffer with ionic strength adjusted to 0.15 by NaCl at pH 4.5 and pH 6.0. A volume of 
40 µL of each of the PEG-10,000 solutions (from 0 to 40% w/v PEG) were added to wells of a 
96-well polystyrene filter plate (Corning#3504, Corning Life Sciences, Corning, NY). Ten µL of 
the protein stock solutions (1 mg/mL) was then added to each well to achieve a final protein 
concentration of 0.2 mg/mL. The plates were incubated at room temperature overnight and then 
were centrifuged at 548 (x g) for 15 min.  The filtrate was collected in a clear 96 well collection 
plate (Greiner Bio-One#655001, Greiner Bio-One North America Inc., Monroe, NC). The 
protein concentration was determined on a NanoDrop 2000 spectrophotometer (NanoDrop 
Products, Wilmington, DE) using 2 µL of filtrate by measuring absorbance at 280 nm. The 





parameter, modified Hill-slope sigmoidal curve equation (Eq.1), using Python (x,y) v.2.7.6.0, an 
open source scientific software based on python language. The % PEGmidpt values and apparent 
solubility value parameters were then calculated from the resulting curve fit52 where t= top 
plateau, b= bottom plateau, mid= x-axis midpoint, and s=slope. The % PEGmidpt values were 
determined by noting the x-axis midpoints. 
𝑦 = 𝑏 + !!!
!! ! !(!"#!!)
                                    (1) 
The apparent solubility values were determined54 by first plotting the same data sets on a 
logarithmic scale from the transition region and then fitting them using equation (2) to 
extrapolate the data to zero % PEG concentrations.  
logSp = logao – A12[PEG]                                (2) 
Under certain assumptions, including non-interaction of PEG with protein, the y intercept of the 
linear fit is the apparent thermodynamic activity (or apparent solubility) of the protein. The p 
values for all four IgG1-Fc samples were determined using the student t-test in Microsoft Excel 
2010 software.  All the truncated glycoforms (Man5-Fc, GlcNAc-Fc, and N297Q-Fc) were 
compared to the HM-Fc as a control. A p value of < 0.05 was accepted as significant.   
2.2.2.2  Differential Scanning Calorimetry (DSC) 
DSC experiments were performed using a MicroCal VP-AutoDSC instrument with an 
autosampler (MicroCal, LLC, Northampton, MA). Thermograms of protein samples (at 0.4 
mg/mL concentration formulated in 20 mM citrate phosphate buffer adjusted to an ionic strength 
of 0.15 by NaCl at pH 4.5 and 6.0) were obtained from 10°C to 100°C with a scanning rate of 
60°C/h.  Data analysis was performed using the MicroCal LLC DSC plug-in for the Origin 7.0 
software package. The raw thermograms of the protein samples were buffer subtracted using the 





obtain the final thermograms. The final thermograms were fit to a non-two-state unfolding model 
with four transitions to calculate the heat capacity peak maximum (Tm values) of the four 
transitions. The onset temperature (Tonset) of the transitions was determined by identifying the 
point where the heat capacity (Cp) value for the thermal transition reached 500 cal mol–1°C–1.29, 
55  
2.2.2.3 Intrinsic (Trp) fluorescence spectroscopy 
The fluorescence spectrum of each of the IgG1 Fc glycoforms was measured in triplicate 
using a Photon Technology International (PTI) Quantum master fluorometer (New Brunswick, 
New Jersey) with 200 µL of 0.2 mg/mL protein solution in 0.2 cm path length quartz cuvettes.  
Samples were excited at 295 nm (>95% Trp emission) and the emission spectra at 10°C were 
recorded from 305 to 405 nm. For thermal stability measurements, the temperature was raised in 
increments of 1.25°C from 10 to 90°C with a heating rate of 15°C/h. Data were collected and 
spectra were buffer subtracted and analyzed using an in-house software (MiddaughSuite). The 
maximum peak position (λmax) values were calculated using a “spectral center of mass” method 
(MSM) that results a red shift in the peak position by 10–14 nm compared with the actual value, 
but produces a more reproducible measure of spectral shift and a higher signal to noise ratio.51 
2.2.2.4 Extrinsic fluorescence spectroscopy 
The extrinsic fluorescence measurements were performed using a MX3005P QPCR 
system (Agilent Technologies). Samples contained 0.2 mg/mL protein in a total sample volume 
of 100 µL.  The Sypro™ orange dye was purchased from Invitrogen, Inc. (Carlsbad, CA) and 
was supplied in a concentrated form (5000x) and dissolved in dimethyl sulfoxide (DMSO).  The 
stock was diluted to 40x in water and then added to the protein samples to achieve 1x dye 





and the emission intensity change with temperature at 610 nm was followed. The temperature 
was raised from 25 to 90°C using 60°C/h heating rate and 1˚C as a step size.  Data were 
transferred to Excel software (Microsoft, Redmond, Washington) for data analysis. Protein 
samples were run in triplicate and corresponding buffer blanks were run and subtracted from 
each sample spectrum. The fluorescence intensity was plotted against temperature as described 
previously.51 
2.2.2.5 OD 350 nm measurements 
Turbidity measurements were performed using a Cary 100 UV-Visible 
spectrophotometer (Varian medical Systems, Inc., Palo Alto, California) equipped with a 12 cell 
holder with a peltier type temperature controller. Samples contained 0.2 mg/mL protein with a 
total volume of 250 µL in 1 cm path length quartz cells. Optical density at 350 nm was 
monitored as the temperature was raised in increments of 1.25˚C from 10 to 90˚C with a heating 
rate of 60˚C/h.  Protein samples were run in triplicate and corresponding buffer blanks were run 
and subtracted from each sample. The OD at 350nm was plotted against temperature as 
described previously. 51 
2.2.2.6 Construction of EPDs and Radar Charts 
Three-index Empirical Phase Diagrams (EPDs) and Radar Charts were employed to 
visualize the biophysical stability of the four IgG1-Fc glycoforms using in-house software 
(MiddaughSuite).  Detailed descriptions of the construction of both three-index EPDs and radar 
charts are published elsewhere.56,57 Briefly, the 3-index EPDs display structural changes in 
proteins as color changes, based on data sets obtained from three biophysical techniques as a 
function of solution pH and temperature. The three biophysical data sets in this work are 





position, and optical density at 350 nm. For the 3-index EPDs, each dataset was mapped to three 
color components – red, green, and blue, respectively.  For each of the four IgG1-Fc glycoforms, 
and their corresponding extrinsic Sypro Orange fluorescence and turbidity measurements, the 
minimum value in a dataset was mapped to the loss of the color component (e.g., black), and the 
maximum value to the full color intensity. For Trp fluorescence peak position, however, the 
maximum value was mapped to the loss of color component and minimum value to the full color 
component for better visualization. The combination of these RGB values produced a single 
color at each point in pH and temperature space indicating overall structural changes due to the 
applied environmental stress. The individual RGB components were displayed in a separate 
panel alongside the three-index EPDs (see Supplemental Figures 2.4 and 2.5) since the explicit 
display of its RGB components can be helpful in better understanding the interpretation of color 
changes. The color green from intrinsic Trp fluorescence indicates protein structure closest to the 
native state (least amount of structural change).  The color red appears as the Sypro Orange 
binding increases indicating structural alterations in the protein. The blue color appears when 
higher turbidity is measured by optical density values at 350 nm indicating protein aggregation. 
To better define regions of structural similarities and differences, a k-means clustering 
algorithm was applied to the three datasets for identifying boundaries of similar color regions. 
The k-means clustering algorithm calculates k central points (or centroids) in which all samples 
belong to each cluster whose mean is the calculated centroid. The number of clusters (k) was 
selected in advance by visual assessment of the 3-index EPDs and raw biophysical data stability 
profiles.51 
Radar charts were generated to display average readouts of three biophysical datasets 





minimum value in an averaged dataset for a cluster was mapped to the center of the radar chart 
and the maximum value to the outer circumference. Connecting values in each axis yields a final 
polygon to represent a specific structural state.51,56,57 Polygons in a radar chart have smaller areas 
if the protein stays closer to its native state; thus less change is observed from a baseline of the 
analytical readouts from each technique.  
2.3 Results 
2.3.1 Initial Comparisons of Relative Solubility and Conformational Stability  
An assessment of the apparent solubility (thermodynamic activity) of the four IgG1-Fc 
glycoform variants was performed using PEG precipitation as described previously52-54(see 
Methods section). As shown in Figure 2.2, protein vs. % PEG concentration plots were generated 
at pH 4.5 (Figure 2.2A, 2.2B and 2.2C) and pH 6.0 (Figure 2.2D, 2.2E and 2.2F) for various 
glycoforms in a NaCl containing formulation. For ease of comparison, each of the Fc glycoform 
variants (Man5-Fc, GlcNAc-Fc, and N297Q-Fc) were plotted versus the high mannose HM-
IgG1-Fc glycoform. The plots show a sigmoidal curve, demonstrating that as the crowding agent 
PEG concentration increases; there is a point at which a decrease in the amount of the protein in 
solution occurs in a quantifiable manner. The N297Q-Fc at pH 4.5 begins to precipitate rapidly 
as the PEG concentration is increased, and deviates from the typical sigmoidal curve, possibly 
indicating structural alterations in the protein and/or direct interaction between the PEG and 
protein.   
As shown in Figure 2.3A and 2.3B, the % PEGmidpt value is the weight % PEG required 
to reduce the protein concentration by 50% of its initial value. For each of the glycoforms, a 
trend of decreasing % PEGmidpt values with increasing solution pH was observed. More subtle 





Figures 2.2D, E, F and 2.2A, B, C). In terms of general trends, the HM-Fc showed the highest % 
PEGmidpt values followed by Man5-Fc, GlcNAc-Fc and then the non-glycosylated N297Q IgG1-
Fc. Differences in % in PEGmidpt values between the HM-Fc vs. Man5-Fc and GlcNAc-Fc were 
statistically significant at pH 4.5, but at pH 6.0, the differences between HM-Fc vs. Man5-Fc 
were not significant. Significant differences in % PEGmidpt values between the HM-Fc vs. either 
GlcNAc-Fc or N297Q-Fc were observed at both pH values.   
As shown in Figure 2.3C and 2.3D, the apparent solubility (thermodynamic activity) 
values can be calculated by extrapolation to zero PEG concentration53,54 (see Methods section). 
These values showed trends similar to those found with % PEGmidpt in terms of Fc 
oligosaccharide structure and solution pH. At both pH values, the apparent activity values 
between HM-Fc vs. Man-5 glycoforms showed no statistically significant differences. The 
apparent activity values of HM-Fc vs. either GlcNAc-Fc or N297Q-Fc showed statistical 
significant differences at both pH 4.5 and 6.0.   
The overall conformational stability of all the four IgG1-Fc glycoforms at pH 4.5 and pH 
6.0 in a NaCl containing buffer was probed by DSC. Representative thermograms of HM-Fc, 
Man5-Fc, GlcNAc-Fc and N297Q-Fc are shown in Figure 2.4 A-D, respectively. Each of the 
four IgG1-Fc glycoforms showed two major endothermic peaks which could be mathematically 
fit to two Tonset values (Tonset1, Tonset2) and four Tm values (Tm1 , Tm2, Tm3 and Tm4) as 
summarized in Table 2.1. Based on previous studies with human IgG Fc glycoforms from the 
Jefferis lab,58 the Tonset1, Tm1 and Tm2 values correspond to the unfolding of the CH2 domain of 
the IgG1-Fc, while the Tonset2, Tm3 and Tm4 values correspond to the unfolding of the IgG1-Fc 
CH3 domain. In general, these values were lower at pH 4.5 than 6.0 for each of the four IgG1-Fc 





units was observed for the Tonset1, Tm1 and Tm2 values, which correspond to the CH2 domain 
containing the N-linked glycosylation site at pH 4.5 condition: highest values were observed for 
HM-Fc and Man5-Fc, intermediate for GlcNAc-Fc and the lowest for N297Q-Fc (See Table 2.1). 
At the higher pH 6.0 conditions, differences in conformational stability (the Tonset 1, Tm1 and Tm2 
values) versus type of glycosylation were observed when comparing the aglycosylated versus the 
glycosylated forms.    
2.3.2 Physical Stability of IgG1-Fc Proteins as a Function of pH and Temperature using 
High Throughput Biophysical Analyses 
To evaluate the structural integrity and physical stability of the four different IgG1-Fc 
glycoforms over a wider range of conditions, high throughput biophysical analyses were utilized 
using relatively small amounts of material (compared to PEG and DSC analysis). First, the 
structural integrity of the overall tertiary structure of the four IgG1-Fc glycoforms was evaluated 
by measurement of intrinsic Trp fluorescence at 10°C, at pH values from 4.0-7.5 (increments of 
0.5) in formulations containing either NaCl (formulation 1) or Sucrose (formulation 2). For each 
Fc glycoform, the wavelength of maximum intensity (λ max) at each pH was calculated and found 
to be in the range of 328 to 334 nm with standard deviations calculated from triplicate 
measurements of up to ~2 nm  (see Supplemental Figure 2.1). These results indicated that the 
four glycoforms were overall similar (with some minor differences noted).  
The stability of the overall tertiary structure of the four glycoforms was evaluated by 
collecting the intrinsic Trp fluorescence spectra, and plotting the changes in λmax, as a function of 
increasing temperature at each pH condition in the two formulations as shown in Figure 2.5A 
(NaCl) and Figure 2.6A (Sucrose). Note that the λmax values in Figures 2.5A and 2.6A are red 





2.2A and 2.3A with the same physical stability data shown with corresponding standard 
deviation (SD) error bars from triplicate measurements). In formulation 1 (NaCl) with increases 
in temperature, all of the Fc glycoforms showed a subtle increase in peak positions followed by a 
more sudden increase (transition) before plateauing (Figure 2.5A).  Similar trends were observed 
in formulation 2 (sucrose) in Figure 2.6A. 
 The Tm values of thermal transitions were calculated for each of the four IgG1-Fc 
glycoforms at each of the eight pH values in both formulations (see plot of values in the thermal 
stability panel in Figures 2.5A and 2.6A). In general, the Tm values of the intrinsic fluorescence 
thermal transitions for the four glycoforms followed trends dependent upon the type of 
glycoform, the solution pH, and the formulation (NaCl and sucrose). First, the Tm values of 
thermal transitions were the highest for HM-Fc and Man5-Fc followed by intermediate values 
for GlcNAc-Fc and the lowest values for N297Q-Fc under all pH conditions examined and in 
both formulations. Second, for each of the four glycoforms and in both of formulations, the Tm 
values increased with increases in solution pH. These results suggest that the HM-Fc and Man5-
Fc glycoforms display similar, yet distinct, physical stability of the tertiary structure, followed by 
the GlcNAc-Fc with intermediate stability, with the N297Q-Fc aglycosylated form the least 
thermally stable. Each of the IgG1-Fc glycoforms showed lower tertiary structure stability at 
acidic pH values, with increasing thermal stability as the solution pH increased. Finally, the Tm 
values for each of the IgG-Fc glycoforms at each solution pH were relatively higher in 
formulation 2 (sucrose) than in formulation 1 (NaCl).  To better display this latter effect, the 
differences in Tm values (ΔTm) between formulations (sucrose versus NaCl) at each pH 
condition, and for each of the four Fc proteins, are also shown in Figure 2.7A. These differences 





4.0, 4.5 and 5.0).  Each of the four glycoforms is more stable with respect to the overall tertiary 
structure in formulation 2 (sucrose) than in formulation 1 (NaCl).   
A similar set of experiments were performed with extrinsic fluorescence analysis (see 
Figures 2.5B and 2.6B), where Sypro Orange was used as a probe for detecting protein structural 
alterations seen as increased fluorescence intensity upon exposure of the dye to increased apolar 
environments (presumably as a result of structural changes and/or aggregate formation by the 
protein). Alterations in apolar nature of the four IgG1-Fc glycoforms vs. temperature were 
monitored by following changes in Sypro Orange fluorescence intensity in the two formulations. 
(See Supplementary Figures 2.2B and 2.3B for the same physical stability data with 
corresponding SD error bars from triplicate measurements). The Sypro Orange fluorescence peak 
intensity at the starting temperature (10°C) in the N297Q-Fc in both formulations trended 
relatively higher, and showed more variability across the pH range, compared to other three 
forms. The GlcNAc-Fc also displayed similar elevated signals at low pH, but to somewhat lesser 
extent than the aglycosylated Fc protein.  
The Tm values of the transitions in the Sypro Orange fluorescence intensity versus 
temperature curves were calculated and plotted for the four Fc glycoforms at all 8 pH conditions 
in both formulations; see thermal stability panels in Figures 2.5B and 2.6B. As certain proteins at 
some pH conditions exhibited multiple thermal transitions, Tm values of the major thermal 
transition were calculated for simplicity for these initial comparisons. The Tm values of extrinsic 
Sypro Orange fluorescence thermal transitions for the four IgG1-Fc glycoforms again followed 
specific trends dependent upon the type of glycoform, the solution pH, and the formulation 
composition (NaCl and sucrose). First, the Tm values of major transitions in peak intensity versus 





intermediate values for GlcNAc-Fc and lowest values for N297Q-Fc in both formulations.  
Second, for each of the four IgG1-Fc glycoforms, the Tm values increased with increases in the 
solution pH in both the formulations. Additionally, in both formulations for all four proteins, two 
thermal transitions were observed at lower pH values (e.g., pH 4.0, 4.5, 5.0) (see Figures 2.5B 
and 2.6B). Finally, the Tm values for each of the glycoforms were relatively higher in 
formulation 2 (sucrose) than in formulation 1 (NaCl).  The differences in Tm values (ΔTm) 
between the sucrose and NaCl formulations for the four IgG1-Fc proteins are plotted in Figure 
2.7B. Note that the differences are more prominent at lower pH values (e.g., pH 4.0, 4.5 and 5.0). 
These results indicate that with respect to their tertiary structure stability as measured by 
extrinsic Sypro orange fluorescence measurements, the N297Q aglycosylated form is least 
thermally stable, followed by the GlcNAc-Fc glycoform with intermediate stability, and the 
highest thermal stability seen with the HM-Fc and Man5-Fc glycoforms. These trends in the 
physical stability profiles are similar to the intrinsic fluorescence spectroscopy results.  For the 
less stable glycoforms, the lower pH values (4.0 and 4.5), trended toward an apparent higher 
surface hydrophobicity even at lower temperatures, suggesting some level of structural alteration 
under these conditions.  Each of the glycoforms is more thermally stable in sucrose than in NaCl 
under most pH conditions tested, particularly at the lower pH values (e.g., 4.0, 4.5 and 5.0).   
As final set of experiments, the temperature-induced aggregation was evaluated by 
monitoring optical density (OD) changes at 350 nm (average of 3 replicates) as a function of 
increasing temperature from pH 4.0-7.5 (at intervals of 0.5) and in the two formulations (see 
Figures 2.5C and 2.6C). (See Supplementary Figures 2.2C and 2.3C with the same physical 
stability data with corresponding SD error bars from triplicate measurements.) Differences in 





formulation conditions. The HM-Fc and Man5-Fc glycoforms did not show any notable 
increases in OD350 values as the temperature increased across all of the pH conditions tested in 
both formulations. The GlcNAc-Fc and N297Q-Fc samples displayed single thermal transitions 
between pH 5.0 to 7.0 in both formulations. The GlcNAc-Fc glycoform showed two transitions 
at pH 6.0 in formulation 2 (sucrose), and a single thermal transition at pH 7.5 in formulation 1 
(NaCl). At pH 4.0 and 4.5, no detectable changes in OD350 values versus temperature were 
observed for all of the four glycoforms in both the formulations.  
The onset temperature values (Tonset), where a rapid increase in OD350 was observed, 
were calculated for each of the four glycoforms at all eight pH conditions and in both 
formulations (Figure 2.5C and 2.6C). The Tonset values were determined by noting the 
temperature at which the transition starts. The Tonset values for triplicate runs were in the range of 
77-85°C with standard deviations (SD) from 0 to 2.6°C for the four Fc glycoforms. However, the 
GlcNAc-Fc at pH 6.0 in formulation 2 (sucrose) showed the first Tonset at 54.1°C and a second at 
75.3°C. The results indicate that GlcNAc-Fc is the most aggregation prone glycoform followed 
by the N297Q-Fc. The HM-Fc and Man5-Fc Fc proteins are not prone to aggregation at any of 
the solution conditions tested here. 
2.3.3 Physical Stability Evaluations and Comparisons between IgG1-Fc glycoform 
variants using Data Visualization Techniques 
Using the physical stability data sets acquired from intrinsic fluorescence spectroscopy, 
extrinsic Sypro orange fluorescence, and turbidity measurements, 3-index empirical phase 
diagrams (EPDs) (left panels) and radar charts (right panels) were constructed for each of the 
individual IgG1-Fc glycoforms formulated in either NaCl (Figure 2.8) or sucrose (Figure 2.9). 





shown in Supplementary Figures 2.4 and 2.5.  Analysis of the raw biophysical data, the 3-index 
EPDs, and their corresponding individual RGB color indices were then used as a basis to visually 
identify regions with similar structural characteristics. These numerical values were then used for 
clustering analysis to identify the primary structural regions for each protein (as a function of pH 
and temperature) as displayed in the radar chart diagrams on the right panels of Figure 2.8 and 
Figure 2.9. 
In each of the four Fc proteins in 2 formulations, the 3-index EPDs show a green region 
that represents a state in which the IgG1-Fc glycoforms exist in their most native-like 
conformation. In this green region, minimal structural changes were observed in Trp 
fluorescence position, whereas other color components were suppressed on account of low 
signals from their corresponding techniques. In the radar charts, region A corresponds to this 
native-like green region in the EPD displayed as a polygon with the smallest area.  Further, the 
percent areas of this native-like region A were calculated. The percent areas for region A in 
formulation 1 (NaCl) for both HM-Fc and Man5-Fc were 51%, GlcNAc-Fc 40% and N297Q-Fc 
26%, while the percent areas for region A in formulation 2 (sucrose) were 56%, 55%, 51% and 
48% for HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc, respectively.  
Similarly, regions B and C in the radar charts correspond to the bright red/orange and 
dark red colors in the 3-index EPDs. These regions represent structurally altered forms of the Fc 
glycoforms as indicated by increases in the Sypro orange fluorescence (region B) and 
fluorescence peak position (region C). Region D in the radar charts, observed in the GlcNAc-Fc 
and N297Q-Fc forms only, represents an aggregated state of the Fc glycoforms with increased 
optical density at 350nm. This region D in the radar chart corresponds to a blue color in the 3-





index EPDs and radar charts in both formulations across all pH conditions that were tested 
(Figures 2.8 and 2.9) as described in the discussion. 
2.4 Discussion 
The objective of this work was to examine the effect of the oligosaccharide structure 
occupying both of the N-linked 297 glycosylation sites in a series of four well-defined IgG1-Fc 
proteins on physical stability and solubility of these proteins under different solution conditions 
(pH, temperature and formulation additives). The HM-Fc, Man5-Fc, and GlcNAc-Fc glycoforms 
along with the N297Q-Fc aglycosylated protein were first evaluated by DSC and in a PEG 
precipitation assay, a previously described method to assess the relative apparent solubility of 
protein molecules by measuring the amount of PEG required to precipitate the protein from 
solution.51,56,57 Because these 2 methods require relatively large amounts of protein (several 
milligrams), the 4 proteins were evaluated in only 1 formulation (citrate-phosphate buffer with 
NaCl) at 2 pH values (4.5 and 6.0). In the next set of experiments, 3 different high-throughput 
biophysical analyses were utilized since relatively small amounts of protein are required (~0.1-
0.2 mg per condition). This allowed us to assess the physical stability of the four IgG1-Fc 
proteins under a range of solution conditions, including a wider range of temperature (10 ˚C -
90˚C), solution pH (4.0-7.5) and different formulation additives (NaCl vs sucrose). The latter not 
only permitted more extensive evaluations to compare the effect of oligosaccharide structure on 
IgG1-Fc physical stability, but provided much larger datasets required for the modeling of 
biosimilarity described by Kim JH et al.50 
Solubility of mAbs is a crucial aspect of formulation development and can affect 
stability, activity, and potentially immunogenicity. Glycosylation is known to affect protein 





glycosylation type with mAbs.  For example, 1 previous report demonstrated an additional 
glycosylation within the Fab region of a mAb greatly increased solubility59, while another 
showed dramatic decreased solubility due to additional glycosylation of the variable region of an 
isolated human IgG cryoimmunoglobulin.60 In this work, we examined the effect of 
oligosaccharide structure occupying both of the N297 sites in the CH2 domain in an IgG1-Fc. 
Relative apparent solubility (thermodynamic activity) profiles of IgG1-Fc glycoforms were 
determined using PEG precipitation assay measured by a combination of the curve shape (PEG 
versus protein concentrations), PEG midpoint numbers, and apparent solubility (thermodynamic 
activity) values. A trend of oligosaccharide structure vs. IgG-Fc apparent solubility  
(thermodynamic activity) was established with the HM-Fc and Man5-Fc glycoforms displaying 
the highest (yet distinct) relative values, GlcNAc-Fc glycoform showing intermediate, and the 
N297Q-Fc aglycosylated form having the lowest relative values at both pH 4.5 and pH 6.0.   
Similarly, when conformational stability of the four Fc glycoforms was initially assessed 
by DSC at pH 4.5 in the NaCl-containing formulation, the thermal onset (Tonset1) and thermal 
melting temperatures (Tm1 and Tm2), corresponding to the CH2 domain of IgG-Fc proteins, 
displayed higher temperatures with increasing the glycan size. HM-Fc and Man5-Fc glycoforms 
had the highest relative thermal stability, intermediate stability was shown by the GlcNAc-Fc 
glycoform, and the N297Q-Fc aglycosylated form displayed the lowest stability. At pH 6.0, 
notable differences in Tonset1, Tm1 and Tm2 values were noted only between the glycosylated vs. 
the aglycosylated Fc proteins. Differences in DSC thermal melting values between glycosylated 
(G2 form) and aglycosylated (peptide-N-glycosidase [PNGase] treated) human IgG1-Fc at pH 





These initial experiments established a key role of Fc glycosylation oligosaccharide 
structure in the apparent solubility and conformational stability of the IgG-Fc glycoproteins 
under the limited experimental conditions. The physical stability profiles of the four IgG1-Fc 
proteins under a wider range of solution conditions, including temperatures (10 ˚C-90˚C), 
solution pH (4.0-7.5) and different formulation additives (NaCl vs sucrose), were then examined. 
As shown in Figures 2.5 and 2.6, large physical stability data sets, consisting of thousands of 
data points, were generated and then analyzed by data visualization techniques developed 
previously in our labs56,57 including three-index empirical phase diagrams and radar charts 
(Figures 2.8 and 2.9). These data visualization tools permit a direct comparison of the physical 
stability profiles of each of the 4 IgG1-Fc proteins across a wide range of environmental 
conditions.  
As a starting point in these comparisons, the different structural alterations in the proteins 
that occur due to exposure to different temperature and pH were identified by analysis the data 
from the three biophysical methods as summarized in the radar chart displays in Figures 2.8 and 
2.9. For example, the 4 glycoforms of IgG1-Fc show different physical stability profiles by 
comparing the areas of region A (native-like) in the radar charts. In formulation 1 (NaCl) and 2 
(sucrose), the temperatures at which the transitions from the native region (A) to the structurally 
altered regions (B and C) occur at the highest values (across the pH range) in the HM-Fc and 
Man5-Fc glycoforms, intermediate in the GlcNAc-Fc glycoform and the lowest in the N297Q-Fc 
aglycosylated form.  Furthermore, the percent area of native like region A (green colored region) 
is the highest in the HM-Fc and Man5-Fc glycoforms, intermediate in the GlcNAc-Fc glycoform 
and least in the N297Q-Fc glycoform as described above. These results reveal that the HM-Fc 





with the aglycosylated N297Q-Fc form being the least thermally stable. There is also an increase 
in the intensity and area of region B (orange and red color) from HM-Fc, Man5, GlcNAc to 
N297Q-Fc glycoforms, which indicates that the HM-Fc and Man5-Fc manifest overall lower 
exposure of hydrophobic surfaces than the GlcNAc-Fc and N297Q-Fc forms, with the N297Q-Fc 
having the highest overall exposed apolar areas. The presence of region D in the radar charts in 
the GlcNAc-Fc and N297Q-Fc samples shows the increased aggregation propensity of these 2 
samples compared to the HM-Fc and Man5-Fc glycoforms. 
In both formulations, each of the IgG1-Fc glycoforms show decreased thermal stability at 
lower pH values. The physical stability profile increases with increases in pH, as indicated by the 
temperatures at which the structural transitions from the native-like region (A) to the structurally 
altered regions (B ,C, D) occur in the radar charts. We observed similar trends previously with 
the di-glycosylated HM-Fc and aglycosylated N297Q-Fc molecules in a NaCl buffer when used 
as controls to evaluate the effect site occupancy and Asn/Asp residues at site N297.51  In 
addition, the effect of the formulation conditions on the physical stability of each IgG1-Fc 
glycoform is also evident. The areas of the native like region A (green region) in the radar charts 
are higher in the formulation 2 (with sucrose) compared to region A in formulation 1 (with salt). 
In the presence of sucrose, the temperatures at which the transitions from the native region (A) to 
the structurally altered regions (B and C) occur are higher in all four glycoforms than in 
formulation 1 (with salt).  These results indicate that sucrose offers improved thermal physical 
stability profiles for each of the four glycoforms of IgG1-Fc compared to NaCl, particularly at 
the lower pH conditions.  
It is of interest to compare our results with recent studies from other labs examining other 





Zheng et al18 compared glycosylation variants of a Chinese Hamster Ovary (CHO) produced 
IgG1 full-length mAb which included a G0 form, an afucosylated variant of G0 (that exhibits 
enhanced ADCC), a high mannose form, and a deglycosylated form (from PNGase treatment). 
Through a comparison of higher order structure, thermal unfolding, protease digestion and 
stability between these glycosylation variants, it was concluded that deglycosylated and high 
mannose IgG1 forms were relatively less stable (e.g., as shown by DSC in a pH range of 4.0-
7.5), while the G0 and afucosylated G0 forms showed higher thermal stability.  The high 
mannose and deglycosylated forms also showed more rapid pepsin digestion.18 In another study 
by Zheng et al (2011)61, a comparison between fully glycosylated forms and PNGase-cleaved 
deglycosylated forms of IgG1 mAbs showed decreased thermal stability of the CH2 domains of 
the deglycosylated forms by DSC at pH 5.5.  In our studies, we have seen similar trends with 
decreased conformational stability (DSC) and physical stability profiles of non-glycosylated 
N297Q IgG1-Fc compared to the HM-Fc and Man5-Fc forms.  However, the HM-Fc and Man-5-
Fc were shown to be overall similar by DSC and their physical stability profiles, with some 
minor differences noted between the 2 forms depending on the analytical method, solution pH 
and formulation. This could reflect differences between IgG1-Fc versus a full-length IgG1 mAb 
as well as differences in HM content in the two studies (Man9 vs. this study with HM 
glycoforms having distributions of Man8-Man12, with the majority in Man8 forms).  
Zheng et al.61 showed by SEC that deglycosylated IgG1 mAbs had higher aggregation 
rates than their glycosylated counterparts as a result of an accelerated stability study at pH 5.5.  
These results correlate with our studies that show the GlcNAc-Fc and the non-glycosylated 
N297Q-Fc (glycoforms with 1 GlcNAc sugar and no sugar, respectively) have the highest 





Fc and Man5-Fc which showed no aggregation). Similar findings regarding the non-aggregating 
tendencies of high-mannose IgG1 mAbs were shown as a result of real time and accelerated 
stability studies.20 Finally, the effect of pH, temperature and salt on the stability, acid induced 
unfolding and aggregation of CHO (glycosylated) and Escherichia coli (aglycosylated) derived 
IgG1 Fc molecules has also been examined.19,62  An interesting observation was made regarding 
a critical role of the CH2 domain in determining the rate and extent of Fc aggregation, which 
correlated with the presence or absence glycosylation at the Asn-297.62 It has been proposed that 
the presence of glycosylation in the CH2 domain masks hydrophobic aggregation motifs and is 
crucial in preventing aggregation of IgG mAbs.63 It was also demonstrated that CHO derived 
(glycosylated) IgG1-Fc protein is not only more compact and more thermally stable than the E. 
coli derived (aglycosylated) protein at neutral pH, but the thermal stability was pH and salt 
dependent where lower pH and higher salt conditions were more unfavorable. Similar effects of 
solution conditions were observed in our studies where IgG1-Fc glycoform stability increased 
with increasing solution pH and in presence of sucrose (instead of NaCl).   
This work not only demonstrates the effect of oligosaccharide structure of IgG1-Fc on 
pharmaceutical properties (e.g., apparent solubility and physical stability) under different 
solution conditions, but also contributes towards the development of new analytical approaches 
and data visualization tools to assess structural integrity and conformational stability and makes 
comparisons between different versions of the same biopharmaceutical molecule (using well-
defined IgG1-Fc glycoforms as a model system). This systematic approach of using EPDs and 
radar charts to compare physical stability profiles successfully recognizes subtle similarities and 
differences among different versions of the same protein (as would be done in comparability or 





pattern) or formulation composition (NaCl vs. sucrose), physical stability differences between 
the 8 different samples (4 different Fc glycoforms in 2 different formulations) was established. 
Thus, this model system shows proof of concept of an efficient protocol to evaluate the effect of 
process and product changes on the structural integrity and physical stability as part of 
comparability assessments.41,42,64 Future applications could also address potential stability 
differences between different batches of the same process due to lot-to-lot variability of process 
and product impurities. Similar challenges now exist for establishing similarity between 
biopharmaceuticals produced by innovator versus biosimilar manufacturers. Comparative data 
sets of molecules containing information on post-translational modifications, higher-order 
structures and accelerated stability are an important part of formulation development and 
biosimilarity assessments.  As described by (Kim JH et al)50, these large physical stability data 
sets are used as a model system to establish a new method of mathematical modeling for 














Table 2.1: Summary of Thermal Onset Temperatures (Tonset1, Tonset2) and Thermal Melting 
Temperatures (Tm1, Tm2, Tm3, Tm4) for the four IgG1-Fc glycoforms (HM-Fc, Man5-Fc, GlcNAc-
Fc and N297Q-Fc) at two different pH conditions (pH 4.5 and pH 6.0) measured by DSC. 
Samples were prepared at 0.4 mg/mL in 20 mM citrate–phosphate buffer and adjusted to an ionic 
strength of 0.15 by addition of NaCl. Results are reported in °C as average and standard 








 Tonset1 Tonset2 Tm1 Tm2 Tm3 Tm4 
pH 6.0 
HM-Fc 55.0±0.8 72.4±0.3 61.7±0.3 66.0±0.2 80.7±2.6 82.1±2.4 
Man5-Fc 56.7±0.6 71.9±0.3 62.7±0.3 66.0±0.0 78.4±0.1 83.4±0.1 
GlcNAc-Fc 58.5±0.4 72.1±0.3 62.9±0.8 65.5±0.5 77.7±0.3 83.2±0.1 
N297Q-Fc 52.5±0.2 71.2±0.7 57.2±1.1 61.0±0.4 79.0±0.0 83.4±0.0 
pH 4.5 
HM-Fc 42.8±1.7 64.0±3.4 49.8±0.4 53.9±0.2 73.8±1.1 78.9±0.2 
Man5-Fc 42.0±2.1 60.5±0.7 50.1±0.2 53.5±0.1 71.7±0.2 77.8±0.2 
GlcNAc-Fc 39.9±0.3 65.4±0.4 45.9±0.6 50.0±0.3 73.0±0.1 78.6±0.0 






Figure 2.1: Schematic representation of the four well-defined IgG1-Fc glycoforms characterized 
in this work in terms of physical stability profiles.  The high mannose IgG1-Fc (HM-Fc) was 
expressed in yeast and purified, and upon treatment with enzymes α-mannosidase 1A and 
endoglycosidase-H, produced two fully homogeneous glycoforms IgG1-Fc Man5GlcNAc2 
(Man5-Fc) and IgG1-Fc GlcNAc (GlcNAc-Fc), respectively.  Site-directed mutagenesis was 











Figure 2.2: Concentration of each IgG1-Fc glycoform (HM-Fc, Man5-Fc, GlcNAc-Fc and 
N297Q-Fc) versus amount of PEG added to solution. Each panel shows results of HM-Fc for 
ease of comparison. Samples were formulated in citrate-phosphate buffer with ionic strength 
adjusted to 0.15 by NaCl at pH 4.5 (A,B,C) and pH 6.0 (Panel D,E,F), respectively.  The error 







Figure 2.3: Comparison of apparent solubility (thermodynamic activity) parameters of the each 
of IgG1-Fc glycoforms (Man5-Fc, GlcNAc-Fc and N297Q-Fc) to HM-Fc glycoform by PEG 
precipitation assay at pH 4.5 and pH 6.0. A and B show the comparison of PEGmidpt values (w/v) 
at pH 4.5 and pH 6.0, respectively.  C and D show the comparison of the apparent solubility 
(activity) values at pH 4.5 and pH 6.0, respectively. Error bars indicate the standard deviation of 
3 replicates. * Statistical significance compared to the HM-Fc with a p value <0.05 is indicated. 
**No calculated parameters for N297Q-Fc at pH 4.5 were possible due to the non-ideal nature of 







Figure 2.4: Comparison of representative curve-fitted DSC thermograms of 4 IgG1-Fc 
glycoforms; HM-Fc (Panel A), Man5-Fc (Panel B), GlcNAc-Fc (Panel C) and N297Q-Fc (Panel 
D) at two different pH conditions (pH 4.5 and pH 6.0). Samples were a 0.4 mg/mL in 20 mM 











Figure 2.5: Biophysical characterization of four well-defined glycoforms of IgG1-Fc (HM-Fc, 
Man5-Fc, GlcNAc-Fc and N297Q-Fc) vs. temperature across the pH range of 4.0–7.5 in a 
solution containing NaCl (formulation 1). Biophysical measurements include (A) intrinsic Trp 
fluorescence, (B) extrinsic Sypro Orange fluorescence spectroscopy, and (C) optical density at 
350 nm. Thermal stability panel displays Tm values obtained from intrinsic Trp fluorescence and 
extrinsic Sypro orange fluorescence thermal melting curves, and Tonset values obtained from 
turbidity (O.D. at 350 nm versus temperature) measurements. Samples were prepared at 0.2 







Figure 2.6: Biophysical characterization of four glycoforms of IgG1-Fc (HM-Fc, Man5-Fc, 
GlcNAc-Fc and N297Q-Fc) vs. temperature across the pH range of 4.0–7.5 in a solution 
containing sucrose (formulation 2). Biophysical measurements include (A) intrinsic Trp 
fluorescence, (B) extrinsic Sypro Orange fluorescence spectroscopy, and (C) optical density at 
350 nm. Thermal stability panel displays Tm values obtained from intrinsic Trp fluorescence and 
extrinsic Sypro orange fluorescence thermal melting curves, and Tonset values obtained from 
turbidity (O.D. at 350 nm versus temperature) measurements. Samples were prepared at 0.2 







Figure 2.7: Summary of thermal stability trends vs. solution pH for the 4 well-defined IgG1-Fc 
glycoforms in sucrose vs. NaCl containing formulations.  Bar chart displays of ΔTm values of 
each protein in sucrose versus NaCl, ΔTm = (Tm sucrose–Tm NaCl), as obtained from (A) 
intrinsic fluorescence and (B) extrinsic Sypro orange fluorescence thermal melting curves. The 
IgG1-Fc glycoforms (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) were formulated in 20 mM 
citrate phosphate buffer at the indicated pH values with either NaCl added to I=0.15 (formulation 








Figure 2.8: Data visualization of the physical stabilty data sets (see Figure 2.5) of the 4 well-
defined IgG1-Fc glycoforms in formulation 1 (NaCl). 3-index empirical phase diagrams (left 
panels) and radar charts (right panels) for each IgG1-Fc protein (HM-Fc, Man5-Fc, GlcNAc-Fc 
and N297Q-Fc) across the pH range of 4.0–7.5 and temperature range of 25°C-90°C are shown. 
Biophysical measurements include intrinsic Trp and extrinsic Sypro Orange fluorescence 
spectroscopy, as well as optical density at 350 nm. Samples contained 0.2 mg/mL in 20 mM 






Figure 2.9: Data visualization of the physical stabilty data sets (see Figure 2.6) of the four well-
defined IgG1-Fc glycoforms in formulation 2 (sucrose). Three-index empirical phase diagrams 
(left panels) and radar charts (right panels) for each of the IgG1-Fc proteins (HM-Fc, Man5-Fc, 
GlcNAc-Fc and N297Q-Fc) across the pH range of 4.0–7.5 and temperature range of 25-90°C 
are shown. Biophysical measurements include intrinsic Trp and extrinsic Sypro Orange 
fluorescence spectroscopy as well as optical density at 350 nm. See Figure 2.5 legend for 





mg/mL in 20 mM citrate-phosphate buffer at indicated pH with 10% sucrose (w/v; formulation 
2). 
In figures 2.8 and 2.9, Regions A (Green) represent regions where the IgG-Fc Fc proteins exist in 
the native-like conformation. Regions B (Orange) and C (Brown) represent regions where the 
same proteins exist at an altered structural state as seen from an increase in Sypro Orange and 
Trp fluorescence signals, respectively. Region D (Blue) represents a region where the Fc 
























Supplementary Figure 2.1: Intrinsic (Trp) fluorescence spectra at 10°C of four well-defined 
glycoforms of IgG1-Fc (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) across the pH range of 
4.0–7.5 in 2 solutions containing either NaCl (formulation 1-NaCl) or sucrose (formulation 2-
sucrose). The λmax values are also shown for each protein at each pH condition. Each of the 











Supplementary Figure 2.2: Biophysical characterization of four well-defined glycoforms of 
IgG1-Fc (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) versus temperature across the pH range 
of 4.0–7.5 in a solution containing NaCl (formulation 1). Biophysical measurements include (A) 
intrinsic Trp fluorescence, (B) extrinsic Sypro Orange fluorescence spectroscopy, and (C) optical 
density at 350 nm. Thermal Stability panel displays Tm values obtained from intrinsic Trp 
fluorescence and extrinsic Sypro orange fluorescence thermal melting curves, and Tonset values 
obtained from turbidity (O.D. at 350 nm vs. temperature) measurements. Samples were prepared 
at 0.2 mg/mL in 20 mM citrate phosphate buffer with NaCl added to I=0.15 at the indicated pH 





ranged from 0-2 nm, the SD of Sypro orange fluorescence intensity ranged from 5-970 
fluorescence intensity units, and the SD of optical density ranged from 0.001-0.07 OD. The SD 
of Tm values obtained from intrinsic Trp fluorescence ranged from 0.1-1.6°C, SD of  Tm values 
obtained from extrinsic Sypro orange fluorescence thermal melting curves ranged from 0-4.0°C, 
and the SD of the Tonset values obtained from turbidity (O.D. at 350 nm vs. temperature) 























Supplementary Figure 2.3: Biophysical characterization of four glycoforms of IgG1-Fc (HM-
Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) vs. temperature across the pH range of 4.0–7.5 in a 
solution containing sucrose (formulation 2). Biophysical measurements include (A) intrinsic Trp 
fluorescence, (B) extrinsic Sypro Orange fluorescence, and (C) optical density at 350 nm. 
Thermal Stability panel displays Tm values obtained from intrinsic Trp fluorescence and extrinsic 
SYPRO orange fluorescence thermal melting curves, and Tonset values obtained from turbidity 
(O.D. at 350 nm vs. temperature) measurements.  Samples were prepared at 0.2 mg/mL in 20 
mM citrate-phosphate buffer, 10% sucrose (w/v) at the indicated pH values.  Each sample was 
run in triplicate and the standard deviation (SD) of peak positions ranged from 0-2 nm, the SD of 





of optical density ranged from 0.001-0.07 OD.  The SD of Tm values obtained from intrinsic Trp 
fluorescence ranged from 0.05-1.6°C, the SD of Tm values obtained from extrinsic Sypro orange 
fluorescence thermal melting curves ranged from 0.1°C -1.7°C, and the SD of Tonset values 

























Supplementary Figure 2.4: Data visualization of the physical stabilty data sets (see Figure 2.5) 
of the four well-defined IgG1-Fc glycoforms in formulation 1 (NaCl). 3-index empirical phase 
diagrams (left panels) alongside readouts from individual RGB components (right panels) for 
each IgG1-Fc protein (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) across the pH range of 
4.0–7.5 and temperature range of 25°C 90°C are shown. Biophysical measurements include 





350 nm (B). The combination of these RGB values produces a single color at each pH and 
temperature point.  In the three-index EPDs, green represent regions where the IgG-Fc Fc protein 
exists in the native-like conformation. Regions orange and brown represent regions where the 
same proteins exist at an altered structural state as seen from an increase in Sypro Orange and 
Trp fluorescence signals, respectively. Blue region represents a region where the Fc 
glycoproteins are in an aggregated state as seen by an increased optical density signal.  See 
Methods section for description of preparation of 3-index EPDs.  Samples contained 0.2 mg/mL 





















Supplementary Figure 2.5: Data visualization of the physical stabilty data sets (see Figure 2.6) 
of the four well-defined IgG1-Fc glycoforms in formulation 2 (sucrose). Three-Index Empirical 
Phase Diagrams (left panels) alongside readouts from individual RGB components (right panels) 
for each IgG1-Fc protein (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) across the pH range of 
4.0–7.5 and temperature range of 25°C-90°C are shown. Biophysical measurements include 
intrinsic Trp fluorescence(G), extrinsic Sypro Orange fluorescence spectroscopy(R), and optical 





and temperature point. In the three-index EPDs, green represent regions where the IgG-Fc Fc 
protein exists in the native-like conformation. Regions orange and brown represent regions 
where the same proteins exist at an altered structural state as seen from an increase in Sypro 
Orange and Trp fluorescence signals, respectively. Blue region represents a region where the Fc 
glycoproteins are in an aggregated state as seen by an increased optical density signal.  See 
Methods section for description of preparation of three-index EPDs. Samples contained 0.2 

























1. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA 2007. The impact of 
glycosylation on the biological function and structure of human immunoglobulins. Annual 
review of immunology  25:21-50. 
2. Alain Beck TW, Christian Bailly and Nathalie Corvaia May 2010. Strategies and 
challenges for the next generation of therapeutic antibodies. Nature Reviews Immunology  
10:345-352. 
3. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA 2014. Emerging Principles 
for the Therapeutic Exploitation of Glycosylation. Science  343(6166). 
4. Ecker DM, Jones SD, Levine HL 2015. The therapeutic monoclonal antibody market. 
mAbs  7(1):9-14. 
5. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianferani S 2013. 
Characterization of therapeutic antibodies and related products. Analytical chemistry  85(2):715-
736. 
6. Niwa R, Satoh M 2015. The current status and prospects of antibody engineering for 
therapeutic use: focus on glycoengineering technology. Journal of pharmaceutical sciences  
104(3):930-941. 
7. Jefferis R 2009. Glycosylation as a strategy to improve antibody-based therapeutics. 
Nature reviews Drug discovery  8(3):226-234. 
8. Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, Jefferis R 2001. 
Role of oligosaccharide residues of IgG1-Fc in FcγRIIb binding. Journal of Biological Chemistry  
276(49):45539-45547. 
9. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P 2003. Structural Analysis of 
Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural 
Integrity. Journal of Molecular Biology  325(5):979-989. 
10. Hristodorov D, Fischer R, Linden L 2013. With or without sugar? (A)glycosylation of 





11. Yu X, Baruah K, Harvey DJ, Vasiljevic S, Alonzi DS, Song B-D, Higgins MK, Bowden 
TA, Scanlan CN, Crispin M 2013. Engineering Hydrophobic Protein–Carbohydrate Interactions 
to Fine-Tune Monoclonal Antibodies. Journal of the American Chemical Society  135(26):9723-
9732. 
12. Lin C-W, Tsai M-H, Li S-T, Tsai T-I, Chu K-C, Liu Y-C, Lai M-Y, Wu C-Y, Tseng Y-C, 
Shivatare SS, Wang C-H, Chao P, Wang S-Y, Shih H-W, Zeng Y-F, You T-H, Liao J-Y, Tu Y-
C, Lin Y-S, Chuang H-Y, Chen C-L, Tsai C-S, Huang C-C, Lin N-H, Ma C, Wu C-Y, Wong C-
H 2015. A common glycan structure on immunoglobulin G for enhancement of effector 
functions. Proceedings of the National Academy of Sciences  112(34):10611-10616. 
13. Liu L 2015. Antibody Glycosylation and Its Impact on the Pharmacokinetics and 
Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins. Journal of 
pharmaceutical sciences  104(6):1866-1884. 
14. Anthony RM, Wermeling F, Ravetch JV 2012. Novel roles for the IgG Fc glycan. Ann N 
Y Acad Sci  1253:170-180. 
15. Li H, d'Anjou M 2009. Pharmacological significance of glycosylation in therapeutic 
proteins. Current opinion in biotechnology  20(6):678-684. 
16. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer 
R 2012. Production, characterization, and pharmacokinetic properties of antibodies with N-
linked mannose-5 glycans. mAbs  4(4):475-487. 
17. Sola RJ, Griebenow K 2009. Effects of glycosylation on the stability of protein 
pharmaceuticals. Journal of pharmaceutical sciences  98(4):1223-1245. 
18. Zheng K, Yarmarkovich M, Bantog C, Bayer R, Patapoff TW 2014. Influence of 
glycosylation pattern on the molecular properties of monoclonal antibodies. mAbs  6(3):649-658. 
19. Li CH, Narhi LO, Wen J, Dimitrova M, Wen ZQ, Li J, Pollastrini J, Nguyen X, Tsuruda 
T, Jiang Y 2012. Effect of pH, temperature, and salt on the stability of Escherichia coli- and 
Chinese hamster ovary cell-derived IgG1 Fc. Biochemistry  51(50):10056-10065. 
20. Lu Y, Westland K, Ma YH, Gadgil H 2012. Evaluation of effects of Fc domain high-
mannose glycan on antibody stability. Journal of pharmaceutical sciences  101(11):4107-4117. 
21. Wang W, Singh S, Zeng DL, King K, Nema S 2007. Antibody structure, instability, and 
formulation. Journal of pharmaceutical sciences  96(1):1-26. 
22. Jefferis R 2012. Isotype and glycoform selection for antibody therapeutics. Archives of 





23. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G 2012. Revisiting the role of 
glycosylation in the structure of human IgG Fc. ACS chemical biology  7(9):1596-1602. 
24. Buck PM, Kumar S, Singh SK 2013. Consequences of glycan truncation on Fc structural 
integrity. mAbs  5(6):904-916. 
25. Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, Shitara K, 
Kato K 2006. Glycoform-dependent conformational alteration of the Fc region of human 
immunoglobulin G1 as revealed by NMR spectroscopy. Biochimica et biophysica acta  
1760(4):693-700. 
26. Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR 2009. Characterization of IgG1 
Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass 
Spectrometry. Analytical chemistry  81(7):2644-2651. 
27. Kameoka D, Masuzaki E, Ueda T, Imoto T 2007. Effect of buffer species on the 
unfolding and the aggregation of humanized IgG. Journal of biochemistry  142(3):383-391. 
28. Wang T, Kumru OS, Yi L, Wang YJ, Zhang J, Kim JH, Joshi SB, Middaugh CR, Volkin 
DB 2013. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal 
antibody antigen-binding fragment. Journal of pharmaceutical sciences  102(8):2520-2537. 
29. Cheng W, Joshi SB, He F, Brems DN, He B, Kerwin BA, Volkin DB, Middaugh CR 
2012. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a 
model IgG2 monoclonal antibody: conformational stability and kinetic aggregation 
measurements. Journal of pharmaceutical sciences  101(5):1701-1720. 
30. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL 2011. Glycosylation 
influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnology 
Journal  6(1):38-44. 
31. Hristodorov D, Fischer R, Joerissen H, Muller-Tiemann B, Apeler H, Linden L 2013. 
Generation and comparative characterization of glycosylated and aglycosylated human IgG1 
antibodies. Molecular biotechnology  53(3):326-335. 
32. Raju TS. 2010. Impact of Fc Glycosylation on Monoclonal Antibody Effector Functions 
and Degradation by Proteases. In Shire SJ, Gombotz W, Bechtold-Peters K, Andya J, editors. 
Current Trends in Monoclonal Antibody Development and Manufacturing, ed., New York, NY: 
Springer New York. p 249-269. 
33. Liu H, Bulseco GG, Sun J 2006. Effect of posttranslational modifications on the thermal 





34. Sedlak E, Schaefer JV, Marek J, Gimeson P, Pluckthun A 2015. Advanced analyses of 
kinetic stabilities of iggs modified by mutations and glycosylation. Protein science : a publication 
of the Protein Society  24(7):1100-1113. 
35. Sola RJ, Griebenow K 2010. Glycosylation of therapeutic proteins: an effective strategy 
to optimize efficacy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene 
therapy  24(1):9-21. 
36. Hayes JM, Cosgrave EF, Struwe WB, Wormald M, Davey GP, Jefferis R, Rudd PM 
2014. Glycosylation and Fc receptors. Current topics in microbiology and immunology  382:165-
199. 
37. Sethuraman N, Stadheim TA 2006. Challenges in therapeutic glycoprotein production. 
Current opinion in biotechnology  17(4):341-346. 
38. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R 2011. Acceptable changes 
in quality attributes of glycosylated biopharmaceuticals. Nature biotechnology  29(4):310-312. 
39. Beck A, Reichert JM 2012. Marketing approval of mogamulizumab: a triumph for glyco-
engineering. mAbs  4(4):419-425. 
40. Wei Y, Li C, Huang W, Li B, Strome S, Wang LX 2008. Glycoengineering of human 
IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation. 
Biochemistry  47(39):10294-10304. 
41. Federici M, Lubiniecki A, Manikwar P, Volkin DB 2013. Analytical lessons learned from 
selected therapeutic protein drug comparability studies. Biologicals : journal of the International 
Association of Biological Standardization  41(3):131-147. 
42. Lubiniecki A, Volkin DB, Federici M, Bond MD, Nedved ML, Hendricks L, Mehndiratta 
P, Bruner M, Burman S, Dalmonte P, Kline J, Ni A, Panek ME, Pikounis B, Powers G, Vafa O, 
Siegel R 2011. Comparability assessments of process and product changes made during 
development of two different monoclonal antibodies. Biologicals : journal of the International 
Association of Biological Standardization  39(1):9-22. 
43. Bui LA, Hurst S, Finch GL, Ingram B, Jacobs IA, Kirchhoff CF, Ng CK, Ryan AM 2015. 
Key considerations in the preclinical development of biosimilars. Drug Discov Today  20 Suppl 
1:3-15. 
44. Crommelin DJ, Shah VP, Klebovich I, McNeil SE, Weinstein V, Fluhmann B, 
Muhlebach S, de Vlieger JS 2015. The similarity question for biologicals and non-biological 
complex drugs. European journal of pharmaceutical sciences : official journal of the European 





45. Alsenaidy MA, Kim JH, Majumdar R, Weis DD, Joshi SB, Tolbert TJ, Middaugh CR, 
Volkin DB 2013. High-throughput biophysical analysis and data visualization of conformational 
stability of an IgG1 monoclonal antibody after deglycosylation. Journal of pharmaceutical 
sciences  102(11):3942-3956. 
46. Chaudhuri R, Cheng Y, Middaugh CR, Volkin DB 2014. High-throughput biophysical 
analysis of protein therapeutics to examine interrelationships between aggregate formation and 
conformational stability. The AAPS journal  16(1):48-64. 
47. Yageta S, Lauer TM, Trout BL, Honda S 2015. Conformational and Colloidal Stabilities 
of Isolated Constant Domains of Human Immunoglobulin G and Their Impact on Antibody 
Aggregation under Acidic Conditions. Molecular pharmaceutics  12(5):1443-1455. 
48. Okbazghi SZ, More AS, White DR, Duan S, Shah IS, Joshi SB, Middaugh CR, Volkin 
DB, Tolbert TJ 2016. Production, Characterization, and Biological Evaluation of Well-Defined 
IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis. Journal of pharmaceutical 
sciences  105(2):559-574. 
49. Mozziconacci O, Okbazghi S, More AS, Volkin DB, Tolbert T, Schoneich C 2016. 
Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc 
Glycoforms. Journal of pharmaceutical sciences  105(2):575-587. 
50. Kim JH, Joshi SB, Tolbert TJ, Middaugh CR, Volkin DB, Smalter Hall A 2016. 
Biosimilarity Assessments of Model IgG1-Fc Glycoforms Using a Machine Learning Approach. 
Journal of pharmaceutical sciences  105(2):602-612. 
51. Alsenaidy MA, Okbazghi SZ, Kim JH, Joshi SB, Middaugh CR, Tolbert TJ, Volkin DB 
2014. Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site 
occupancy and Asp/Gln residues at site Asn 297. Journal of pharmaceutical sciences  
103(6):1613-1627. 
52. Gibson TJ, McCarty K, McFadyen IJ, Cash E, Dalmonte P, Hinds KD, Dinerman AA, 
Alvarez JC, Volkin DB 2011. Application of a high-throughput screening procedure with PEG-
induced precipitation to compare relative protein solubility during formulation development with 
IgG1 monoclonal antibodies. Journal of pharmaceutical sciences  100(3):1009-1021. 
53. Toprani VM, Joshi SB, Kueltzo LA, Schwartz RM, Middaugh CR, Volkin DB 2016. A 
Micro-Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for 
Monoclonal Antibody Design and Formulation Development. Journal of pharmaceutical sciences  
105(8):2319-2327. 





55. Manikwar P, Majumdar R, Hickey JM, Thakkar SV, Samra HS, Sathish HA, Bishop SM, 
Middaugh CR, Weis DD, Volkin DB 2013. Correlating excipient effects on conformational and 
storage stability of an IgG1 monoclonal antibody with local dynamics as measured by 
hydrogen/deuterium-exchange mass spectrometry. Journal of pharmaceutical sciences  
102(7):2136-2151. 
56. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR 2011. Multidimensional 
methods for the formulation of biopharmaceuticals and vaccines. Journal of pharmaceutical 
sciences  100(10):4171-4197. 
57. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR 2012. Improved data visualization 
techniques for analyzing macromolecule structural changes. Protein Science  21(10):1540-1553. 
58. Ghirlando R, Lund J, Goodall M, Jefferis R 1999. Glycosylation of human IgG-Fc: 
influences on structure revealed by differential scanning micro-calorimetry. Immunology Letters  
68(1):47-52. 
59. Wu S-J, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, 
Raju TS, Jacobs SA, Teplyakov A, Gilliland GL, Feng Y 2010. Structure-based engineering of a 
monoclonal antibody for improved solubility. Protein Engineering, Design and Selection  
23(8):643-651. 
60. Middaugh C, Litman G 1987. Atypical glycosylation of an IgG monoclonal 
cryoimmunoglobulin. Journal of Biological Chemistry  262(8):3671-3673. 
61. Zheng K, Bantog C, Bayer R 2011. The impact of glycosylation on monoclonal antibody 
conformation and stability. mAbs  3(6):568-576. 
62. Latypov RF, Hogan S, Lau H, Gadgil H, Liu D 2012. Elucidation of acid-induced 
unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. The Journal of 
biological chemistry  287(2):1381-1396. 
63. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, Middaugh 
CR, Volkin DB, Weis DD 2013. Effects of salts from the Hofmeister series on the 
conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal 
antibody. Biochemistry  52(19):3376-3389. 
64. Alsenaidy MA, Jain NK, Kim JH, Middaugh CR, Volkin DB 2014. Protein comparability 
assessments and potential applicability of high throughput biophysical methods and data 





Chapter 3 Comparative Evaluation of Well-defined Mixtures of IgG1-Fc 

























Monoclonal antibody therapeutics (mAbs) are one of the largest selling and fastest 
growing biological therapeutics used for treatment of diseases including various cancers and 
autoimmune disorders such as rheumatoid arthritis.1,2 Their development process is complicated 
due to their complex and delicate structures and their production in living cells. Even though 
innovator mAb biologics show highest sales and clinical utility for providing life-altering 
therapies, they come with a high price tag especially for chronic conditions that require 
continuous long-time treatment.1,2 Additionally, the top selling blockbuster mAb biologics like 
Rituxan and Humira have had their patents expire recently (in 2016 in the USA) while others 
(Xolair, Erbitux, Remicade, Avastin, Herceptin, Prolia) are on the verge of expiry in a couple of 
years. This has driven the pharmaceutical manufacturers to develop biosimilars as lower cost 
alternatives.1,2 Biosimilars are approved copies or generic versions of a biologic therapeutic often 
known as innovator product that can be manufactured after the innovator’s patent expires. It is 
estimated that cost of biosimilars will be 50–70% of the original manufacturer's price.3 The 
approval of biosimilars is based on demonstrating that the biosimilar is “highly similar” to the 
licensed innovator product in terms of quality, safety and efficacy.  
The primary and higher order structures (HOS) of biologics are very delicate in nature and 
further complicated by heterogeneity due to the addition of post-translational modifications like 
glycosylation. N-glycosylation is a conserved PTM on Asn-297 of the Fc region of antibodies 
and therapeutic mAbs, which results in significant structural heterogeneity of mAbs. Depending 
on the type of recombinant expression system, cell culture conditions and additives, the 
glycosylation pattern on the mAb can vary. Different types of N-glycan structures attached to the 




binding of Fc region to C1q complement protein in serum and increased the CDC (complement 
dependent cytotoxicity) while having moderate effect on ADCC (antibody dependent cell 
mediated cytotoxicity).4-6 The binding of non-fucosylated IgG Fc glycoforms to FcɣRIIIa 
receptors increased significantly with increase in ADCC activity as compared to fucosylated 
complex glycoforms of IgG.7 Apart from affecting effector functions of mAbs, glycosylation 
affects the pharmacokinetic properties and immunogenicity of mAbs as well. For example, mAbs 
having high mannose type of glycans (Man5/Man8/Man9) showed increased clearance and α1, 
3-bound galactose, N-glycylneraminic acid (NGNA) showed adverse immune reactions.8,9  
N-glycosylation is also known to affect the HOS structure, flexibility and stability of 
mAbs, and recently it was shown that the glycans are dynamic as well and affect various 
properties of mAbs by influencing the HOS. 5,10-16 Hence, when the mode of action of a 
therapeutic mAbs involves Fc effector function, glycosylation causes the main source of 
heterogeneity and can impact the purity, safety, efficacy of the product making it a critical 
quality attribute (CQA).4 CQA is a property that should be maintained within appropriate limits 
to ensure desired product quality, safety and efficacy, which can be achieved by control of 
manufacturing procedures.4,17 Similarly, in biosimilar development, the biosimilar developer has 
to develop novel manufacturing methods (owing to proprietary nature of innovator’s 
manufacturing protocols) to attempt to duplicate the glycan heterogeneity that is found in the 
innovator product.18 Practically, glycan heterogeneity between the biosimilar can be controlled 
by tight manufacturing procedures, but it is extremely challenging and near to impossible to 
reproduce glycans content exactly, thus the goal is to produce a glycan content that is “highly 
similar” to the innovator. Hence, an extensive analytical characterization of glycosylation is 




the art analytical techniques. Similarly, when a manufacturing protocol is changed, for example, 
cell line change or expression parameter change, extensive analytical characterization is required 
to ascertain that the pre-change and the post-change products are highly similar and do not show 
meaningful clinical differences. 
The Food and Drug Administration (FDA) guidance documents recommend a couple of 
approaches to demonstrate biosimilarity, in which analytical characterization is the most 
fundamental aspect. In the step-wise approach for demonstrating biosimilarity between a 
proposed biosimilar and innovator product, establishing analytical biosimilarity is the first step.17 
It is the responsibility of the biosimilar manufacturer to conduct extensive tests to demonstrate 
similarity.  These characterizations involve physicochemical characterizations like molecular 
weight determination, analyzing complexity of the protein (higher order structure and 
posttranslational modifications), degree of heterogeneity, impurity profiles, and degradation 
profiles denoting stability.19 Additionally, biological characterization is also required for 
example, if part of the mechanism of action of a particular mAb is ADCC or CDC, then FcɣRIIIa 
receptor binding or C1q binding needs to be performed, respectively. When the biosimilar 
product attributes in terms of physicochemical structure and biological activity are not 
comparable to that of the innovator product, various process steps are modified to bring the 
attributes within the variability of the innovator product. This process is repeated until the 
attributes of biosimilar product match or are highly similar to those of innovator product.1 
Depending on the extent of similarity of these attributes between the biosimilar and the innovator 
product, the type and extent of preclinical and clinical trials can be modified. Thus, analytical 
characterization with respect to chemical, physical structure and biological activity is required to 




pre-clinical and clinical trials more streamlined, which will cut down costs of biosimilars making 
them more affordable for patients. FDA guidance documents recommend that the CQAs 
obtained from analytical studies should be identified and classified according to the risk of their 
potential impact on product quality and the clinical outcomes using appropriate statistical models 
or methods.20 Once identified, the CQA needs to be compared between various batches of 
innovator drug and biosimilar and the extent of uncertainty must be decided. However, the 
assessment of uncertainty can be relatively subjective and often lacks appropriate statistical 
reasoning or an approach of combining differences in each individual data set.17 
An alternative approach to comparing each CQA, is a more holistic approach for 
comparison which can combine differences from individual data sets.21 Recent FDA guidance 
refers to using a more holistic approach of fingerprint analysis which says “it may be useful to 
compare the quality attributes of the proposed biosimilar product with those of the reference 
product using a meaningful fingerprint-like analysis algorithm that covers a large number of 
product attributes and their combination with high sensitivity using orthogonal methods.22 
Previous work in our laboratory, as described in the introduction (Chapter 1), has shown that 
data visualization tools such as empirical phase diagrams (EPDs) and radar charts can be used to 
locate patterns of differences in HOS among different proteins and IgG1-Fc glycoforms. These 
tools can summarize multiple CQAs from multiple techniques between different samples and 
provide a qualitative evaluation of HOS and physical stability between different groups. Also, 
physical stability of different glycoforms in different formulations was tested to simulate follow-
on biologics or biosimilars that might have different formulations than the originator.23 These 
biophysical stability data sets can be utilized to establish a mathematical model based on 




The production of model proteins, extensive physicochemical characterization and stability 
profile of individual model IgG1-Fc glycoproteins was carried out as described in Chapter 2. To 
better understand the CQAs, development of holistic data visualization tools and development of 
initial mathematical model were performed on the four individual IgG Fc glycoforms as 
described in Chapter 2. The overall goal of this study was to simulate a more real world problem 
of biologics and innovator products by making mixtures of the four well-defined glycoforms of 
IgG1-Fc (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc), performing analytical characterization 
and using the data sets to develop mathematical models based on machine learning approaches to 
compare samples. To make the mixtures that would represent the heterogeneity in biosimilar and 
innovator products, the four well-defined homogenous glycoforms (HM-Fc had distribution of 
well-defined high mannose forms ranging from Man8-Man12; Man8 being the most abundant) 
were mixed in different ratios to achieve seven well-defined mixtures that showed a wide range 
of properties from subtle to evident. Mixtures that were anticipated to show evident differences 
were 50% mixtures of HM-Fc with 50% of Man5-Fc, GlcNAc-Fc or N297Q-Fc while those that 
would show subtle differences were mixtures of 90% HM-Fc with 10% Man5-Fc, GlcNAc-Fc or 
N297Q-Fc. Lastly, a more complex mixture was made which had 25% of each glycoform. The 
initial characterization of these mixtures showed no differences with respect to protein content, 
purity, charge heterogeneities, high molecular weight species and tertiary structure as assessed 
by ultraviolet (UV) spectroscopy, SDS-PAGE, capillary isoelectric focusing (cIEF), size 
exclusion chromatography (SEC) and intrinsic tryptophan fluorescence. As extensive physical 
characterization is the fundamental step in biosimilarity assessments, all the seven mixtures were 
characterized extensively for their physical stability and solubility by utilizing high-throughput 




stability, tertiary structure stability, hydrophobic exposure and aggregation propensity of these 
seven mixtures were probed by assays developed in the Chapter 2: PEG precipitation assay, 
DSC, intrinsic tryptophan fluorescence spectroscopy, extrinsic Sypro Orange fluorescence 
spectroscopy and OD350 turbidity. The four well-defined IgG Fc glycoforms studied in Chapter 
2 also served as controls in this study. A stressed pH condition of pH 4.5 was also used along 
with pH 6.0 to study the physical properties of these mixtures by the above techniques. The 
biophysical techniques showed similar stability profile trends of the mixtures as were anticipated 
based on the properties of the individual types. Mixtures containing Man5-Fc and HM-Fc 
showed higher physical stability, intermediate stability was seen in mixtures of GlcNAc-Fc and 
HM-Fc, and mixtures of HM-Fc and N297Q-Fc showed the least stable physical profile. Also, 
the 90% mixtures showed subtle differences compared to the 50% mixtures, as expected. DSC 
and PEG solubility methods, especially at stressed conditions (pH 4.5), were very successful at 
demonstrating subtle differences in the physical stability and relative solubility profiles of these 
mixtures. In addition, this study established correlations between the physical stability, chemical 
stability and biological activity of these well-defined mixtures (which were studied in Schöneich 
and Tolbert laboratories at KU, respectively). The large stability and solubility analytical data 
sets generated from these mixture studies are currently being utilized to refine and validate the 
machine learning based mathematical model to assess overall biosimilarity in the Deeds 
laboratory at KU. 
3.2 Materials and Methods 
3.2.1 Materials 
For relative solubility and biophysical characterization and stability studies, all the 




adjusted to 0.15 by NaCl at pH 4.5 and 6.0. Dialysis was performed at 4°C using Slide-A-Lyzer 
dialysis cassettes (Life technologies, Grand Island, NY) with a 10 kDa molecular weight cutoff, 
with three buffer exchanges; two exchanges at 4 hour intervals and one overnight. All the 
samples were filtered by Millex-GV-0.22 uM syringe filter units (EMD Millipore, Billerica, 
MA) before measurements. For PEG solubility studies, samples were concentrated by Millipore 
Amicon Ultra-0.5 mL centrifugal device (EMD Millipore, Billerica, MA) with a MW cut off of 
10 kDa to obtain a final protein stock concentration of 1 mg/mL. Components of all buffers 
including, sodium phosphate and sodium chloride as well as PEG-10,000 were purchased from 
Sigma-Aldrich (St Louis, MO) while citric acid monohydrate and citric acid anhydrous were 
purchased from Fisher Scientific at the highest purity grade. 
3.2.2 Methods 
3.2.2.1 Preparation of Mixtures IgG1 Fc 
After producing and purifying the four IgG1-Fc glycoforms (the starting materials: HM-
Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) as mentioned previously,24 these were dialyzed at 4°C 
overnight in a 20 mM citrate phosphate buffer with ionic strength adjusted to 0.15 by NaCl at pH 
6.0. Dialysis was performed at 4°C using Slide-A-Lyzer dialysis cassettes (Life technologies, 
Grand Island, NY) with a 10 kDa molecular weight cutoff, with three buffer exchanges; two 
exchanges at 4h intervals and one overnight. After dialysis, the final concentration of the four 
IgG1-Fc proteins, also known as controls, were adjusted to 0.5mg/mL and were mixed in 
different ratios as seen in Figure 3.1 to obtain seven different mixtures. The final concentration 
of protein in the mixtures was 0.5 mg/mL and the seven mixtures and 4 controls were stored in 




3.2.2.2 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
For the reduced samples, each of the IgG1 Fc proteins (7 µg) were mixed with 2X 
TrisHCl SDS loading dye containing 100 mM DTT and incubated at 70 °C for 2 min.  The 
reduced IgG1 Fc samples were then separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis using NuPAGE 4-12% Bis-Tris gradient gel (Life Technologies, Grand Island, 
NY) gels and a MES running buffer (Life Technologies).24 A similar method was followed for 
non-reduced samples of IgG1 Fc proteins except DTT was omitted during the incubation step. 
The running time for all the gels was 60 min at 150 V. Protein bands were visualized by staining 
with Coomassie blue R250 (Teknova, Hollister, CA) and destained with a mixture of  30% 
methanol, 10% acetic acid, and 60% ultrapure water. Gel images were recorded using an 
Alphaimager (Protein Simple, Santa Clara, CA) gel imaging system. 
3.2.2.3 Size exclusion chromatography (SEC) 
Experiments were performed using a Shimadzu high-performance liquid chromatography 
system equipped with a photodiode array detector capable of recording UV absorbance spectra 
from 200 to 400 nm and a temperature controlled auto sampler. A Tosoh TSK-Gel Bioassist 
G3SWxL column (7.8 mm ID x 30.0 cm L) and a corresponding guard column (TOSOH 
Biosciences, King of Prussia, Pennsylvania) were used for Fc protein characterization. First, the 
SEC column was equilibrated for at least 10 column volumes (CV) with a mobile phase 
containing 200 mM sodium phosphate, pH 6.8, and a flow rate of 0.7 mL/min at 30 0C column 
temperature as mentioned previously.24 Next, the column was calibrated using gel filtration MW 
standards (Bio-Rad, Hercules, CA) before and after the runs of IgG1-Fc glycoforms to ensure 
column and HPLC system integrity. All Fc samples were centrifuged at 14,000 g for 5 min 




mg/mL were injected in a volume of 50 µL, and a 30 min run time was used for elution. Peak 
quantification was carried out using LC solutions software (Shimadzu, Kyoto, Japan). The errors 
for monomer percent for all the samples represent SD of triplicate measurements. 
3.2.2.4 Capillary isoelectric focusing (cIEF) 
The determination of isoelectric points (pIs) of all the IgG1-Fc glycoforms using 
capillary isoelectric focusing (cIEF) were performed with an iCE280 analyzer from Convergent 
Biosciences (now Protein Simple, Toronto, Canada) equipped with a microinjector. A FC 
Cartridge (Protein Simple, Toronto, Canada) with 50 mm, 100 µm I.D. fluorocarbon-coated 
capillary and built-in electrolyte tanks were used for focusing. The cartridge was calibrated by 
hemoglobin standard (Protein Simple, Toronto, Canada) before and after focusing of IgG1-Fc 
samples to ensure its integrity. For focusing, a sample mixture was prepared where each of the 
IgG1 Fc glycoforms were mixed with urea (Fischer Scientific), methyl cellulose (Protein Simple, 
Toronto, Canada), sucrose (Pfanstiehl Inc., Waukegan, IL), N,N,N',N'-Tetramethylethane-1,2-
diamine (Sigma-Aldrich, St Louis, MO) and Pharmalyte 3–10 (GE Healthcare Biosciences, 
Pittsburgh, PA). The final protein concentration in the sample mixture was 0.2 mg/mL. All the 
IgG1 Fc glycoforms were resolved using a pre-focusing time of 1 minute at 1500 V and a 
focusing time of 7 minutes at 3000 V. Observed peaks were calibrated using two pI markers with 
values of 5.84 and 8.18. The separation was monitored at 280 nm by a CCD detector. 
Quantitation of the peaks was done using Chromperfect® software. The error bars for pI values 
of all the samples represent standard deviation (SD) of triplicate measurements. 
3.2.2.5 UV Spectroscopy 
Absorbance spectra were obtained over the wavelength range of 200–400 nm employing 




were analyzed in a quartz cuvette with a 1-cm path length and the absorbance value at 280 nm 
was used to calculate the concentration of proteins. Second-derivative spectra were calculated 
using Origin software to determine peak positions. Results are reported showing triplicate runs of 
all the samples. 
3.2.2.6 PEG Precipitation Assay 
The experimental protocol was adapted from Toprani et al.25 Stock solutions of PEG-
10,000 ranging from 0 to 40% w/v PEG were prepared in 20 mM citrate phosphate buffer with 
ionic strength adjusted to 0.15 by NaCl at pH 4.5 and pH 6.0. A volume of 40 µL of each of the 
PEG-10,000 solutions (from 0 to 40% w/v PEG) were added to wells of a 96-well polystyrene 
filter plate (Corning#3504, Corning Life Sciences, Corning, NY). Ten µL of the protein stock 
solutions (1 mg/mL) was then added to each well to achieve a final protein concentration of 0.2 
mg/mL.  The plates were incubated at room temperature overnight and then were centrifuged at 
1233 (x g) for 15 min. The filtrate was collected in a clear 96 well collection plate (Greiner Bio-
One#655001, Greiner Bio-One North America Inc., Monroe, NC). The protein concentration was 
determined on a NanoDrop 2000 spectrophotometer (NanoDrop Products, Wilmington, DE) 
using 2 µL of filtrate by measuring absorbance at 280 nm. Each samples were run in triplicates 
and the data was analyzed using Python (x,y) v.2.7.6.0, an open source scientific software based 
on python language and the % PEGmidpt values and apparent solubility value parameters were 
then calculated as described before.23,25 
3.2.2.7 Differential Scanning Calorimetry (DSC) 
DSC experiments were performed using a MicroCal VP-AutoDSC instrument with an 
autosampler (MicroCal, LLC, Northampton, Massachusetts). Triplicate measurements of all 




60°C/h. Data analysis was performed using the MicroCal LLC DSC plug-in for the Origin 7.0 
software package to obtain the final DSC thermograms and the onset temperature (Tonset) of the 
first transition for all the samples as described before.23 
3.2.2.8 Intrinsic (Trp) fluorescence spectroscopy 
The fluorescence spectra were measured in triplicate using a Photon Technology 
International (PTI) Quantum master fluorometer (New Brunswick, New Jersey) with 200 µL of 
0.2 mg/mL protein solution in 0.2 cm path length quartz cuvettes. Samples were excited at 295 
nm (>95% Trp emission) and the emission spectra from 10°C to 90°C in increments of 1.25°C 
were recorded from 305 to 405 nm. The spectra were analyzed and the maximum peak position 
(λmax) values were calculated using a “spectral center of mass” method (MSM) as described 
before1. From the peak position (λmax) versus temperature plots transition midpoint temperatures 
(Tm) were calculated for all the samples. 
3.2.2.9 Extrinsic fluorescence spectroscopy 
The extrinsic fluorescence measurements were performed in triplicates using a MX3005P 
QPCR system (Agilent Technologies). Samples contained 0.2 mg/mL protein in a total sample 
volume of 100 µL. The Sypro™ orange dye was purchased from Invitrogen, Inc. (Carlsbad, CA) 
and was diluted in water and then added to the protein samples to achieve 1x dye concentration 
as reported before23. Using custom filter sets, the samples was excited at 492 nm, and the 
emission intensity change with temperature at 610 nm was followed. The temperature was raised 
from 25°C to 90°C using 60°C/h heating rate and 1˚C as a step size. Data analysis was carried 
out to obtain fluorescence intensity against temperature plots and the transition midpoint 




3.2.2.10 Optical density (OD) 350 nm measurements 
Turbidity measurements were performed using a Cary 100 UV-Visible spectrophotometer 
(Varian medical Systems, Inc., Palo Alto, California) equipped with a 12 cell holder with a 
peltier type temperature controller. Samples contained 0.2 mg/mL protein with a total volume of 
250 µL in 1 cm path length quartz cells. OD at 350 nm was monitored as the temperature was 
raised in increments of 1.25˚C from 10 to 90˚C with a heating rate of 60˚C/h. Protein samples 
were run in triplicate and corresponding buffer blanks were run and subtracted from each 
sample. The OD at 350 nm was plotted against temperature as described previously.23  
3.3 Results 
3.3.1 Initial comparisons of purity, high molecular weight species, charge heterogeneities 
and structural integrity of well-defined mixtures of IgG1-Fc glycoforms  
Approximately 99% purity was achieved for each of the seven IgG1-Fc mixtures and four 
controls IgG1-Fc (individual glycoforms) as determined by both reduced and non-reduced SDS-
PAGE gels (Figure 3.2). Size exclusion high performance liquid chromatography (SEC) was 
then used to evaluate purity (under non-denaturing conditions) to determine if aggregates were 
present in controls and mixtures before starting their biophysical and binding analysis. (Figure 
3.3 shows representative SEC chromatograms of each of the controls and mixtures). The 
monomeric purity of mixtures and controls was determined by SEC, as shown in the Table 3.1, 
and the results indicate that all the IgG1-Fc mixtures and controls are monomeric (97-99 %) with 
small levels of aggregates present across the IgG1-Fc samples (1-3 %). Characterization of the 
isoelectric point (pI) range of the seven mixtures and controls of IgG1-Fc glycoforms by 
capillary isoelectric focusing (cIEF) showed pI of 7.2 in the base buffer. Figure 3.4 shows 




controls. Figure 3.5 A shows second derivative UV-visible absorption spectra of the four IgG1-
Fc controls and seven mixtures. No changes in the ultraviolet absorption peak positions of the 
three aromatic amino acids (Phe, Tyr, Trp see Figure 3.5 B for the peak locations) were observed 
indicating no major differences in tertiary structure in the base buffer, across all the samples. The 
structural integrity of the overall tertiary structure of the four IgG1-Fc glycoform controls and 
the seven mixtures was evaluated by measurement of intrinsic Trp fluorescence at 10°C at pH 
values 4.5 and 6.0 (see Figure 3.6). For each sample, the wavelength of maximum intensity (λ 
max) at 10°C at each pH was calculated and was found to be overall similar and in the range of 
328 to 330 nm with standard deviations calculated from triplicate measurements of up to ~0.6 
nm. These results indicated that the spectra for the controls and mixtures were overall similar at 
10°C at both pH 4.5 and pH 6.0. The fluorescence intensity obtained for each protein represents 
the average values of all the tryptophan residues present in the protein. 
3.3.2  Relative Apparent Solubility 
An assessment of the apparent solubility (thermodynamic activity) of four IgG1-Fc 
glycoform controls (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) and their seven mixtures was 
performed using PEG precipitation as described previously (see Methods section).  Protein 
versus % PEG concentration plots were generated for all the samples at pH 4.5 and pH 6 
respectively, in the formulation buffer as shown in Figure 3.7 (for mixtures) and Figure 3.8 A 
and D (for controls). The solubility curves of the mixtures (see Figure 3.7) show a sigmoidal 
curve, demonstrating that as the crowding agent (PEG) concentration increases; there is a point 
at which a decrease in the amount of the protein in solution occurs in a quantifiable manner.  For 
ease of comparison, the protein versus % PEG concentration plots for the four controls were 




curves show differences between the controls with regard to glycosylation and pH as seen 
previously in Chapter 2. As seen in Figure 3.8 A, at pH 4.5 the N297Q-Fc begins to precipitate 
rapidly as the PEG concentration is increased, and deviates from the typical sigmoidal curve, 
possibly indicating structural alterations in the protein and/or direct interaction between the PEG 
and protein, which is consisent with the previous results.23  
Figure 3.8 B and E show % PEGmidpt values (which is the weight % PEG required to 
reduce the protein concentration by 50% of its initial value) at pH 4.5 and pH 6 respectively, for 
all samples.  For each sample, a trend of decreasing % PEGmidpt values with increasing solution 
pH from 4.5 to 6 was observed indicating decreasing solubility as the solution pH increased. In 
terms of general trends of the four controls, the HM-Fc showed the highest % PEGmidpt value 
followed by Man5-Fc, GlcNAc-Fc and lastly, the non-glycosylated N297Q-Fc at pH 4.5 (Figure 
3.8 B) as seen previously1. At pH 6 (Figure 3.8 E), the HM-Fc and Man5-Fc did not show 
significant differences in the % PEGmidpt that was similar to previous results1 while GlcNAc-Fc 
showed intermediate % PEGmidpt values followed by the N297Q-Fc showing the least.  
Similarly with the mixture samples, subtle differences were observed in % PEGmidpt at pH 
6 (Figure 3.8 E) than at pH 4.5 (Figure 3.8 B) where more prominent differences were observed. 
At both pH 4.5 and 6, 50% mixtures of HM-Fc (Mixtures 1, 2 and 3 which are 50% mixtures of 
HM-Fc with 50% Man5-Fc, 50% GlcNAc-Fc and 50% N297Q-Fc respectively) showed a similar 
trend with % PEGmidpt as observed in their respective controls from which they are made. For 
example, Mixture 1 showed the highest % PEGmidpt value, Mixture 2 intermediate and Mixture 3 
the least which correlated with the trend observed in their respective controls which was in 
decreasing order of % PEGmidpt: Man5-Fc control >GlcNAc-Fc control>N297Q-Fc control. All 




the pH conditions. Also, Mixture 3 which had 50% N297Q-Fc with 50% HM-Fc did not 
precipitate as rapidly as the 100% N297Q-Fc control.  At pH 4.5 (Figure 3.8 B) and 6 (Figure 3.8 
E), % PEGmidpt values of the 90% mixtures of HM-Fc (Mixtures 4, 5 and 6 which are 90% 
mixtures of HM-Fc with 10% Man5-Fc, 10% GlcNAc-Fc and 10% N297Q-Fc respectively), 
showed subtle differences between their % PEGmidpt in the order of decreasing % PEGmidpt:  
Mixture 4> Mixture 5> Mixture 6. This trend was subtle but similar to the trend observed in the 
50% mixtures (Mixture 1, 2 and 3), which is dependent on the trend observed in the controls 
from which they were prepared. All the 90% mixtures of HM-Fc showed slightly lower % 
PEGmidpt values than the HM-Fc control but were higher than their respective 50% mixtures at 
pH 4.5 while the trends were similar and differences were subtle at pH 6. Mixture 7 (which was 
25% mixture of each of HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) showed similar % 
PEGmidpt values to Mixture 1 (HM: Man5::50:50) and 5 (HM:GlcNAc::90:10), but slightly higher 
values than Mixture 6 (90%HM-Fc:10%N297Q-Fc) at pH 4.5 and the differences were subtle at 
pH 6. To summarize, we can rank order the solubility profiles of IgG1-Fc glycoform mixtures 
from high to low by following the % PEGmidpt values that decreased in the following order: 
Mixture 4> Mixture 1> Mixture 5> Mixture 7> Mixture 6> Mixture 2> Mixture 3 at pH 4.5. 
However, at pH 6 even though the trend was similar it was difficult to rank order the solubility 
profiles of mixtures due to subtle differences between the % PEGmidpt. Mixture 3, which had a 
higher percent (50%) of the N297Q-Fc control, showed the lowest % PEGmidpt, while Mixture 4 
which had high percent (90%) of the HM-Fc and 10% Man5-Fc showed the highest % PEGmidpt 
value at pH 4.5. The 50% (Mixture 1) and 90% (Mixture 4) mixtures of HM-Fc with Man5-Fc 
showed % PEGmidpt values lower than the HM-Fc control and higher than the Man5-Fc control.  




showed % PEGmidpt values lower than the HM-Fc control and higher than the GlcNAc-Fc 
control. In addition, similar results were seen for 50% (Mixture 3) and 90% (Mix 6) of HM-Fc 
with N297Q-Fc. 
As shown in Figure 3.8 C and 3.8 F, the apparent solubility (thermodynamic activity) 
values were calculated by extrapolation to zero PEG concentration (see Methods section) in pH 
4.5 and pH 6, respectively.  These values showed trends similar to those found with % PEGmidpt 
in terms of Fc glycan structure of the controls and solution pH.  At both pH values, the apparent 
activity values between HM-Fc vs. Man5-Fc glycoforms showed no significant differences.  The 
apparent activity values of GlcNAc-Fc were lower than the HM-Fc and Man5-Fc at pH 4.5 and 
6. The N297Q-Fc showed the lowest apparent activity value at pH 6. At both pH 4.5 (Figure 3.8 
C) and 6 (Figure 3.8 F), the apparent solubility values all mixtures followed similar trends as % 
PEGmidpt values. Apparent solubility values for Mixture 3 (50%HM-Fc::50%N297Q-Fc) were 
lowest at both pH 4.5 and 6 but were higher than the N297Q-Fc control due to the presence of 
50% of HM-Fc control.  However, as the errors were higher in apparent solubility calculations, it 
was difficult to rank order the solubility profiles of the mixtures.  
3.3.3 Overall Conformational Stability and Tertiary Structure Stability  
Differential scanning calorimetry was used to assess the overall conformational stability 
of the four IgG1-Fc glycoform controls and their mixtures as the samples were heated from 10°C 
to 100 °C. Figure 3.9, shows representative DSC thermograms of all the samples obtained at 
both pH 4.5 and 6 which showed two major endothermic peaks, as seen previously.23 For direct 
comparison between the samples, the Tonset values of the first transition were calculated and 
plotted as a bar chart representation at pH 4.5 (Figure 3.12 A) and pH 6 (Figure 3.12 B). Based 




to the unfolding of the CH2 and CH3 domains of the IgG-Fc respectively26. The Tonset values 
calculated in this study represent the temperatures of onset of transition in the CH2 domain of the 
IgG1-Fc of all samples. The thermal melting temperatures for CH3 domain of controls did not 
show significant differences under pH 4.5 and pH 6 as observed before,23 thus they were not 
shown here assuming subtle differences in the mixtures will not be observed. 
 Intrinsic Trp fluorescence spectroscopy and Sypro Orange fluorescence spectroscopy 
were utilized as two complementary techniques to evaluate the stability of the overall tertiary 
structure of the glycofrom controls and 7 mixtures. The intrinsic Trp fluorescence spectra were 
collected at pH 4.5 and 6 and the changes in λmax (MSM peak position) as a function of 
increasing temperature (every 1.25°C starting from 10°C to 90°C) were plotted for all samples as 
shown in Figure 3.10.  The λmax is senitive to the environment around the tryptophan residues 
and as a result can be used as probe to study changes in the higher-order structure of proteins 
often accompanied by shift of λmax to longer wavelengths (red shift). As seen in the 
representative peak position plots for all the samples at pH 4.5 and pH 6 (Figure 3.10), there is 
no change in λmax values up to certain temperatures. However, more dramatic increase 
(transition) in λmax is observed as the temperature increases before plateauing off. The melting 
temperatures (Tm, which is the midpoint temperature of a thermal transition) of thermal 
transitions were calculated as mentioned before23 and plotted as bar chart at both pH 4.5 and 6 
(see Figure 3.12 C and 3.12 D respectively). Sypro Orange was used as a probe for detecting 
protein structural alterations seen as increased fluorescence intensity upon exposure of the dye to 
increased apolar environments (presumably as a result of structural changes and/or aggregate 
formation by the protein). Sypro Orange fluorescence peak intensity was collected as a function 




temperatures (Tm, which is the midpoint temperature of a thermal transition) of thermal 
transitions were calculated as mentioned before23 and plotted as bar chart at both pH 4.5 and 6 
(see Figure 3.12 E and 3.12 F, respectively). 
In general, the Tonset and Tm values of the DSC and intrinsic/extrinsic fluorescence 
thermal transitions for all the controls and mixtures followed trends that depend upon the type of 
glycoform and the solution pH as noted previously.1 The DSC results showed that Tonset values of 
all the samples were lower at pH 4.5 (Figure 3.12 A) than 6 (Figure 3.12 B). Similarly, Tm  
values obtained at pH 4.5 and pH 6 from intrinsic tryptophan fluorescence (Figure 3.12 C and 
3.12 D) and extrinsic Sypro Orange fluorescence (Figure 3.12 E and 3.12 F) were lower in pH 
4.5 than pH 6 demonstrating the lower conformational and tertiary structure stability of all the 
controls and mixtures at lower pH conditions. Also, the Sypro Orange fluorescence peak 
intensity at the starting temperature (25°C) for all samples was relatively higher at pH 4.5 than at 
pH 6 (Figure 3.11). For all the samples, higher fluorescence peak intensity at lower pH condition 
suggests relatively increased surface hydrophobicity and presumably some level of structural 
alteration even at lower temperatures. 
For the IgG1-Fc glycoform controls, a trend of decreasing conformational stability with 
the truncation of carbohydrate units was observed for the Tonset values at pH 4.5 where the 
highest values were observed for HM-Fc and Man5-Fc controls (Man5 trended slightly higher 
than HM-Fc but within error), followed by GlcNAc-Fc and the lowest for N297Q-Fc control 
(Figure 3.12 A). Similarly, Tm values of thermal transitions obtained from intrinsic Trp 
fluorescence (Figure 3.12 C) and Sypro Orange fluorescence (Figure 3.12 E) were the highest for 
HM-Fc and Man5-Fc  (Man5 trended slightly higher than HM-Fc in Sypro Orange) followed by 




DSC (Figure 3.12 B) showed similar trends as observed at pH 4.5, where N297Q-Fc was the 
least stable; however the differences between the other three controls were subtle. Also Tm  
values from Intrinsic Trp fluorescence (Figure 3.12 D) and Sypro Orange fluorescence (Figure 
3.12 E) showed similar trends as pH 4.5. The Sypro Orange fluorescence peak intensity (Figure 
3.11) at the starting temperature (25°C) for N297Q-Fc control in both pH conditions trended 
relatively higher as compared to the other three controls suggesting increased surface 
hydrophobicity of N297Q-Fc even at lower temperatures. These results suggest that the HM-Fc 
and Man5-Fc glycoforms display highest stability of the tertiary structure, followed by the 
GlcNAc-Fc with intermediate stability, and the N297Q-Fc aglycosylated form having the least 
thermal tertiary structure stability as seen before.23 Interestingly, Man5-Fc trended a bit higher in 
stability than HM-Fc as observed by DSC and Sypro Orange which was not seen in a previous 
study that utilized different batches of controls and showed HM-Fc to have highest stability23 by 
these techniques.  
The 50% mixtures of HM-Fc (Mix 1, 2 and 3 which were which were 50% mixtures of 
HM-Fc with 50% Man5-Fc, 50% GlcNAc-Fc and 50% N297Q-Fc respectively) showed large 
differences in conformational stability following the trend from highest to lowest Tonset values at 
pH 4.5 (Figure 3.12 A) as shown; Mixture 1 (HM:Man5::50:50)> Mixture 2 
(HM:GlcNAc::50:50)> Mixture 3 (HM:N297Q-FC::50:50). This trend was similar to the 
stability trend observed in their respective controls which was with decreasing order of stability 
Man5-Fc>GlcNAc-Fc>N297Q-Fc. Similarly at pH 4.5, Mixtures 1, 2 and 3 showed relatively 
large differences in Tm values obtained from intrinsic Trp fluorescence (Figure 3.12 C) and 
Sypro Orange fluorescence (see Figure 3.12 E), and followed the trend similar to their individual 




versus type of glycosylation in the mixtures were subtle than pH 4.5 and showed similar trends 
as observed at pH 4.5. Similarly, differences in tertiary structure stability (see Tm in Figure 3.12 
D and 3.12 F) versus type of glycosylation in the mixtures were subtle at pH 6 than at pH 4.5. 
The 90% mixtures of HM-Fc (Mixtures 4, 5 and 6 which were 90% mixtures of HM-Fc with 
10% Man5-Fc, 10% GlcNAc-Fc and 10% N297Q-Fc respectively) and Mixture 7 (which was 
25% mixtures of each of HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) showed subtle 
differences in conformational stability by DSC and their Tonset values were almost similar to 
those of 100% HM-Fc controls at both pH conditions (see Figure 3.12 A and 3.12 B). This 10% 
mixture of Man5-Fc, GlcNAc-Fc and N297Q-Fc (Mixtures 4, 5 and 6 respectively) with 90% 
HM-Fc showed equivalent stability to the HM-Fc control as it is the most abundantly present in 
these mixtures. Similar results were observed by intrinsic Trp fluorescence (see Figure 3.12 C 
and 3.12 D) and Sypro Orange fluorescence (see Figure 3.12 E and 3.12 F) at both pH 
conditions; however, the Tm values obtained for Mixture 7 were slightly lower than 100%  HM-
Fc control.  
Differences between the N297Q-Fc control and its mixtures with HM-Fc were observed 
easily at both pH 4.5 and pH 6 where 100% N297Q-Fc control that had the least conformational 
stability, showed increased stability as the % of HM-Fc increased from  50% (Mixture 3) to 90% 
(Mixture 6). Overall, Mixture 7 (which was 25% mixtures of all controls) showed intermediate 
stability between Mixture 3 and Mixture 6. The GlcNAc-Fc control also showed similar increase 
in conformational stability upon mixing with increasing amounts of HM-Fc, but the ability to 
distinguish between 50% and 90% mixtures was subtle at both pH 4.5 and 6. 50 % and 90% 




Man5-Fc controls except Mixture 1, which can be distinguished at pH 4.5 where it showed 
highest stability as it had high amounts of the most stable Man5-Fc (50%). 
3.3.4 Aggregation propensity by Turbidity 
Temperature induced aggregation profile of the IgG1-Fc glycoform controls and seven 
mixture samples was evaluated by monitoring optical density (OD) changes of the samples at 
350 nm as a function of increasing temperature at pH 4.5 and 6.0 (See Figure 3.13). Differences 
in aggregation pattern were observed with the type of glycoform and the solution pH.  The HM-
Fc and Man5-Fc IgG1-Fc controls did not show any notable increases in OD350 values as the 
temperature increased across both pH conditions tested as seen before.23 These glycoforms did 
not show the tendency to aggregate by turbidity assay in the conditions tested. The GlcNAc-Fc 
control displayed a single thermal transition at pH 6.0 while the N297Q-Fc control displayed a 
single thermal transition at both pH 4.5 and pH 6.0 as observed before.23 Mixtures 3 and 7 (that 
contained 50% HM-Fc::50% N27QFc and 25% of each HM-Fc, Man5-Fc, GlcNAc-Fc and 
N297Q-Fc, respectively) showed increase in OD 350 values with a single transition as the 
temperature increased at pH 6.0, but did not show any increase in OD350 values at pH 4.5.  
Mixture samples 1, 2, 4, 5 and 6 (that contained 50% HM-Fc::50 % Man5-Fc, 50% HM-Fc::50 
% GlcNAc-Fc , 90% HM-Fc::10% Man5-Fc, 90% HM-Fc::10% GlcNAc-Fc, 90% HM-Fc::10% 
N297Q-Fc, respectively) however, did not show any increase in the OD 350 values with a rise in 
temperature at both the pH conditions. The onset temperatures (Tonset), where rapid increase in 
OD350 was observed, were calculated for all the samples (Figure 3.13). The Tonset values were 
determined by noting the temperature at which the transition starts.  The Tonset values for 
triplicate runs were in the range of 82.0-90.0°C with standard deviations (SD) from 0.1°C -1.2°C 




show Tonset at 82.7°C (SD ranging from 0.5°C -1.0°C) at pH 6.0, while N297Q-Fc shows Tonset at 
82.0°C ± 0.1°C in pH 4.5.  Mixtures 3 and 7 show Tonset values at 90.0°C±0.8°C, 85.5°C ±0.4°C 
and 87.3°C ± 1.2°C, respectively.  
The results indicate that N297Q-Fc is the most aggregation prone of the IgG1-Fc 
glycoform, which shows transitions in both the pH conditions, followed by GlcNAc-Fc which 
showed transition at pH 6.0, while the Tonset of aggregation appears to be the same for both the 
controls. The HM-Fc and Man5-Fc are not prone to aggregation at either of the pH conditions 
tested here. Mixtures 3 and 7 (which have the high percent (50%) of the aggregation prone 
GlcNAc-Fc and N297Q-Fc proteins) show transitions at pH 6.0, while at pH 4.5; the N297Q-Fc 
containing mixtures do not show aggregation unlike the N297Q-Fc control. 
3.4 Discussion 
It is well established that comprehensive analytical characterization is the first step of 
biosimilarity assessments during manufacturing of biotherapeutics. Extensive analytical testing 
with respect to the primary and higher order structures of protein therapeutic candidates is 
essential in establishing the foundation of comparative biosimilarity.27 Also, the first 
experimental key step in biosimilar approval process is assessing comparative structural and 
functional properties between the biosimilar and the reference product and emphasis of the use of 
“orthogonal methods” and “fingerprint-like methods” by the FDA.28 The extensive biophysical 
techniques used in this study are shown to be useful in establishing differences in physical 
stability profile of mixtures of IgG1-Fc glycoforms. Initial characterization of the controls and 
mixtures did not show any significant differences in pI values and overall tertiary structure at pH 
6.0 (without temperature stress) as assessed by cIEF (shown in Figure 3.4) and second-derivative 




4.5 by intrinsic tryptophan fluorescence did not show any differences between the mixtures, and 
the controls at 10°C (see Figure 3.6). SEC was able to distinguish the N297Q-Fc control as it had 
a slightly higher content of high molecular weight species than the other controls and mixtures 
(Table 3.1).  SDS-PAGE analysis showed differences between each of the four IgG1-Fc controls 
except, between HM-Fc and Man5-Fc as observed before.23,24 As seen in Figure 3.2, the large 
sized glycoforms (HM-Fc and Man5-Fc) migrated nearest, GlcNAc-Fc which had intermediate 
size migrated to an intermediate distance, and the lowest sized N297Q-Fc migrated farthest on 
both reduced and non-reduced gels as observed previously.24 Similarly, the components of 50% 
mixtures and 90% mixtures were identified by SDS-PAGE based on the intensities of each band 
and migration of the components within the mixture as compared to controls. However, the 50% 
and 90% mixtures of HM and Man-Fc were not resolved in SDS-PAGE and were analyzed by 
mass spectrometry in the Tolbert lab. Intact mass analysis of the controls and mixtures was 
performed to identify N-glycans in the controls and composition of glycoforms in the mixtures. 
The percentage of glycoform composition in the mixtures was examined using the mass 
spectrometry peak intensity as evaluated previously for identification of glycosylation profiles in 
the controls.24 The results demonstrated that the estimated percentages of the mixture 
components (as shown in Figure 3.1) were accurately determined by mass spectrometry as 
described somewhere else. Other studies also showed that mass spectrometry has proved to be a 
very rapid and reliable tool in glycan content analysis in biosimilar comparability.29,30 Even 
though the information on the chemical structure of glycans can be elucidated by mass 
spectrometry, yet the differences in HOS need a broad array of different analytical techniques. 
It was evident from the results of PEG relative solubility and biophysical characterization 




pure IgG1-Fc controls are dependent on the type of glycoform and solution pH conditions. These 
techniques were able to distinguish structural and physical stability differences in homogenous 
glycoforms of differentially glycosylated IgG1-Fc (controls) and proved to be successful in 
distinguishing the various levels of differences between their mixtures as well. The % PEGmidpt, 
especially at pH 4.5 was most sensitive to monitor the differences between IgG1-Fc glycoform 
mixtures and also was able to successfully rank order their solubility profiles. As the results 
indicate, techniques like DSC, intrinsic and extrinsic fluorescence were successful in 
distinguishing between mixtures up to certain extent (controls and 50% mixtures) however, the 
ability to distinguish between the 90% mixtures (that were expected to show subtle changes) was 
lower. As seen in Figure 3.13, turbidity by OD 350 nm did not show any differences in all the 
mixtures and controls at pH 4.5, except N297Q-Fc, which showed significant increase in OD 350 
signal. However, at pH 6.0 OD 350 was able to detect changes between GlcNAc-Fc and N297Q-
Fc controls and their 50% mixtures (2 and 3) with HM-Fc, however it was not able to distinguish 
between any of the 90% mixtures. The 25 % mixture of all the glycoforms (Mixture 7) showed 
intermediate rise in OD 350 as compared to GlcNAc-Fc and N297Q-Fc controls at pH 6.0.  
Although the above biophysical techniques are considered as low resolution techniques, 
they are high throughput, well established, commonly available and widely used in the industry. 
The use of higher resolution analytical techniques such as NMR, X-ray crystallography, cryo EM 
and H/D exchange mass spectrometry to gain higher order structural information is limited as 
part of analytical comparability studies as a result of certain drawbacks.31 Hence, the biophysical 
techniques used in this work along with two pH conditions and temperature stresses prove useful 
in distinguishing between IgG1-Fc glycoform mixtures with regard to their solubility and 




are not readily apparent when monitored under non-stressed conditions (i.e., at low temperatures 
under neutral pH conditions).31 
In mutation prone diseases like infectious diseases or certain types of cancers it has been 
seen that the monospecific nature of mAbs makes them less effective in treatment. In such 
scenarios, recombinant polyclonal antibodies or antibody cocktails which can have a wide array 
of binding to complex target antigens and could show therapeutic potential.32,33 In such 
therapeutics, it is essential to characterize the individual components of these antibody mixtures 
to gain clinical approval. These products will also show glycosylation variation as seen in mAbs 
and will further complicate their control and characterization. Several analytical tools have been 
used to characterize such mixtures of antibodies including cation exchange chromatography, 
ELISA and mass spectrometry.33 However, not many studies have been conducted to understand 
their physical structure and stability. The biophysical characterization approach utilized in this 
study to characterize mixtures of IgG1-Fc glycoforms could be utilized for characterization of 
these antibody mixtures as well. 
In summary, the four control IgG Fc glycoforms and seven mixtures were evaluated for 
their physical stability and relative solubility profiles using an array of biophysical 
characterization tools. Future work should involve comparing the chemical stability and 
biological functions (performed in other labs at KU) of these mixtures along with these results 
to get a complete idea of their properties so that the mathematical model can determine the 
extent of similarity (biosimilarity) between these mixtures. These analytical tools were 
successful in detecting subtle and major differences in physical properties of these mixtures. 
Some of these assays were redundant and yielded little information (like cIEF, SEC, second 




overall analytical characterization approach by eliminating them or weighing the assays in the 
mathematical model. These studies have generated a large amount of stability and relative 
solubility data set, which will be utilized to develop a mathematical model for determining the 
level of biosimilarity between samples. It would be interesting to see if the developed 






















Table 3.1: Percent monomer content by SEC analysis showed the following results: HM-Fc 
control, Man5-Fc Control, GlcNAc-Fc Control, Mixture 1, Mixture 2, Mixture 3, Mixture 4, 
Mixture 5, Mixture 6, Mixture 7 showed ~ 99.0 % monomer purity and N297Q-Fc Control 
showed 97.9 % monomer purity. The monomer percent values are average calculated from 
triplicate runs, and the standard deviation ranged from 0.0 to 0.1. 
Mixture Average Monomer Percent 
HM-Fc control 99.7±0.0 
Man5-Fc Control 99.7±0.1 
GlcNAc-Fc Control 99.8±0.1 
N297Q-Fc Control 97.8±0.0 
Mixture 1 99.7±0.0 
Mixture 2 99.6±0.1 
Mixture 3 98.9±0.1 
Mixture 4 99.6±0.1 
Mixture 5 99.6±0.0 
Mixture 6 99.4±0.1 













Figure 3.1: Schematic representation of percent of purified IgG1-Fc glycoforms for the 
preparation of various well-defined IgG1-Fc mixtures and the N-linked Asn-297 glycoform 





Figure 3.2: SDS-PAGE characterization of mixtures IgG1-Fc glycoforms under non-reduced 
and reduced conditions. Sample included (See Figure 3.1 for composition of mixtures):  
1.HM-Fc Control;  
2.Man5-Fc Control;  
3.GlcNAc-Fc Control;  
4.N297Q-Fc Control;  
5.Mixture 1(HM-Fc:Man5-Fc::50:50);  
6.Mixture 2(HM-Fc:GlcNAc-Fc::50:50);  
7.Mixture 3(HM-Fc:N297Q-Fc::50:50);  
8.Mixture 4(HM-Fc:Man5-Fc::90:10);  
9.Mixture 5(HM-Fc:GlcNAc-Fc::90:10);  






Figure 3.3: Representative size exclusion chromatography (SEC) characterization of mixtures 
IgG1-Fc glycoforms at 280nm and inset are the zoomed in plots. SEC analysis showed the 
following results: HM-Fc control, Man5-Fc Control, GlcNAc-Fc Control, Mixture 1, Mixture 2, 
Mixture 3, Mixture 4, Mixture 5, Mixture 6, Mixture 7 showed ~ 99.0 % monomer purity and 
N297Q-Fc Control showed 97.9 % monomer purity. The monomer percent values are average 
calculated from triplicate runs, and the standard deviation ranged from 0.0 to 0.1. See Table 3.1 





Figure 3.4: Representative characterization of the isoelectric pH (pI) of mixtures IgG1-Fc 
glycoforms as measured by capillary isoelectric focusing (cIEF). cIEF analysis showed the 
following results for the major species: All the controls and mixtures show pI of 7.2 in 20 mM 
citrate phosphate, 150 mM NaCl buffer, at pH 6.0. The pI values are average values calculated 






Figure 3.5: Absorbance spectra and Second derivative UV-visible absorption spectra.  
A) Absorbance spectra and Second derivative UV-visible absorption spectra of triplicate runs of 
the four IgG1-Fc glycoform controls and seven mixtures from 240-400nm B) A representative 
2nd derivative spectra showing ultraviolet absorption peak positions of the following three 





Figure 3.6: Intrinsic (Trp) fluorescence spectra at 10°C of four IgG1-Fc controls (HM-Fc, 
Man5-Fc, GlcNAc-Fc and N297Q-Fc) and seven mixtures at pH 4.5(red) and pH 6.0 (black). 
The λmax values are also shown for each protein mixture at 10°C (pH 4.5 and pH 6.0). Each of the 
samples were run in triplicate with the standard deviation (SD) of λmax values ranging from 0.2 to 






Figure 3.7: Concentration of IgG1-Fc glycoform mixtures versus amount of PEG added to 
solution at pH 4.5(red) and pH 6.0(black). The error bars denote standard deviation for n = 3 





Figure 3.8: Comparison of % PEG midpoint and apparent solubility (thermodynamic activity) 
parameters of IgG1-Fc glycoform controls and mixtures by PEG precipitation assay at pH 4.5 
(A, B, C) and pH 6.0 (D, E, F). A and D show concentration of IgG1-Fc glycoform controls 
(HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) versus amount of PEG added to solution at pH 
4.5 and pH 6.0, respectively. B and E show the comparison of PEG midpoint (PEGmidpt) values 
(w/v) at pH 4.5 and pH 6.0, respectively. C and F show the comparison of apparent activity 
values at pH 4.5 and pH 6.0, respectively. Error bars indicate the standard deviation of three 
replicates.* No calculated parameters for N297Q-Fc at pH 4.5 were possible due to the non-ideal 





Figure 3.9: Comparison of representative curve-fitted DSC thermograms of IgG1-Fc glycoform 
controls and mixtures at pH 4.5 (red) and pH 6.0 (black). All samples were at 0.4 mg/mL. See 






Figure 3.10: Intrinsic fluorescence spectroscopy thermal melting curves of the 4 different 
glycoform controls of IgG1-Fc and 7 mixtures across the pH 4.5 (red) and pH 6.0 (black). The 
average peak positions of triplicate measurements are shown and the error bars representing the 





Figure 3.11: Extrinsic Sypro Orange fluorescence thermal melting curves in the presence of 
IgG1-Fc glycoform controls and mixture samples at pH 4.5 (red) and 6.0 (black). The average 
peak intensities of triplicate measurements are shown and error bars represent the standard 





Figure 3.12: Thermal stability by DSC, intrinsic tryptophan fluorescence and extrinsic Sypro 
Orange fluorescence. A and B show bar chart representation of Tonset values of four controls and 
seven mixtures of IgG1-Fc glycoforms measured by DSC at pH 4.5 and pH 6.0, respectively. C 
and D show bar chart representation of Tm values of four controls and seven mixtures of IgG1-Fc 
glycoforms measured by intrinsic fluorescence thermal melting curves at pH 4.5 and pH 6.0, 
respectively. E and F show bar chart representation of Tm values of four controls and seven 
mixtures of IgG1-Fc glycoforms measured by extrinsic SYPRO Orange fluorescence thermal 
melting curves at pH 4.5 and pH 6.0, respectively. The error bars indicate the standard deviations 




composition of mixtures. 
	
 
Figure 3.13: Optical density (OD) at 350nm as a function of temperature of the 4 IgG1-Fc 
glycoform controls (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) and seven mixtures of the 
controls at pH 4.5 (red) and pH 6.0 (black). The average OD 350 nm values of triplicate 
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Chapter 4 Correlating the Impact of Glycosylation on the Backbone 






Glycosylation is a widespread and complex post-translational modification occurring 
naturally in human proteins as well as in therapeutic proteins that introduces structural 
heterogeneity.1-4 Development and regulatory approvals of glycosylated monoclonal antibodies 
(mAbs) as well as Fc-fusion proteins, antibody–drug conjugates (ADCs) and antibody fragments 
have increased dramatically over the past three decades.5,6 The IgG1 subclass of antibodies, 
which are the most abundant form found in human serum as well as the most popular subclass 
for approved mAb therapeutics, show N-linked-glycosylation (glycan attached to the amide 
group of asparagine) at Asn-2977-10 located in a conserved amino acid sequence of Asn-X-
Ser/Thr (X: any AA except Pro) in the constant heavy chain of the Fc region.11 The Fc sequence 
is highly conserved in subclasses of IgG (except a few amino acid residues)10 and the 
heterogeneous N-glycan structures are known to modulate different effector functions of IgG 
antibodies like antibody-dependent cellular cytotoxicity (ADCC) and complement dependent 
cytotoxicity (CDC) as well as antibody clearance by affecting FcɣR, C1q and FcRn (observed 
recently) binding, respectively.10,12,13 Naturally occurring N-glycans of IgG1 antibody in the 
human serum are complex, biantennary (consists two arms: one α-1, 3 arm and one α-1, 6 arm) 
type containing a common seven glycan core (4 N-acetyl glucosamine (GlcNAc), and 3 mannose 
(Man)).14,15 Glycan heterogeneity in antibodies exists depending upon the site occupancy 
(symmetric or asymmetric) and type of glycans attached to the common core which governs the 
binding to various receptors affecting the antibody biological functions.16-18 For example, 
presence of terminal and bisecting GlcNAc and absence of Fuc(fucose) increased ADCC by 
increasing receptor affinity, increasing terminal sialylation reduced ADCC, and presence of 




area of research to better understand mechanisms underlying these glycosylation effects so that 
antibodies can be engineered to improve and obtain the desired therapeutic effects.16,19,22-24 
Therapeutic efficacy of IgG mAbs depends on their structural integrity and 
conformational stability, local flexibility and biological functionality.24-27 N-glycosylation at 
Asn-297 of CH2 domain is important for the structural integrity, flexibility, physicochemical 
stability, aggregation stability and PK/PD properties of therapeutic mAbs.19,28-31 Hence, it is 
necessary to closely monitor the molecular heterogeneities like glycosylation and evaluate their 
consequences on product quality, stability, and efficacy during development of mAbs products 
and their corresponding biosimilar candidates.24,32-36 Recombinant therapeutic mAbs that require 
N-glycosylation are produced in mammalian expression hosts (like CHO, SP20 and NSO cells) 
that have the ability to produce human like glycosylation patterns.37,38 Additionally, attempts 
have been made to achieve a high degree of control over glycan heterogeneity and achieving 
glycan reproducibility by ensuring tight controls of the manufacturing protocols.39 However, 
heterogeneity still exists in mAbs produced in these expression systems that could affect the 
product quality, for example, mAbs having unnatural glycans such as the presence of N-
glycolylneuraminic acid (NGNA) when expressed by mouse cell lines (instead of N-
acetylneuraminic acid, NANA), or presence of small amounts (ranging from 1%-20%) of high-
mannose (Man5-Man9) type of glycans.39-42 For example, high mannose (HM) glycoforms of 
IgG showed reduced serum half-life by binding to mannose receptor, increased ADCC and 
reduced CDC activities as compared with complex fucosylated or hybrid glycan antibodies.19,43 
Hence, monitoring glycan content and heterogeneity is a critical product quality attribute during 
therapeutic mAb production, when manufacturing changes (comparability) are made or during 




activity of monoclonal antibodies will help to obtain the desired therapeutic outcome.19,45,46 
Ensuring protein stability within a pharmaceutical dosage form, from manufacturing through 
patient administration, is a critical aspect of therapeutic protein development, where 
physicochemical degradation may lead to loss of potency, aggregation and 
immunogenicity.24,26,47 To improve long-term stability of glycoproteins during pharmaceutical 
development, various glycoengineering strategies have become popular due to stability 
increasing effects of glycans on proteins.48,49 Also, monitoring the impact of glycosylation on 
stability is critical during comparability and biosimilar development due to heterogeneous nature 
of glycosylation and their subtle effects on the physicochemical structure.24,50-52 Hence, it is 
important to understand how glycosylation affects protein stability of antibodies, and in addition, 
the inter-relationships between stability versus the desired biological activity need to be 
established. 
To this end, we generated a series of well defined, near homogenous IgG1-Fc glycoforms 
with serially truncated glycan residues and analyzed them using the physical, chemical and 
receptor binding assays as described previously (resulting in a series of four manuscripts which 
appeared in the February 2016 issue of Journal of Pharmaceutical Sciences).28,29,31,53 For 
example, results showed that different IgG1-Fc glycans not only affect chemical degradation 
differently (especially deamidation of Asn-315 and transformation of Trp-277 into glycine 
hydroperoxide), but also can lead to different impurity profiles.29 Also, correlations of physical 
stability with the size of glycans between HM, Man5, GlcNAc and N297Q IgG1-Fc glycoforms 
was observed, where HM and Man5-Fcs had higher physical stabilities, apparent solubility 
values and stronger receptor binding than the GlcNAc and non-glycosylated N297Q-Fc as 




respectively.28,31 These results showed a correlation of decreased length of glycan with decreased 
physical stability and binding. These large biophysical data sets of these samples generated at 
various pH and temperature conditions were further utilized to develop an integrated 
mathematical model for biosimilarity analysis.53  
In this chapter, we measure the local flexibility of four well-defined glycoproteins by 
pepsin digestion followed by hydrogen deuterium exchange mass spectrometry (HX-MS). HX-
MS provides information on in higher order structure (HOS) by monitoring the protein’s 
backbone amide hydrogen exchange, which is an indicator of solvent exposure and hydrogen 
bonding in the protein. Peptic peptides are analyzed by LC-MS to assess the deuteration level of 
each peptide, so that localized differences in higher order structure is obtained at peptide level. 
HX-MS has been used extensively to investigate subtle higher order structural changes and 
dynamics in mAbs as a consequence of aggregation, reversible self-association, oxidation, 
excipients and mutation.25,54-61 However, only a few extensive HX studies have been carried to 
study the effects of glycosylation on flexibility in different IgG1 and IgG2 antibodies, and 
correlating the impact of a certain glycan to flexibility differences in the Fc were often limited by 
glycan heterogeneities present in the sample, not considering the effects of exchangeable 
hydrogens in glycans and the possibility of glycan effects on the intrinsic kinetics of HX.32,54,55,62 
In this work, we correlate the local structural flexibility alterations, especially in the CH2 domain, 
with IgG1-Fc glycoform’s overall conformational stability, chemical stability and receptor 
binding profiles a previously reported in our laboratories. 28,29,31,53 
 





4.2.1.1 Preparation and initial characterization of IgG1-Fc glycoforms 
The IgG1-Fc glycoforms (high-mannose-Fc (HM-Fc), Man5-Fc, GlcNAc-Fc and N297Q-
Fc) were prepared by expression of HM-Fc in glycosylation-deficient strain of Pichia pastoris 
followed by in-vitro enzymatic digestion of HM-Fc by α-1, 2-mannosidase and endoglycosidase 
H (Endo H) to obtain the truncated Man5-Fc and GlcNAc-Fc, respectively as discussed in 
previous work.31 For the N297Q non-glycosylated IgG1-Fc, mutagenesis was used to remove the 
N-linked glycosylation site as described before.31 The proteins showed high purity, and no 
significant proteolysis products, high molecular weight species (HMWS) and charge 
heterogeneities were present after purification and enzyme truncation as described previously.31 
The HM-Fc was heterogeneous, with N-glycans containing 8 to 12 mannose residues (Man8-
Man12) at each N297 site, with the major glycan being the Man8GlcNAc2 form as characterized 
previously.31 The truncated Man5-Fc, GlcNAc-Fc glycoforms and the non-glycosylated N297Q-
Fc were well-defined and highly homogenous.31 With decreasing glycan size, the HM, Man5, 
and GlcNAc glycoforms IgG1-Fc form a well-defined series of model glycoproteins. The non-
glycosylated N297Q-Fc mutant was used as a negative control in these studies. 
4.2.1.2 Sample preparation for hydrogen exchange mass spectrometry (HX-MS) 
For hydrogen exchange mass spectrometry studies, all four Fc glycoforms were dialyzed 
at 4°C in a 20 mM citrate phosphate buffer with ionic strength adjusted to 0.15 by NaCl at pH 
6.0. Dialysis was performed at 4°C and subsequently, the proteins were concentrated as 
described elsewhere.28 The final adjusted protein stock concentration of 1 mg/mL was 
determined by absorbance at 280 nm as measured by an Agilent 8453 UV–visible 




phosphate and sodium chloride were purchased from Sigma-Aldrich (St Louis, MO) while citric 
acid anhydrous and citric acid monohydrate were purchased from Fisher Scientific all at the 
highest purity grade. Liquid chromatography grade acetic acid and phosphoric acid, tris (2-
carboxyethyl) phosphine hydrochloride (TCEP), porcine pepsin, guanidine hydrochloride, and 
deuterium oxide (99+%D) were purchased from Fluka/Sigma–Aldrich (St. Louis, Missouri). 
Liquid chromatography–mass spectrometry (LC–MS)-grade formic acid (+99%) was purchased 
from Thermo Scientific (Rockford, Illinois). LC-MS-grade water, acetonitrile, and isopropanol 
were purchased from Fisher Scientific (Fair Lawn, New Jersey). 
4.2.1.3 Deuterated labelling buffer preparation 
Deuterium-based labelling buffer contained 0.15 M sodium chloride, and 20 mM citrate-
phosphate at pH 6.0 in 99.9 atom % D2O. The pH of the buffer was then measured and adjusted 
by adding 0.4 units to the pH meter reading which takes into account the correction for the 
deuterium isotope effect when measuring pD with a pH meter.63 The same batch of buffer was 
used for HX experiments for all the four IgG1-Fc glycoforms to avoid any variation in the buffer 
properties. 
4.2.2 Methods 
4.2.2.1 Homology model 
The The X-ray structure of the Fc from Thr108-Lys330 (PDB ID: 1HZH)64 was used as the 
template for the Fc homology models. The sequence identity was 100%, except for N297Q-Fc 





Hydrogen Hydrogen exchange was performed using an H/DX PAL robot (LEAP 
Technologies, Carrboro, North Carolina) and MS measurements were conducted using a QTOF 
mass spectrometer (Agilent 6530, Santa Clara, California) with Agilent 1260 Infinity LC 
System. For HX, deuterium labelling of Fc glycoproteins was performed in triplicates as 
published previously.  Exchange reactions were quenched after incubation for 5 labeling times: 
15 s, 102 s, 103 s, 104 s and 86400 s and the quenched samples were digested by an immobilized 
pepsin column, prepared in-house as published before.65 As previously described elsewhere, a 
standard LC-MS procedure for HX-MS66,67 was used and the carry-over from the pepsin column 
between samples was removed using a two-wash cocktail method.68 All HX-MS measurements 
were made relative to HM-Fc, so this form was run  in parallel in the same day with each of  the 
three glycoforms (Man5-Fc, GlcNAc-Fc and N297Q-Fc) to control for day-to-day variability. 
4.2.2.3 Peptide mapping and glycopeptide identification 
Prior to HX-MS analysis, combination of accurate mass measurements and collision 
induced dissociation (CID) with tandem MS was used to identify a total of 51 peptides listed in 
Supplementary Table 4.1. Identified peptides covered 100% of the primary sequence of the 
heavy chain of the IgG1-Fc glycoforms. Different fragmentation strategies were utilized by using 
different collision energies for fragmentation of the glycopeptides to be able to confidently 
confirm their identities. A preferred list of glycopeptides which had very low MS/MS scores and 
no MS/MS data was made and the glycopeptides in the list were then subjected to fragmentation 
by modifying the collision energy. The following collision energy equation by Agilent was used 
to optimize the collision energy for fragmentation by changing the offset values. 
Collision Energy = !"#$%×
! !
!""




Glycopeptides tend to undergo glycan fragmentation during collision induced dissociation (CID) 
and hence the energy of fragmentation needs to be optimized so that ideally, the glycans undergo 
minimal fragmentation without hindering the peptide backbone (amide bond) fragmentation. It is 
not possible to prevent glycan fragmentation in CID and thus oxoniuim ions that are 
characteristic ions of their respective glycopeptides were utilized to confirm the identity of each 
glycopeptides for the four IgG1-Fc glycoforms.69,70  
4.2.2.4 Deuteration controls 
Deuterium recovery was estimated separately using highly deuterated peptides. The 
deuteration controls of each peptide belonging to each glycoform (HM-Fc, Man5-Fc, GlcNAc-Fc 
and N297Q-Fc) were prepared separately by first collecting peptic peptides following pepsin 
column digestion. The peptides were subsequently dried on a vacuum concentrator and 
reconstituted in H2O buffer, at pH 6.0. Afterwards, the peptides were deuterium labeled for 4 hr 
and analyzed like standard samples. Based on the deuteration controls, the deuterium recovery 
ranged between 30.74% and 80.84%. The deuterium contents in 3 glycopeptide (17, 18, and 19) 
controls of all the 4 IgG1-Fc glycoforms are provided in the Supplementary Table 4.2. 
4.2.2.5 HX-MS data analysis 
Initial peptide LC-MS feature extraction and centroid calculations were carried out using 
HDExaminer (Sierra Analytics, Modesto, CA). All MS results were individually inspected to 
insure reliability. Retention time window adjustments were manually applied as needed. 
Additional numerical and statistical analysis was carried out in Excel (Microsoft, Redmond, 









×100%   (1) 
where m denotes peptide centroid mass and t is the HX time. tm  is the mean of the centroid value 
from triplicate measurements, m0 is the theoretical centroid mass of the undeuterated peptide, 
and m∞  is mean of the centroids obtained from the deuteration control. 
Differential exchange, ∆HX! values at each HX time, representing the difference in HX for each 
peptide of IgG1-Fc glycoform (subscript g) relative to the same peptide in the HM-Fc (subscript 
HM-Fc) is given by: 
g,t HM,HX % %t tD DΔ = −  (2) 
For mapping HX effects onto an Fc homology model, HX data from all time points for each 
peptide were averaged into a single value, ∆HX, representing the average difference in HX 















  (3) 
where the index i covers the range of discrete HX times ti. For overlapping peptides covering the 
same residues, statistically significant differences, defined subsequently, took precedence over 
insignificant results. There were no cases of significant differences of opposite sign, i.e., no cases 
where both significantly faster and slower exchange were observed in overlapping peptides. 
Standard error was propagated assuming random, uncorrelated error based on conventional error 








ε =  (4) 
where s denotes the sample standard deviation i.e., ( ) ( )2 1x x n− −∑ . Significant differences 
were identified using the criterion that the measured differential exchange was three-fold greater 
than the propagated standard error (i.e., ∆HX > 3𝜀). More specifically, the propagated standard 

















































×100  (6) 



































































































×100  (8) 
Where m∞  is mean of the centroids obtained from the deuteration control for each glycopeptide 
of each IgG1-Fc glycoform (subscript g) and the HM-Fc (subscript HM-Fc). 
4.3 Results 




The backbone flexibility of IgG1-Fc as a function of N-linked glycosylation was 
analyzed by incubating four Fc constructs with well-defined glycosylation: High Mannose (HM), 
Man5, GlcNAc and N297Q in D2O buffer containing 20 mM citrate-phosphate buffer and 0.15 
M NaCl (pH 6.0) for varying periods of time. The labeled samples were subsequently quenched, 
digested, and analyzed by LC-MS. A total of 51 IgG1-Fc peptides were reproducibly generated 
by pepsin digestion, resulting in sequence coverage of 100% for the constant heavy chain of 
IgG1-Fc of the four glycoforms. For convenience, the peptides are indexed sequentially from the 
N-terminus (peptide 1) to C-terminus (peptide 51) as listed in Supplemental Table 4.1. Figure 4.1 
shows the progression of HX, a readout of  the Fc backbone flexibility, in three peptic peptides 
17, 18 and 19 that span heavy chain (HC) residues 278-299, 278-300 and 282-300 respectively, 
and include the C’E loop and glycosylation site. As seen in Figure 4.1, the rate of hydrogen 
exchange in these three glycopeptides showed an inverse trend of faster HX with decreasing 
glycan size: HX was fastest in non-glycosylated N297Q-Fc, intermediate in GlcNAc-Fc, and 
slowest in Man5-Fc and Man8-Fc (HM-Fc). The Man5 form exchanged faster than Man8 in 
glycopeptides 17 and 18, but similar exchange was observed between these forms in 
glycopeptide 19. Although there are interesting trends in the glycopeptide data in Figure 4.1, 
several factors make more direct and quantitative comparisons of HX rates between these three 
glycopeptides problematic (see Discussion section).  
The HX kinetics for three glycopeptide segments of the individual high mannose forms 
(Man8-Man12) are shown in Figure 4.2. The high mannose glycopeptides 17 and 18 cover 
residues 278-299 and 278-300 similar to results shown for other glycoforms in Figure 4.1, 
however an additional glycopeptide covering residues 278-306 was identified in the high 




high mannose Fc suggesting that differences in glycosylation might alter pepsin digestion 
specificity. There are subtle, but statistically significant, differences in hydrogen exchange 
kinetics observed in glycopeptide 17. In general, the Man8 form exchanges more slowly than the 
Man5 (as seen in Figure 4.1) and Man9-Man12 glycoforms (as seen in Figure 4.2). The HX rate 
trends in Man5 and HM glycopeptides 18, 19 and 278-306 (as seen in Figures 4.1 and 4.2) are 
similar to peptide 17, but more subtle. The above results indicate that the degree of change in HX 
depended on the degree of glycan size, suggesting that backbone flexibility near the 
glycosylation site is minimized by glycans of intermediate length. This result suggests that 
higher mannose forms might promote greater flexibility in the backbone in regions proximal to 
the glycosylation site, but such conclusions based on these trends should be viewed as tentative, 
given the many limitations in the more direct and quantitative analysis of the HX results on the 
glycopeptides (see Discussion section).  
4.3.2 Glycosylation has distal effects on Fc Backbone Flexibility 
The hydrogen exchange kinetics for eight peptides representing regions distal from the 
glycosylation site for each of the four IgG1-Fc glycoforms are shown in Figure 4.3. Peptide 2 
(HC residues 225-240) covers the hinge and proximal CH2 domain, peptide 4 (HC residues 235-
252), peptide 12 (HC residues 262-277), peptide 23 (HC residues 301-306) and peptide 24 (HC 
residues 306-318) all cover the CH2 domain, peptide 27 (HC residues 334-348) covers the CH2 
and CH3 domain interface, and peptide 34 (HC residues 359-367) and peptide 48 (HC residues 
424-447) cover the CH3 domain. The rates of HX in these regions give a qualitative readout of 
the backbone dynamics. For example, peptide 23 (HC residues 301-306) and peptide 34 (HC 
residues 359-367) in the CH2 and CH3 domain respectively, exchange slowly, indicating that 




exchanges rapidly, indicating that the protein backbone is dynamic in this region. The data in 
Figure 4.3 also show that the HX rate is affected by the glycans. For example, the HX rate of 
peptide 2 is much faster in the non-glycosylated N297Q-Fc compared to HM-Fc, Man5-Fc and 
GlcNAc-Fc. This result indicates higher flexibility of the hinge and proximal CH2 domain 
regions in the deglycosylated Fc. Hydrogen exchange kinetics for HM and Man5-Fcs were 
similar in the regions spanned by peptides 4 and 23 from the CH2 domain. However, in peptide 
12, exchange by Man5-Fc was slightly slower than HM-Fc (differences are apparent at 104 s and 
86400 s) while in peptide 24 HX was faster (differences at 10 s, 102 s and 103 s) than HM-Fc. In 
the CH2 domain peptides 4,12,23,24, and 27, there is a trend from fastest HX in the 
aglycosylated (N297Q) form, to intermediate HX by the GlcNAc-Fc to equal, slow HX by HM-
Fc and Man5-Fc.  These results indicate that as the size of the glycan attached to N297 is 
truncated from HM or Man5 down to GlcNAc or is completely removed (in N297Q-Fc), the 
flexibility in these CH2 domain regions increases. In contrast, the extent of glycosylation did not 
have a substantial effect on CH3 domain peptides 34 and 48, except that HX was slightly faster in 
these regions for N297Q-Fc suggesting that complete removal of the glycan causes increased 
flexibility of the CH3 domain as well, distal from the glycosylation site in the quaternary Fc 
structure. 
4.3.3 Flexibility Differences in IgG1-Fc glycoforms (focusing on aggregation hot spots, 
deamidation hot spots and glycopeptide C’E loop) 
HX difference plots in Figure 4.4 show the effects of altered glycosylation in the IgG1-Fc 
glycoforms (Man-5 Fc, GlcNAc-Fc and aglycosylated N297Q) relative to high mannose species 
for all 51 peptides covering the IgG1-Fc at each individual HX time. The vertical axes are the 




HM-Fc glycoform, used as the baseline. For calculating differential HX in glycopeptides 17-19, 
Man8 was used as the baseline, as it showed the slowest HX among the different HM form 
glycopeptides (see Figure 4.2). The peptides are indexed from the N- to C-terminus and 
represented on the horizontal axes. The locations of each peptide are provided in Supplemental 
Table 4.1. A positive value indicates faster exchange by the glycoform than by high mannose 
while a negative value indicates slower exchange. The dashed lines in Figure 4.4 indicate the 
limits for statistical significance as calculated by equation 5. Overall, the HX difference or ΔHX! 
values indicate that backbone flexibility increases in the order of Man5 < GlcNAc < N297Q, as 
shown in Figure 4.4. All of the large significant changes were positive, meaning that the 
backbone flexibility increased in Man5, GlcNAc and N297Q IgG1-Fc states compared to the 
HM-Fc. However, there were also some small, but significant, decreases in HX, meaning that 
some regions exchanged slightly more slowly relative to the baseline HM-Fc. These small 
decreases in HX were in peptides 12 (HC residues: 262-277), 13 (HC residues: 263-277) and 14 
(HC residues: 264-277) of Man5-Fc, in the CH2 domain, peptides 36 (HC residues: 368-380), 38 
(HC residues: 369-379), 41 (HC residues: 377-390) and 46 (HC residues: 405-423) of Man5-Fc, 
in the CH3 domain, and peptides 36 and 46 in the CH3 domain of GlcNAc-Fc.  
Several regions of interest in the CH2 domain (see Discussion section) are denoted in 
Figure 4.4: two aggregation hot spots (as determined by correlation to aggregation propensity 
shown in previous work25,60), a deamidation prone NG site at Asn-315 (shown previously29), and 
the glycopeptide containing C’E loop (the C’E site is essential for the Fc receptor binding, also 
shown in previous work71,72).  Changing the glycan from HM to either GlcNAc or aglycosylated 
caused substantial increases in the rate of HX in both aggregation hotspots and in the 




HX in these regions. Overall, Figure 4.4 shows that decreasing glycan size results in faster HX. 
For each of the peptides spanning the regions of interest denoted in in Figure 4.4, the HX 
difference plots, relative to the high mannose control, show that Man5-Fc exchanges more 
slowly than either GlcNAc-Fc or N297Q-Fc. HX is generally faster in GlcNAc-Fc and fastest in 
N297Q-Fc. Decreasing the glycan size from HM to GlcNAc or removal of the glycan (N297Q-
Fc) caused significant increases in backbone flexibility in the peptides covering the aggregation 
hot spot regions. The effects of glycan removal were stronger (i.e., greater increases in HX rate) 
than simply decreasing the glycan to GlcNAc (see the annotated regions in Figure 4.4). Less 
obvious, but still statistically significant increases in HX occurred in some of these regions when 
the glycan was decreased from HM to Man5. For example, peptide 8 spanning the aggregation 
hot spot region #1 of Man5-Fc showed a significant increase in flexibility at 104 s.  
The Fc contains a deamidation hotspot, NG, at 315-316, which is covered by peptides 24 
and 25. Decreasing the glycan from HM to GlcNAc or removal of the glycan caused 
significantly faster HX exchange in the region of the deamidation hotspot, most evident at 104 s. 
HX by Man5-Fc also was significantly faster in this region than HM-Fc, but the degree of 
increase was smaller than GlcNAc and N297QFc.  
Several glycopeptides, 17-19, cover the C’E loop region. Here, the high mannose form is 
heterogeneous, Man8-Man12. Man8 was selected as the baseline to represent HX by the HM-Fc 
in this region. Here, all the Man5, GlcNAc, and N297Q glycoforms exchanged faster than the 
Man8 glycoform except for glycopeptide 19 where there was no significant difference between 
HX by Man5 and Man8. This effect extends into another region, peptide 16 (HC residues 278-
293), that begins on the N-terminal side of the C’E loop. There are other regions, such as the 




glycan is shortened or removed. These trends must be viewed with caution, however, because of 
potential artifacts arising in the HX kinetics of glycopeptides.73 We will return to this point in the 
Discussion. 
4.3.4 Homology Mapping of Flexibility Differences in IgG1-Fc glycoforms 
Figure 4.5 shows the difference plots of HX effects as a function of glycosylation, using 
the average HX difference across all time points compared to the high mannose Fc control and 
also displays the results as mapped onto a homology model of the IgG1-Fc. Additionally, regions 
of interest are mapped on to a homology model as seen in Figure 4.5, panel A. The vertical axis 
in Figure 4.5, panel B shows the average HX difference ( HXΔ , as defined by equation 3) across 
all HX time points for all 51 peptides between each IgG1-Fc glycoform versus the HM-Fc 
baseline. In this representation, the changes in backbone flexibility (increases or decreases) 
presented in Figure 4.4 are averaged over all the five HX time points. The significant differences 
in ∆HX were mapped onto the homology model (Figure 4.5, panel C). For overlapping peptides 
with conflicting results, significant changes were given priority (see Materials and Methods for 
more details). Regions with strongly increased HX (∆HX > 5%) and weakly increased HX (∆HX 
< 5%) as compared to HM-Fc were mapped in dark blue and cyan colors on the homology 
model, respectively. While, regions with decreased HX as compared to HM-Fc are colored pink, 
regions with no significant difference in HX with respect to HM-Fc are colored gray and the 
glycans are colored green. There were significant differences in the glycopeptides (17-18) and a 
trend that correlated with the size of N-glycan attached. However, as already noted, direct and 
quantitative comparison of glycopeptides is complicated (see Discussion section). In general, 
there was an overall increase in HX rate in the Fc molecules as the glycans were truncated from 




points, the weak Man5-Fc effects are more obvious than in Figure 4.4, especially for the 
aggregation and deamidation hot spot regions. In peptide 8, covering aggregation hot spot #1, 
there was a significant increase in HX by Man5-Fc, but no significant increases in HX in 
peptides 20-23, spanning aggregation hot spot # 2. In the deamidation hotspot, spanned by 
peptides 24 and 25, there was a significant increase in flexibility as compared to HM-Fc not 
apparent in the individual time points shown in Figure 4.4.  The CH2 and CH3 domain peptides 
that exchanged more slowly than HM-Fc, as noted for 104 s of labeling in Man5-Fc and GlcNAc-
Fc in Figure 4.4, were not significantly different when averaged over all HX times in Figure 
4.5B, except for one peptide number 12 in Man5-Fc, which showed significant decrease in 
backbone flexibility as compared to HM-Fc (shown in pink region in the homology map in 
Figure 4.5C). The degree of increase in ∆HX values as well as the number of peptides with 
significant increases in flexibility increased with truncation of glycans from Man5 to GlcNAc 
and N297Q (as compared to the high mannose IgG1-Fc control). As seen in Figure 4.5 panel C, a 
few peptides in CH2 and CH3 domains showed significant increase in ∆HX values and flexibility 
of Man5-Fc as compared to HM-Fc. The degree of increase was weak (∆HX < 5%). One region 
also showed decrease in ∆HX values and flexibility as compared to HM-Fc. In GlcNAc-Fc, all 
the peptides in the CH2 domain and a few peptides in the CH3 domain showed significant 
increase in ∆HX  and flexibility as compared to the HM-Fc. While majority of these peptides 
showed a weak degree of increase, a few peptides in the CH2 domain showed strong degree (∆HX 
> 5%) of increase in HX which was not observed in the Man5-Fc. The largest increase in ∆HX 
values and flexibility were seen upon de-glycosylation where essentially the entire IgG1-Fc 




flexibility were observed in all the peptides of CH2 domains and few peptides in the CH3 
domains of N297Q-Fc as compared to HM-Fc. 
4.4 Discussion 
The goal of this work was to examine the effect of glycan size on  the local flexibility of 
four well-defined IgG1-Fc glycoforms in order to correlate these results with known chemical 
stability, conformational stability, aggregation propensity and FcɣRIIIa receptor binding studies 
that were published recently as a series of papers.28,29,31 The hydrogen exchange results in this 
work revealed a trend of increasing backbone flexibility with decreasing N-glycan size (relative 
to high mannose) in the IgG1-Fc molecules. Decreasing the glycan size to Man5 caused smallest 
increase in backbone flexibility (mostly in the CH2 domain and CH2/CH3 interface) relative to 
HM-Fc. Further decreasing the glycan to a single GlcNAc at both Asn-297 sites caused more 
widespread and larger increases in backbone flexibility. Finally, removal of the glycan (N297Q-
Fc) caused the largest increase in backbone flexibility across the entire IgG1-Fc molecule. The 
differences in flexibility were more prominent in the CH2 domain; however, flexibility 
differences in some regions of the CH3 domains were also observed among these four 
glycoforms. 
The overall physical stability, chemical stability and receptor binding profiles of the four 
IgG1-Fc glycoforms were studied previously, and showed a correlation with oligosaccharide 
structure:  HM-Fc and Man5-Fc displayed the highest relative physical stability, followed by 
GlcNAc-Fc, with N297Q-Fc being the least stable.28 Also, apparent solubility values 
(thermodynamic activity) measured by PEG precipitation assay, of these IgG1-Fc glycoforms 
decreased as the glycans were sequentially truncated from HM to non-glycosylated N297Q.28 




the aggregation propensity of the HM-Fc and Man5-Fc, as measured by a turbidity assay.28 
Additionally, HM-Fc and Man5-Fc both had similar high affinities for FcγRIIIa, GlcNAc-Fc had 
relatively low affinity, and the non-glycosylated N297Q-Fc had no measurable affinity for 
FcγRIIIa.31 Similarly, HM-Fc and Man5-Fc showed higher susceptibility for Trp-277 oxidation 
and lower susceptibility towards Asn-315 deamidation than GlcNAc and non-glycosylated 
N297Q IgG1-Fc.29 It is important to see the overall flexibility results of the various IgG1-Fc 
glycoforms in the light of conformational stability, aggregation propensity and receptor binding 
of mAbs in general, as these comparisons should ultimately provide insight into their 
pharmaceutical development as discussed below.   
4.4.1 Correlation of previous aggregation propensity results of IgG1-Fc glycoforms with 
HX Results 
Aggregation is a complex, multi-step process involving both local hot spots (areas of 
local structural alterations and/or enhanced flexibility) and global factors including overall 
conformational and colloidal stability.74 Hydrophobic, aggregation-prone sites in IgG antibodies 
have been identified in both the variable and constant regions of IgG molecules by in silico 
analysis.75 HX-MS studies have identified a particular segment near the Phe-243 in HC residues 
241–252, FLFPPKPKDTLM  (peptides 3-8 in this study) in CH2 domain of the Fc that became 
more flexible in response to a variety of stresses including destabilizing additives (thiocyanate 
and arginine), anti-microbial agents, methionine oxidation, deglycosylation and point mutations 
in CH2.25,54,58,60,66,76 Previously, two separate studies from our lab identified this region as the 
aggregation hotspot (referred to as aggregation hotspot # 1 in this study, see Figure 4.4).25,60  
Additionally, we observed changes in backbone flexibility in another region across the four 




domain. This result was consistent to previously seen increases in flexibility of this region of an 
IgG1 mAb in presence of thiocyanate 25. This particular region exchanges quite slowly, so that 
differences only become apparent after long HX times, as seen in our study and in the previous 
study.25 Increases in backbone flexibility in residues V273-L306 upon substitution of complex 
glycans with high-mannose glycans in an IgG2 antibody have been reported recently by HX-
MS.32  In this region (Y300-L306), the N297Q mutation caused greatest increase in flexibility, 
the GlcNAc-Fc form caused intermediate increase, while Man5-Fc did not cause a significant 
change compared to HM-Fc. Here, we denote this second region as aggregation hot spot # 2 
(peptides 20-23, see Figure 4.4). The extent of change in the backbone flexibility (of these two 
aggregation hot spots in the CH2 domain), conformational instability (studied in Chapter 2), and 
increased aggregation propensity (studied in Chapter 2) of IgG1-Fc glycoforms correlate well 
with decreased size of N-linked glycan.28 As seen in Chapter 2, we have found  that under 
thermal stress, both the non-glycosylated N297Q-Fc and GlcNAc-Fc both aggregated at the same 
onset temperature at pH 6.0 in 150 mM NaCl formulation, but the extent of N297Q-Fc 
aggregation was more extensive as seen the OD 350 values. However, GlcNAc-Fc was more 
aggregation prone in another formulation that contained 10% sucrose instead of NaCl.28 In this 
same assay, HM-Fc and Man5-Fc showed no aggregation under any of the experimental 
conditions tested (see Chapter 2).28 Two phenylalanine residues in this region (Phe-241 and Phe-
243) pack against the glycans in the crystal structure,64 and these interactions would expected to 
be absent in the GlcNAc and non-glycosylated CH2. Although comparisons between HX kinetics 
at the glycan site itself are qualitative in nature (See Figures 4.1 and 4.2, and discussion below), 




core) at the Asn-297 underscores the importance of this core residue in stabilization of the IgG 
backbone, presumably through side chain-glycan interactions. 
4.4.2 Correlation of previous Asn-315 deamidation and Trp-277 oxidation of IgG1-Fc 
glycoforms results with HX results 
It was previously observed that the deamidation of Asn-315 of HM-Fc, Man5-Fc, 
GlcNAc-Fc and N297Q-Fc during a 3-month accelerated stability study at 40°C was dependent 
on the size of N-glycans.29 It was observed that the rate and extent of deamidation of Asn-315 
was faster for GlcNAc-Fc and N297Q-Fc than HM-Fc and Man5-Fc, indicating that trimming or 
removal of the N-glycan promotes deamidation of Asn-315.29 A direct correlation between the 
rate of Asn-315 deamidation and the local flexibility of peptides (24 and 25) containing the Asn-
315 was observed with the four IgG1-Fc glycoforms. We saw that backbone flexibility of the 
CH2 domain in peptides 24 and 25 (containing Asn-315) significantly increased as the size of 
glycan was truncated from HM-Fc, to Man5-Fc, GlcNAc-Fc and non-glycosylated N297Q-Fc 
(see Figure 4.3 for uptake plot of peptide 24, and Figures 4.4 and 4.5 for difference plots of 
peptides 24 and 25). Previous studies have reported deamidation of Asn-315 in IgG mAbs, both 
in vivo and in vitro, and attributed this result to changes in flexibility near Asn-315 region.18,77-82 
We are also examining this intriguing correlation by HX-MS in greater detail elsewhere.83 The 
role of N-glycan size in governing the rate of Asn-315 deamidation by affecting the flexibility in 
this region has not been reported before to best of our knowledge with IgG1-Fc molecules. 
Additionally, an accelerated stability study of the above four IgG1-Fc glycoforms at 40°C 
for 4 weeks showed a different correlation of glycosylation with the rate of degradation of Trp-
277 to glycine hydroperoxide (Gly-277).29 The HM-Fc and Man5-Fc showed higher rate of 




N297Q-Fc, indicating that the decrease in size of N-glycan decreases the degradation of Trp-
277.29 In this HX study, we observed that peptide 12 (HC 262-277) containing Trp-277 in the 
CH2 domain showed highest flexibility in N297Q-Fc (see Figure 4.3), intermediate flexibility in 
GlcNAc-Fc, and least flexibility in HM-Fc and Man5-Fc. In fact, Man5-Fc showed slightly 
lower flexibility in this peptide than HM-Fc at 104s and 105s (see in Figure 4.4 and as seen in the 
homology model in Figure 4.5). Other overlapping peptides containing Trp-277 (peptides 13, 14 
and 15) showed similar overall trends in flexibility with the size of glycans as seen in peptide 12, 
but were subtle and non-significant for Man-Fc (as seen in Figure 4.5). Our results indicate that 
as the glycans were sequentially truncated, the flexibility in peptide 12 increased significantly. 
Thus, there appears to be an inverse correlation of local flexibility, and a direct correlation to 
glycan size, for increasing Trp-277 degradation in this IgG1-Fc.29 In contrast to Asn-315 
deamidation results described above, this result indicates that Trp-277 oxidation rates do not 
correlate with local backbone flexibility of this residue within the backbone structure of the 
IgG1-Fc glycoforms. 
4.4.3 Correlation of previous Fc receptor binding with IgG1-Fc glycoforms with HX 
Results 
A number of studies report the effects of carbohydrate composition on binding affinity of 
mAbs with various Fcγ receptors.84 FcɣRIIIa receptor is the primary target for most therapeutic 
mAbs requiring ADCC action and is the most studied interaction.19,84 X-ray crystallography and 
Fc engineering have identified different regions of IgG1-Fc that are essential for interactions 
with FcɣRIIIa receptors which are the lower hinge (HC residues L235-S239), the BC segment 
(HC residues D265-269E), the C'E segment (residues Q295 and Y296), and the FG segment (HC 




component of mAb binding affinity to FcɣRIIIa. An “open” IgG-Fc structure is the most favored 
conformation for interaction with FcγRIIIa, as seen in the IgG-Fc–FcγRIIIa complex. FcɣRIIIa is 
sensitive to the type of glycosylation present on the Fc region of antibodies; such as removing 
core fucose increased the affinity of Fc for receptor binding but still maintain an open 
conformation while truncation of or removal of other core oligosaccharides resulted in a “closed” 
conformation (collapse) that was unfavorable for binding.71,86 In addition to the conformation of 
the CH2 domain, previous studies have identified an important role for C’E loop dynamics and 
glycan motions in receptor binding.84,87,88 In our previous Fc receptor binding studies with these 
four well-defined IgG1-Fc glycoforms, it was observed that HM-Fc and Man5-Fc had highest 
affinities for FcɣRIIIa, GlcNAc-Fc showed lower affinity, while N297Q-Fc did not show any 
binding to the receptor by two different binding formats as measured by BLI.31  
In this work, we saw a correlation of HX in peptides 17-19 (which include C’E loop, and 
residues Q295 and Y296), peptides 3-4 (containing residues L235-S239), peptides 12-15 
(containing residues D265-269E) and peptides 26-27 (containing residues A327-I332) with the 
size of glycans. We observed that HM-Fc and Man5-Fc show similar HX trends overall, but 
Man5-Fc showed relatively faster HX as compared to HM-Fc in C’E loop peptides 17 and 18 
(see Figure 4.1) and peptides 26-27 which were shown to be significant (see Figures 4.4 and 4.5). 
GlcNAc-Fc showed intermediate rise in HX, while the N297Q-Fc showed the fastest HX as 
compared to HM-Fc in all the peptides. Additionally, we saw significant increase in HX over all 
glycoforms in peptide 16 (residues: Y278-E293) which lies just before the C’E loop which could 
be important for FcɣRIIIa binding, as reported by a HX-MS study on fucose depleted complex 
glycoforms in presence of FcγRIIIa (residues 279-301).55 We observed that as the glycans were 




sequential increase in HX was observed in these peptides as compared to HM-Fc (See Figures 
4.4 and 4.5). Additionally, residues F241-K246 (aggregation hot spot #1 in our study) were 
found important for modulation of glycan motions as studied by NMR,88 and impacted the 
FcγRIIIa binding affinity of Fc fragment. Similarly, we see increased HX in peptides 5-8 
(containing residues 241-246) with decreases in the size of N-glycan in the series of four well-
defined glycoforms of IgG1-Fc.  
In other studies, Man5-Fc and Man8/9-Fc showed enhanced affinity for FcγRIIIa as 
compared to the complex G0F glycoforms of an IgG;89 however, another study showed higher 
rate of HX in the C’E loop glycopeptide (Y278-L306) of Man5 IgG1 than G0F IgG1 and IgG2.32 
These results indicate the importance and involvement of regions other than the C’E loop for 
receptor binding.32 Additionally, GlcNAc-Fc showed intermediate binding to FcγRIIIa in our 
previous studies, even though it does not provide enough backbone interactions to maintain the 
open structure of the CH2 domains (that is favorable to receptor binding) and also showed an 
overall increase in flexibility across the entire CH2 domain by HX-MS. This result again is 
consistent with the notion that importance of the first core GlcNAc in sampling conformations 
that are essential for the binding of Fc to these receptors, which are absent in non-glycosylated 
Fcs. Overall, these results point out towards complex correlations between IgG-Fc 
conformational integrity, local flexibility and strength of interaction with the FcγRIIIa receptors 
that are modulated by the oligosaccharide size for N-glycosylation. Future work in better 
understanding the mechanism of the receptor binding by N-glycan modulation in the context of 
local flexibility measurements of well-defined IgG glycoforms will provide opportunities for 
improved IgG therapeutics.  




Backbone flexibility observations within HM, Man5, GlcNAc and non-glycosylated 
IgG1-Fc glycoforms reported in our work show differences in similar regions of Fc as described 
previously in studies on complex and deglycosylated glycoforms of mAbs.32,54,55,62 Although 
direct, quantitative comparisons across these HX studies are impeded by slight differences in 
peptide coverage, glycan heterogeneities, labelling conditions and data representation methods, 
qualitative comparisons of backbone flexibility trends in different glycoforms of mAbs can be 
drawn. We note that the deuterium uptake curves in this work show a trend with glycan size, 
particularly near the Phe-243 region (peptides 3-8) and at the glycopeptide region Y278-Y300 
(peptides 16-19), similar to several other HX-MS studies on IgG mAbs.32,54,55 Additionally, we 
see other regions that show differences in HX such as residues 300-306 (peptides 20, 21, 22, 23), 
CH2-CH3 interface (peptides 24-27) and the CH3 domain (limited in Man5-Fc, widespread in 
GlcNAc and N297Q-Fcs) in our studies with IgG-Fc molecules, locations which was believed to 
be unaffected by N-glycosylation and was not seen previously in HX studies of mAbs.32,54,55 The 
Phe-243 region is notable because the side chains in this region of the Fc make contact with the 
glycan in X-ray crystal structures.64 The flexibility trends in terms of increased or decreased 
protection are dependent on the presence of N-glycan (deglycosylated vs. glycosylated) and type 
and size of N-linked glycan (complex, hybrid and high mannose). 
A previous study comparing HX of glycosylated (mostly G0F) and deglycosylated IgG1 
antibodies found increased flexibility in residues L236-253M containing the Phe-243 upon 
deglycosylation54 which is similar to our observations in this work with these corresponding 
amino acid residues (in our case residues L235-M252 and peptides 2-8) in N297Q-Fc compared 
to HM-Fc (Man8-Man12). Similarly, another HX-MS study of IgG2 molecules containing HM 




flexibility in the CH2 domain, especially near the Phe-243 residue, as compared to the shorter 
complex glycans (mostly A2G0F).32 The difference in increased backbone flexibility in the 
Man9 glycoform at the Phe-243 residue was attributed to the possibility of removal of contacts 
between complex glycans and Fc residues that were absent in HM.32 Finally, an additional HX-
MS study showed that differential galactosylation affected backbone motion in an IgG1 in 
residues F242-I254 (containing the Phe-243). Hypergalactosylation (G2) caused slower HX 
compared to non-galactosylated (G0) or partially-galactosylated (G1). These differences were 
attributed to a hydrogen bond between galactose and Lys-246. The presence of fucose (G0F, 
G1F, G2F vs G0, G1, G2) however, did not alter HX in this region.55 For the four IgG1-Fc 
glycoforms studied in the present work, there were no significant backbone flexibility 
differences between HM-Fc and Man5-Fc. This result indicates that the Man5 structure is 
essential for the relatively lower backbone flexibility of these IgG1-Fc glycoforms (Man5 and 
HM), and upon truncation of the glycan size in the other two IgG1-Fc (in GlcNAc and N297Q), 
the flexibility of this region increases further, likely due to the loss of stabilizing interactions 
between the glycan and the polypeptide backbone.  
Differences in flexibility were observed at the glycopeptides Y278-L306 and Y278-F300 
in IgG1 and IgG2 mAbs respectively, where HX was faster in high-mannose (Man9, Man5-7) 
and hybrid glycopeptides than in complex glycopeptides (mostly A2G0F) suggesting similar 
backbone flexibility patterns between these two different subclasses of IgG.32 In our studies, 
sequential glycan truncation caused an increase in backbone flexibility at or near the site of 
glycosylation, where truncation from HM (mostly Man8) to Man5 appears to cause a slight 
increase, GlcNAc-Fc caused an intermediate increase while N297Q-Fc caused the greatest 




subsequently). However, in a previous study by Houde et al, glycopeptide residues P292-T308 
showed significant decrease in backbone flexibility upon deglycosylation.54 A couple of 
observations for this contrast effect in the glycopeptide region could be due to the different 
deglycosylation approaches utilized or different techniques utilized for studying the structure and 
flexibility. The previous HX study used PNGase-F treatment for deglycosylation of a fully 
glycosylated antibody54, while, we have utilized a non-glycosylated IgG1-Fc mutant where Asn-
297 was replaced by Gln. The increased protection of the glycopeptide in the PNGase-F treated 
mAb is consistent with the observed collapse and increased compactness of CH2 domains upon 
glycan truncation and deglycosylation as seen before.71,90 However, discrepancy exists in the 
case where an aglycosylated Fc (expressed in E. coli) showed increased radius of gyration in 
solution by SAXS.72 Secondly, crystal structure studies have shown that even though CH2 
domain distances were reduced or increased in aglycosylated Fcs, the C’E loop becomes 
flexible71,72,91 which is inconsistent with the observed decrease in flexibility in the glycopeptide 
region in the HX study by Houde et al. Our results support the observed increases in C’E loop 
flexibility upon glycan truncation (in Man5-Fc and GlcNAc-Fc) and non-glycosylated N297Q-
Fc. 
Another interesting observation in our study is that within the high mannose glycoforms 
of the IgG1-Fc, the Man8 glycopeptide appeared to be relatively the most rigid and that 
backbone flexibility increased as the mannose content increased sequentially to Man12 (see 
Figure 4.2). It was observed previously that sialylated glycoforms of IgG1 and IgG2 showed 
similar enzymatic degradation susceptibility as HM glycoforms and this was related to the 
weakening of interactions between glycans and CH2 domains due to steric effects of bulky 




observed in this work with IgG1-Fc might be due to steric effects caused by the sequential 
addition of bulky mannose units. The Man9 crystal structure also showed increased inter CH2 
domain distance, attributed to the need to accommodate a large, multiply branched glycan in the 
CH2 pocket.92 Interestingly, we observed that when Man8 was truncated to Man5, flexibility in 
the glycopeptide C’E loop appeared to be slightly increased (but was still less than Man12) for 
these IgG1-Fc molecules. However in another study, differences in the glycopeptide region 
(Y278–F300) between Man5-Man7 and Man9 of both full length IgG1 and IgG2 were not 
seen.32 
In HX, glycoform enrichment is not necessary when comparing HX effects in the 
glycopeptides. However, there are a few limitations in direct comparisons of glycopeptides, 
which need to be addressed. First, Guttman and co-workers showed that the acetamido groups of 
the glycan moiety can retain some deuterium after quenching, digestion, and LC separation.73 
Thus, direct comparisons between peptides with different numbers of acetamido groups cannot 
be made unless the measured HX kinetics are adjusted to account for this excess deuteration. In 
cases where glycopeptides have the same number of acetamido groups, this particular factor is 
not a limiting issue. Second, it is unknown whether glycosylation has an effect on chemical 
exchange at amide sites near the glycan. Acetamido groups include the two core N-acetyl 
glucosamine sugars and the modified asparagine/glutamine side chain hydrogens. In another 
study, it was observed that complex, high mannose and hybrid glycans of IgG1 and IgG2 
retained excess deuterium in the glycopeptides that was proportional to the amount of acetamido 
groups. In our study, the HM-Fc (Man8-Man12) and Man5-Fc all have three acetamido groups: 
two GlcNAcs and one modified Asn side chain. GlcNAc-Fc has two acetamido groups: one 




principle, the observed HX could be adjusted for HX in the glycan acetamido groups. This trend 
is apparent in the roughly 0.4 Da mass increase as seen in Supplemental Table 4.2 as the number 
of glycan acetamido groups increases from zero to two to three. However, if there are differences 
in back-exchange between peptides with different glycoforms, the comparisons become 
problematic. A final complication is that the HM IgG1-Fc is a distribution of 8 to 12 mannose 
residues at the glycosylation site on each chain. The majority of heavy chains carry the Man8 
glycan, as characterized in a previous study.31 Our ability to interpret hydrogen exchange results 
in the case of the high mannose glycoforms is more limited because of the heterogeneity of 
glycosylation on the adjacent chain. Effectively, the observed HX kinetics for any high mannose 
glycopeptide is averaged across all high mannose forms (Man8-Man12) on the other half of the 
Fc. 
Finally, in all of the previous studies as well as our work, HX differences in specific 
regions of the CH2 domains were observed as a consequence of different glycosylation, however 
in our studies with IgG1-Fc, we also observed additional differences in the CH2-CH3 interface 
(residues 306-348, peptides 24-27) and in the CH3 domains that were not previously reported 
with mAbs. Again, there was a trend where the backbone flexibility of Man5-Fc was greater than 
HM-Fc near the CH2-CH3 domain interface. On the other hand, decreasing the glycan to 
GlcNAc-Fc and removal of the glycan with N297Q-Fc increased the backbone flexibility in this 
region to a much greater degree than the effect observed with Man5-Fc. Increase in flexibility in 
the CH2-CH3 interface (especially at L317 and N318) was also observed recently in a 
deglycosylated Herceptin which supports destabilization and increased flexibility of Fc by 
increased CH2-CH3 interface breathing motions upon deglycosylation.62 Another region where 




were residues 300-306 (peptides 20-23). Changes in this region were not reported in other HX-
MS measurements of other non-glycosylated mAbs,54,62 but upon environmental stress, this 
















Figure 4.1: Trends in the HX kinetics of 3 different peptides containing the N-linked Asn297 
glycosylation site located in the four different well-defined IgG1-Fc glycoforms. The extent of 
HX has been corrected for back-exchange using deuteration controls as defined by equation (1). 













Figure 4.2: Trends in the HX kinetics of 3 different peptides containing different high mannose 
oligosaccharide structures at the N-linked Asn297 glycosylation site in the high mannose IgG1-
Fc glycoform. The extent of HX has been corrected for back-exchange using deuteration controls 
as defined by equation (1). Error bars represent sample standard deviation from three 






Figure 4.3: Differences in the HX kinetics of 8 representative peptides found in the four well-
defined IgG1-Fc glycoforms in different regions distal from the N-linked Asn297 glycan 
attachment site. The extent of HX has been corrected for back-exchange using deuteration 
controls as defined by equation (1). Error bars represent sample standard deviation from three 









Figure 4.4: Differential deuterium uptake of 51 peptides at five HX times Differential HX in 51 
peptides of three different IgG1-Fc glycoforms compared to the high mannose IgG1-Fc control. 
ΔHX in Man5-IgG1-Fc (blue), GlcNAc-IgG1-Fc (green), and N297Q-IgG1-Fc (red) relative to 
HM-IgG1-Fc at pH 6.0 calculated as defined by equation (2) is shown. For the HM-IgG1-Fc 
glycopeptides (peptide # 17, 18 and 19) data are shown for the most abundant form, Man8. The 
peptides are indexed from N- to C-terminus. The corresponding locations and sequences are 
listed in the supporting information in Supplementary Table 4.1. The yellow region denotes the 




domains, is shown in CH2 domain. Each bar represents an average of three independent HX 
measurements. The dashed lines define the limit of statistical significance as described in the 
Methods section. The regions of interest to correlate with previously published stability and 
receptor binding data are as follows: Glycopeptide (peptides 17-19 at 102 s), Aggregation hot 
spot #1 (peptides 3-8, at 103 s), Aggregation hot spot #2 (peptides 20-23, at 105 s) and 
Deamidation hot spot (peptides 24,25 at 104 s). The above regions of interest are pointed out at 
particular labelling times that showed the largest differences in HX. * denote the peptides from 
the important regions that showed significant differences, but are not clearly visible due to the 

















Figure 4.5: Averaged per-peptide trends in altered HX kinetics relative to the high mannose 
glycoform. A) Regions of interest as mentioned in Figure 4.4 are mapped on to a homology 
model  B) HX kinetics of Man5-Fc (blue), GlcNAc-Fc (green) and N297Q-Fc (red) with respect 




for peptide length by using deuteration controls as defined by equation (3). The dashed lines 
represent the threshold for statistical significance as detailed in the Methods section as defined 
by equation. The arrows represent the regions of interest. C) Statistically significant ∆HX in dark 
blue, cyan and pink colors is mapped onto a homology model indicating areas of strongly 
increased local flexibility where ∆HX > 5%, weakly increased local flexibility where ∆HX < 5% 
and decreased local flexibility, respectively as compared to the high mannose glycoform. The 



































1 225 234 TCPPCPAPEL Hinge 
2 225 240 TCPPCPAPELLGGPSV Hinge-CH2 
3 235 251 LGGPSVFLFPPKPKDTL CH2 
4 235 253 LGGPSVFLFPPKPKDTLM CH2 
5 241 251 FLFPPKPKDTL CH2 
6 241 252 FLFPPKPKDTLM CH2 
7 242 251 LFPPKPKDTL CH2 
8 242 252 LFPPKPKDTLM CH2 
9 253 260 ISRTPEVT CH2 
10 253 261 ISRTPEVTC CH2 
11 253 262 ISRTPEVTCV CH2 
12 262 277 VVVDVSHEDPEVKFNW CH2 
13 263 277 VVDVSHEDPEVKFNW CH2 
14 264 277 VDVSHEDPEVKFNW CH2 
15 266 277 VSHEDPEVKFNW CH2 
16 278 293 YVDGVEVHNAKTKPRE CH2 
17 278 299 YVDGVEVHNAKTKPREEQYN*ST CH2 
18 278 300 YVDGVEVHNAKTKPREEQYN*STY CH2 
19 282 300 VEVHNAKTKPREEQYN*STY CH2 
20 300 305 YRVVSV CH2 
21 300 306 YRVVSVL CH2 
22 301 305 RVVSV CH2 
23 301 306 RVVSVL CH2 
24 306 318 LTVLHQDWLNGKE CH2 
25 307 318 TVLHQDWLNGKE CH2 
26 319 333 YKCKVSNKALPAPIE CH2 
27 334 348 KTISKAKGQPREPQV CH2/ CH3 
28 349 358 YTLPPSRDEL CH3 
29 349 364 YTLPPSRDELTKNQVS CH3 
30 349 356 YTLPPSRDELTKNQVSL CH3 
31 349 366 YTLPPSRDELTKNQVSLT CH3 
32 357 365 ELTKNQVSL CH3 
33 359 365 TKNQVSL CH3 
34 359 367 TKNQVSLTC CH3 
35 368 376 LVKGFYPSD CH3 
36 368 380 LVKGFYPSDIAVE CH3 
37 369 376 VKGFYPSD CH3 




39 369 380 VKGFYPSDIAVE CH3 
40 377 380 IAVE CH3 
41 377 390 IAVEWESNGQPENN CH3 
42 377 398 IAVEWESNGQPENNYKTTPPVL CH3 
43 381 398 WESNGQPENNYKTTPPVL CH3 
44 392 398 KTTPPVL CH3 
45 399 404 DSDGSF CH3 
46 405 423 FLYSKLTVDKSRWQQGNVF CH3 
47 411 425 TVDKSRWQQGNVFSC CH3 
48 424 447 SCSVMHEALHNHYTQKSLSLSPGK CH3 
49 426 447 SVMHEALHNHYTQKSLSLSPGK CH3 
50 429 447 HEALHNHYTQKSLSLSPGK CH3 





















Supplementary Table 4.2: Measured deuterium content in fully deuterated controls in three 
glycopeptides (# 17, 18, and 19) of IgG1-Fc glycoforms.  
Note: The numbers of acetamido groups in each type of N-glycan are shown. The average values 
and standard deviations are in units of Da and were obtained from triplicate measurements. See 































Man8-Fc 3 12.2 ± 0.1 12.0  ± 0.1 10.8  ± 0.2 
Man5-Fc 3 12.1 ± 0.6 12.0  ± 0.3 10.7  ± 0.7 
GlcNAc-Fc 2 11.0  ± 0.4 11.5  ± 0.2 10.4  ± 0.2 
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The process and formulation development of protein biopharmaceutical such as 
monoclonal antibodies (mAbs) is a long, complex and expensive endeavor. The main 
characteristics of mAbs which make their development challenging are 1) their large molecular 
weight combined with their complex, fragile and heterogeneous (due to PTMs) primary and 
higher order structures, 2) complex production using living cells that we have limited control and 
knowledge of, 3) multifaceted behaviors and interaction with other molecules in the human 
system, and 4) limitation of the analytical tools used to characterize them.1-3 It is required for the 
manufacturers of novel biologics and biosimilars to prove to the regulatory authorities that all 
necessary studies have been conducted and their product is biologically active and safe and 
efficacious for use in an identified patient population.4 Hence, it is of utmost importance to make 
an effort in improving our understanding about the physicochemical properties and develop 
better analytical tools for studying these molecules to achieve minimum risk for their utilization 
as therapeutics. Each mAb biologic or biosimilar product has different structural characteristics, 
a glycosylation patterns and stability profiles by virtue of different variables during their 
development such as raw materials, cell lines, manufacturing procedures, formulations, container 
closures, delivery devices, etc.  
It is well known that N-glycosylation affects the structure, stability and can severely 
impact the safety and therapeutic efficacy of mAb drug candidates, hence monitoring and 
controlling them in a drug product is crucial. Multiple attempts have been made to control and 
characterize the type and content of glycosylation heterogeneity in biologics. Currently, HPLC-
MS techniques are the most popular for glycosylation profiling and primary structure analysis of 




characterization. However, studying the impact of glycosylation on higher order structure  of 
mAbs has remained a challenge due to complexity of the glycosylation and the need for multiple 
and improved biophysical characterization tools to accesses all aspects of their complex HOS 
especially in case of comparability and biosimilarity assessments.2 Therefore, biophysical 
analysis of mAbs in attempt to investigate the impact of glycosylation during their formulation 
development and in comparability/biosimilarity exercises is necessary and was the main focus of 
this PhD thesis project.  
5.2 Chapter summaries and future work 
5.2.1 Chapter 2 
The well-defined glycoforms of IgG1-Fc produced in this work serve as model proteins 
to develop novel analytical tools for comparability and biosimilarity assessments. Additionally, 
this study provides improved understanding of the impact of N-glycosylation on higher order 
structure and stability profile of IgG1-Fc proteins in different formulations. Four homogenous, 
well-defined glycoforms of IgG1-Fc (HM-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc) were 
achieved using genetically modified yeast cells and in vitro enzymatic synthesis. Routinely used 
low resolution, higher throughput biophysical tools for formulation development in the 
biopharmaceutical industry, like PEG precipitation along with UV, intrinsic and extrinsic 
fluorescence spectroscopy, as well as DSC and turbidity were employed for extensive physical 
stability characterization of these glycoforms to evaluate their solubility, tertiary structure, 
overall conformation, and aggregation propensity, respectively. The information provided by 
these techniques was relatively low in molecular resolution; where in the signals were an average 




from which more detailed biophysical analysis was developed to monitor subtle changes in HOS 
upon glycosylation which was by exposing the proteins to a wide range of stresses. Thus, 
conformational stability is used as a sensitive surrogate for probing for subtle differences in HOS 
between the different IgG1-Fc glycoforms. 
 Forced degradation studies expose the molecules to extreme conditions and allows for 
detection of subtle higher order differences in a short amount of time. In our studies, we exposed 
the four IgG1-Fc glycoforms to a wide range of pH (4-7.5 with 0.5 unit increments) and 
temperature conditions (from 25°C-90°C with 1.25°C increments). These studies showed 
differences in physical stability with respect to glycosylation across the different glycoforms. We 
observed that the physical stability profile of IgG1-Fc glycoforms showed a trend of decreasing 
stability with decreasing the glycan size. Physical stability of the HM-Fc and Man5-Fc was the 
highest, followed by GlcNAc-Fc, and the least stability was observed for N297Q-Fc. It was also 
observed that the GlcNAc-Fc and N297Q-Fc showed higher aggregation propensities above pH 
5. Further, the forced degradation studies allowed us to develop stability indicating assays 
(intrinsic and extrinsic fluorescence spectroscopy as well as OD350 turbidity) which required 
least amount of material and successfully detected subtle changes in HOS of these proteins. 
These high throughput techniques developed in this study can be essential tools in early 
candidate selection and assessing developability of mAbs where only small amounts of material 
are available. Further, the above stability indicating assays were utilized for monitoring the 
physical stability of various mixtures of these glycoforms (in Chapter 3) and also can be 
employed for future long-term stability studies of these four glycoforms. Additionally, the forced 
degradation studies allowed us to monitor the stability of these four glycoforms in two different 




A large amount of data was generated from these forced degradation studies in two 
different formulations over large pH and temperature conditions, which was utilized to develop 
data visualization tools (like EPD and radar charts) to make relative comparisons of the physical 
stability profile of the IgG1-Fc glycoforms. These tools present a complimentary approach to 
study and compare the HOS changes in these glycoproteins and offer a more efficient way to 
compare a large stability data sets obtained from multiple and various analytical techniques. 
Further, we utilized the EPD and radar charts to compare the physical stability of these four 
glycoforms of IgG1-Fc in two different formulations. This data visualization approach could be 
applied to comparability exercises or biosimilarity where the products are compared pre and post 
changes such as process and formulation changes or when the biosimilar formulation might be 
different than the originator, respectively.  
In terms of future work, although the biophysical stability data sets, along with EPD and 
radar charts analysis, showed subtle differences between these proteins, it will be interesting to 
correlate these forced degradation studies with real time stability studies of these glycoforms by 
the same or different analytical tools for monitoring the physicochemical stability during storage. 
In addition, a major analytical challenge for the utility of these novel data visualization tools for 
comparability and biosimilarity applications will be their ability to define the precision of EPD’s 
phase transitions and radar chart’s clusters for incorporating the degree of variability observed 
during data collection and this could be addressed in future work. Finally, this approach of 
producing well-defined IgG Fc glycoforms from yeast and in vitro enzyme synthesis can be 
utilized in future to prepare more human like complex glycoforms like G0, G0F, G2F, G2 and 
sialic acid. The HOS analysis of full length mAbs as a function of Fc N-glycosylation should 




mAbs. It would be interesting in future studies to see if N-glycosylation in Fc can affect the 
antigen binding of these glycoforms in their Fab domains. 
5.2.2 Chapter 3 
After initial qualitative comparisons of HOS and physical stability profiles of the four 
IgG1-Fc glycoforms, the next goal was to develop a quantitative comparative mathematical 
model to assess biosimilars vs originator molecules.  As a step to achieve that, the four well-
defined model glycoforms of IgG1-Fc showing a wide range of biophysical (studied in Chapter 
2), chemical and biological (studied in other KU laboratories) properties were mixed in various 
proportions to potentially mimic heterogeneity in glycosylation that may be observed in 
biosimilar vs. originator drug products. Seven mixtures were prepared and were predicted to 
have subtle and evident differences in receptor binding and physicochemical properties. The 
study in Chapter 2 allowed us to understand the properties of the individual well-defined 
glycoforms beforehand, and hence we were able to optimize the properties of mixtures and 
expected them to show subtle (90% mixtures of HM-Fc with Man5-Fc, GlcNAc-Fc and N297Q-
Fc) or evident differences (50% mixtures of HM-Fc with Man5-Fc, GlcNAc-Fc and N297Q-Fc). 
Another complex mixture was prepared which had 25% of all the four glycoforms of IgG1-Fc. 
The previously studied individual four well-defined IgG1-Fc glycoforms in Chapter 2 were 
utilized as controls in this study. Many of the physical characterization stability indicating assays 
that were developed in Chapter 2 were utilized in this study to investigate the ability of these 
techniques to successfully detect the expected higher order structural differences between these 
mixtures. These studies demonstrated high sensitivity of PEG precipitation solubility assay and 
DSC for distinguishing between the mixtures at two different pH conditions (4.5 and 6.0). Stress 




pH 6.0. All the biophysical data sets generated from these studies are being utilized by the Deed 
laboratory at KU, to develop a mathematical model, which will be able to predict biosimilarity 
quantitatively. The ability to accurately predict differences between the mixtures showed the 
importance of these routinely used high-throughput techniques in evaluating comparability and 
biosimilarity and indeed these form the foundation of comparability exercises. As mentioned by 
the FDA “the more comprehensive and robust the comparative structural and functional 
characterization is, the stronger the scientific justification for a selective and targeted approach to 
animal and/or clinical testing.” 4 We see that this array of biophysical techniques were able to 
detect changes in the mixtures of different glycoforms that were not subtle, but still can be useful 
in comparative biosimilarity exercises.  
In terms of future work, mAb biosimilars are more complex and have multiple 
distributions of glycoforms, along with the entire molecule vs an antibody fragment, and can be 
formulated in different excipients. These variables could make it difficult for the global 
biophysical tools to distinguish between subtle differences of a biosimilar and an innovator. It 
will be interesting to see if the above biophysical characterization tools can identify and 
characterize excipients-related impurities in these glycoform mixtures and their ability to 
critically assess the differences in detail. It should be noted that changes in N-glycosylation 
patterns might lead to measurable changes in biological activity but might not lead to changes is 
HOS. Also, subtle HOS changes due to different glycans might not be detected by biophysical 
techniques.5 Hence, in such cases were biophysical tools are not sensitive to demonstrate any 
changes, more advanced and high resolution tools like HX-MS and NMR spectroscopy could 
find utility as described in the next chapter of this thesis work.  




Lastly, a higher resolution technique (HX-MS) was utilized to study the HOS of these 
glycoforms. HX-MS provides understanding of dynamics of proteins which can be correlated 
with physicochemical stability and biologically activity of mAbs. However, the relation between 
N-glycosylation, dynamics and stability of mAbs is complex and is often difficult to elucidate 
due to the heterogeneous nature of glycosylation.6 Previously, not all changes in mAb 
glycosylation were shown to correspond to changes in dynamics, stability and biological activity 
making it difficult to correlate these attributes with glycosylation.6 However, it is well known 
that complete removal of N-linked oligosaccharides severely affect a mAb’s biological 
properties and stability although the underlying mechanism is unclear.7 This dissertation 
contributed towards exploring the mechanisms of changes in physical stability of IgG1-Fc 
(studied in Chapter 2) as a function of well-defined N-glycosylation by studying changes in local 
backbone dynamics of these glycoforms. The results were also correlated to physical stability 
results obtained from Chapter 2 along with chemical stability and biological function data 
(FcɣRIIIa receptor binding data) of these glycoforms studied in other KU laboratories.  
It was found that sequential truncation of N-glycans resulted in a trend of increased 
backbone flexibility of the IgG1-Fc most probably due to loss of multiple contacts with the 
protein backbone. We demonstrated that sequentially decreasing the glycan size from high 
mannose (Man8-Man12) to Man5, GlcNAc and non-glycosylated increased the backbone 
flexibility of IgG1-Fc molecules. The trends observed included Man5-Fc showing similar and 
relatively lowest flexibility of the glycoforms, intermediate increase in flexibility was shown by 
GlcNAc-Fc, and the non-glycosylated N297Q-Fc showed highest increase in flexibility of the 
IgG1-Fc (as compared to HM-Fc). However, high mannose glycans (Man8-12) showed 




and was probably caused by steric effects of these bulky glycans, which weakened the 
interaction between the glycan and CH2 domain as previously seen in sialic acid glycoforms of 
IgG2-Fc.8  
Previously, increase in conformational flexibility was observed in a region in the CH2 
domain of mAbs in the presence of excipients3 and salts9, which was recognized as an 
aggregation hot spot.9 In this study, we found increase in flexibility of this aggregation hot spot 
region in the CH2 domains of GlcNAc and N297Q-Fc that make these glycoforms more 
susceptible to aggregation and conformational destabilization. We also identified another region 
that showed increase in flexibility with decrease in glycan size (in GlcNAc and N297Q-Fc) that 
might contribute to the aggregation (aggregation hot spot 2) of these glycoforms. This region, in 
spite of showing increased flexibility in the presence of excipients and salts, it was not 
recognized as an aggregation hot spot in previous studies with mAbs.3,9  
Interestingly, results from FcɣRIIIa binding data of these four glycoforms (studied in 
Tolbert lab at KU) were compared with these flexibility results and showed a correlation of 
decreased binding10 with increase in flexibility in the receptor binding peptide (C’E loop) as the 
glycans were truncated. Chemical stability results of these four glycoforms from the Schoneich 
laboratory at KU, showed a complicated relationship with flexibility. Decreased rate and extent 
of deamidation of Asn-315 was observed with increased glycan size (in HM-Fc and Man5-Fc)11 
while we saw least flexibility of the Asn315 containing peptide in HM-Fc and Man5-Fc. 
However, rate of conversion of Trp-277 into glycine hydroperoxide was increased with increase 
in glycan size (highest for HM-Fc and Man5-Fc, lowest for GlcNAc and non-glycosylated 
N297Q-Fc IgG1-Fc),11 while we saw lower flexibility in the Trp-277 peptide as the glycan size 




impurity profile across the purified glycoform preparations due to differences in glycosylation 
(e.g., trace metal ion content). This possibility should be considered in future work.  
This study improves our understanding of N-glycosylation and its impact on chemical 
stability, physical stability, biological activity and flexibility of these well-defined IgG1-Fc 
glycoforms. In terms of future work, flexibility trends of the four glycoforms of IgG1-Fc 
observed from this study can also be applied to full length mAbs of the same IgG subclass of IgG 
as well as other subclasses as they have almost identical amino acid sequences (except a few 
amino acid residues) in the N-glycosylation site with the Fc domain. This approach should also 
be utilized further for studying complex and well-defined glycoforms of full length mAbs that 
showed subtle differences in physical stability but significant differences in Fc ɣ receptor 
binding. 
 It was observed previously that even though forced degradation studies showed 
differences between complex glycoforms and aglycosylated IgG mAbs, their long term stability 
was not affected by glycosylation.12,13 Hence, changes in physical and chemical stability and 
receptor binding of different glycoforms of mAbs can be explored upon long-term storage and/or 
stressed conditions in a variety of excipients containing liquid formulations. This future work 
may help better explain and understand the inter-relationships between changes in real time 
protein stability with respect to glycosylation from the outlook of local dynamics, 
physicochemical stability and biological activity.   
Although, higher resolution analytical tools like HX-MS have not been routinely utilized 
especially in early stages of protein drug formulation development due to their high cost and 
requirement of highly specialized expertise, the increased utility of HX-MS in protein 




laboratories.14 It is also been shown to be valuable in high priority activities like lot-to-lot 
comparisons as well as comparability and biosimilarity assessments.15 Even though utilization of 
higher resolution-tools to find subtle changes in HOS of mAbs for comparability and 
biosimilarity assessments provides state-of-the-art structural information of a protein molecule in 
a pharmaceutical dosage form, a lot of time and resources are still needed, not only to make HX-
MS more accessible for routine pharmaceutical development, but also to figure out the clinical 
consequences, if any, of these structural differences.1 The holistic approach to study local 
flexibility with respect to physicochemical stability and biological activity of well-defined IgG1-
Fc glycoforms described in this work shows the promise of HX-MS as a tool for protein 
formulation development as well as comparability and biosimilarity assessment of glycosylated 
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